COSCIENS Biopharma (CSCI) 20-F 28 Mar 22 2021 FY Annual report (foreign) Financial data

Cover

Cover - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Entity Addresses [Line Items]
Document Type	20-F
Amendment Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-38064
Entity Registrant Name	AETERNA ZENTARIS INC.
Entity Central Index Key	0001113423
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	c/o Norton Rose Fulbright Canada, LLP
Entity Address, Address Line Two	222 Bay Street
Entity Address, Address Line Three	Suite 3000, PO Box 53
Entity Address, City or Town	Toronto
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	M5K 1E7
Title of 12(b) Security	Common Shares
Trading Symbol	AEZS
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Document Accounting Standard	International Financial Reporting Standards
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	121,397,007
ICFR Auditor Attestation Flag	false
Auditor Firm ID	1263	271
Auditor Name	Ernst & Young LLP	PricewaterhouseCoopers LLP
Auditor Location	Montreal, Canada	PwC Tower, 18 York Street, Suite 2600, Toronto, Ontario, Canada M5J
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	Weismüllerstr. 50
Entity Address, City or Town	Frankfurt am Main
Entity Address, Country	DE
Entity Address, Postal Zip Code	D-60314
City Area Code	49
Local Phone Number	69-426020
Contact Personnel Name	Klaus Paulini
Contact Personnel Email Address	KPaulini@aezsinc.com

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents (note 6)	$ 65,300	$ 24,271
Trade and other receivables (note 7)	1,314	1,681
Inventory (note 8)	73	21
Income taxes receivable (note 22)	2,361	601
Prepaid expenses and other current assets (note 9)	1,772	1,040
Total current assets	70,820	27,614
Restricted cash equivalents (note 10)	335	338
Property, plant and equipment (note 11)	42	22
Right of use assets (note 12)	150	157
Identifiable intangible assets (note 13)	625	59
Goodwill (note 14)	8,130	8,815
Total assets	80,102	37,005
Current liabilities
Payables and accrued liabilities (note 15)	2,672	2,199
Current portion of provisions (note 16)	34	92
Income taxes payable (note 22)	115	123
Current portion of deferred revenues (note 5)	4,815	2,193
Current portion of lease liabilities (note 17)	130	135
Total current liabilities	7,766	4,742
Deferred revenues (note 5)	1,493	3,289
Deferred gain (note 13)	98
Lease liabilities (note 17)	31	49
Employee future benefits (note 18)	17,485	15,435
Provisions (note 16)	243	279
Total liabilities	27,116	23,794
SHAREHOLDERS’ EQUITY
Share capital (note 19)	293,410	235,008
Warrants (note 19)	5,085	12,402
Other capital (note 19)	89,788	89,505
Deficit	(334,619)	(322,659)
Accumulated other comprehensive loss	(678)	(1,045)
Total shareholders’ equity	52,986	13,211
Total liabilities and shareholders’ equity	$ 80,102	$ 37,005

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity (Deficiency) - USD ($) $ in Thousands		Issued capital [member]	Warrants [Member]	Other equity interest [member]	Retained earnings [member]	Accumulated Other Comprehensive Loss Income [Member]	Total
Balance - December 31, 2020 at Dec. 31, 2018		$ 222,335		$ 89,342	$ (309,781)	$ 11	$ 1,907
Balance, shares at Dec. 31, 2018	[1]	16,440,760
IfrsStatementLineItems [Line Items]
Net loss					(6,042)		(6,042)
Foreign currency translation adjustments						83	83
Actuarial loss on defined benefit plan (note 18)					(1,068)		(1,068)
Comprehensive loss					(7,110)	83	(7,027)
Share issuance from the exercise of warrants, stock options and deferred share units		$ 906		(329)			577
Share issuance from the exercise of warrants, stock options and deferred share units, shares	[1]	228,750,000
Issuance of common shares and warrants, net of transaction costs (note 19)		$ 1,287					1,287
Issuance of common shares and warrants, net of transaction costs (note 19), shares	[1]	3,325,000
Share-based compensation costs (note 19)				793			793
Balance - December 31, 2021 at Dec. 31, 2019		$ 224,528		89,806	(316,891)	94	(2,463)
Balance, shares at Dec. 31, 2019	[1]	19,994,510
IfrsStatementLineItems [Line Items]
Net loss					(5,118)		(5,118)
Foreign currency translation adjustments						(1,139)	(1,139)
Actuarial loss on defined benefit plan (note 18)					(650)		(650)
Comprehensive loss					(5,768)	(1,139)	(6,907)
Issuance of common shares and warrants, net of transaction costs (note 19)		$ 10,480	5,025	(362)			15,143
Issuance of common shares and warrants, net of transaction costs (note 19), shares	[1]	42,684,103
Share-based compensation costs (note 19)				61			61
Reclassification of warrants to equity (note 19)			7,377				7,377
Balance - December 31, 2021 at Dec. 31, 2020		$ 235,008	12,402	89,505	(322,659)	(1,045)	13,211
Balance, shares at Dec. 31, 2020	[1]	62,678,613
IfrsStatementLineItems [Line Items]
Net loss					(8,368)		(8,368)
Foreign currency translation adjustments						367	367
Actuarial loss on defined benefit plan (note 18)					(3,592)		(3,592)
Comprehensive loss					(11,960)	367	(11,593)
Issuance of common shares and warrants, net of transaction costs (note 19)		$ 29,082	1,897				30,979
Issuance of common shares and warrants, net of transaction costs (note 19), shares	[1]	23,586,207
Share-based compensation costs (note 19)				311			311
Exercise of warrants (note 19)		$ 29,833	(9,746)				20,087
Exercise of warrants (note 19), shares	[1]	35,111,187
Transfer of warrant issuance costs upon exercise of warrants (note 19)		$ (532)	532
Exercise of deferred share units (note 19)		$ 19		(28)			(9)
Exercise of deferred share units (note 19), shares	[1]	21,000
Balance - December 31, 2021 at Dec. 31, 2021		$ 293,410	$ 5,085	$ 89,788	$ (334,619)	$ (678)	$ 52,986
Balance, shares at Dec. 31, 2021	[1]	121,397,007
[1]	Issued and paid in full.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenues (notes 5 and 25)
License fees	$ 1,670	$ 911	$ 74
Development services	3,337
Product sales		2,370	129
Royalties	68	67	45
Supply chain revenue	185	304	284
Total revenues	5,260	3,652	532
Operating expenses (note 20)
Cost of sales	90	2,317	410
Research and development expenses	6,574	1,506	1,837
General and administrative expenses	5,916	4,759	6,615
Selling expenses	1,351	1,134	1,214
Restructuring costs			507
Impairment of right of use asset			22
Gain on modification of building lease (notes 12 and 17)		(219)
(Reversal) impairment of other asset		(139)	169
Total operating expenses	13,931	9,358	10,774
Loss from operations	(8,671)	(5,706)	(10,242)
Gains due to changes in foreign currency exchange rates	215	572	87
Change in fair value of warrant liability		1,147	4,518
Other finance costs	(21)	(736)	(593)
Net finance income	194	983	4,012
Loss before income taxes	(8,477)	(4,723)	(6,230)
Income tax recovery (expense) (note 22)	109	(395)	188
Net loss	(8,368)	(5,118)	(6,042)
Items that may be reclassified subsequently to profit or loss:
Foreign currency translation adjustments	367	(1,139)	83
Items that will not be reclassified to profit or loss:
Actuarial loss on defined benefit plans	(3,592)	(650)	(1,068)
Comprehensive loss	$ (11,593)	$ (6,907)	$ (7,027)
Net loss per share (basic) (note 26)	$ (0.07)	$ (0.12)	$ (0.35)
Net loss per share (diluted) (note 26)	$ (0.07)	$ (0.12)	$ (0.35)
Weighted average number of shares outstanding (note 26)
Basic	114,924,497	41,083,163	17,494,472
Diluted	114,924,497	41,083,163	17,494,472

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (8,368)	$ (5,118)	$ (6,042)
Items not affecting cash and cash equivalents:
Change in fair value of warrant liability		(1,147)	(4,518)
Transaction costs of warrants issued, expensed as finance cost		732	550
Provision for restructuring and other costs (note 16)	23	(383)	511
Impairment of right of use asset			22
(Reversal) impairment of other asset		(139)	169
Gain on modification of building lease (notes 12 and 17)		(219)
Depreciation and amortization (notes 11, 12 and 13)	145	232	315
Share-based compensation costs (note 19)	311	61	793
Employee future benefits (note 18)	161	217	262
Amortization of deferred revenues	(1,670)	1,257	(74)
Foreign exchange gain on items denominated in foreign currencies	(179)	(688)	(87)
(Gain) loss on disposal of property, plant and equipment (note 12)	(1)	(2)	10
Other non-cash items	95	133	(126)
Interest accretion on lease liabilities (note 17)	7	(19)	(66)
Payment of income taxes (note 22)	(1,605)	(1,448)
Changes in operating assets and liabilities (note 21)	2,500	2,402	(2,444)
Net cash used in operating activities	(8,581)	(4,129)	(10,725)
Cash flows from financing activities
Proceeds from issuance of common shares (note 19)	34,200
Proceeds from issuances of common shares and warrants (note 19)		23,500	4,988
Transaction costs	(3,221)	(2,767)	(795)
Proceeds from exercise of warrants, stock options and deferred share units	20,087		314
Proceeds on deferred gain (note 13)	98
Payments on lease liabilities (note 17)	(127)	(265)	(614)
Net cash provided by financing activities	51,037	20,468	3,893
Cash flows from investing activities
Proceeds for disposals of property, plant and equipment (note 11)	1	6
Purchase of intangible assets (note 13)	(609)
Purchase of property, plant and equipment (note 11)	(30)
(Decrease) increase in restricted cash equivalents	(20)	50	50
Net cash (used in) provided by investing activities	(658)	56	50
Effect of exchange rate changes on cash and cash equivalents	(769)	38	108
Net change in cash and cash equivalents	41,029	16,433	(6,674)
Cash and cash equivalents – beginning of year	24,271	7,838	14,512
Cash and cash equivalents – end of year (note 6)	$ 65,300	$ 24,271	$ 7,838

Business overview

Business overview	12 Months Ended
	Dec. 31, 2021
Business overview	1. Business overview Summary of business Aeterna Zentaris (the “Company” or “Aeterna”) is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only United States (“US”) Food and Drug Administration (“FDA”) and European Medicines Agency-approved oral test indicated for the diagnosis of patients with adult growth hormone deficiency (“AGHD”). Macrilen™ is currently marketed in the US through a license agreement, as amended, between the Company and Novo Nordisk Health Care AG (“Novo”). The Company is also dedicated to the development of therapeutic assets and has recently taken steps to establish a pre-clinical pipeline to potentially address unmet medical needs across a number of indications with a focus on rare or orphan indications and with the potential for pediatric use. COVID-19 impact Coronavirus, or COVID-19, a contagious disease that was characterized by the World Health Organization as a pandemic in early 2020, continues to affect the global community. The spread of COVID-19 may continue to impact our operations, including the potential interruption of our clinical trial activities and of our supply chain. For example, the rise in the Omicron variant in the COVID-19 pandemic has caused delays in site initiation and patient enrollment in our Phase 3 DETECT clinical trial for diagnostic use in childhood-onset growth hormone deficiency. Additionally, sales activities for Macrilen™ in the US may be impacted due to delays of diagnostic activities on AGHD in the US. Further, the COVID-19 pandemic may also cause some patients to be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay our ability to conduct clinical trials or release clinical trial results on a timely basis and could delay our ability to obtain regulatory approval and commercialize our product candidates. Management will continue to monitor and assess the impact of the pandemic on its judgments, estimates, accounting policies and amounts recognized in these consolidated financial statements. As of December 31, 2021, the Company assessed the possible impacts of COVID-19 on its consolidated financial results. The Company has evaluated its financial assets, property, plant and equipment, intangible assets, and goodwill for impairment and no changes from the carrying amount were required in the reporting period. Reporting entity The accompanying consolidated financial statements include the accounts of Aeterna Zentaris Inc., an entity incorporated under the Canada Business Corporations Act The registered office of the Company is located at 222 Bay Street, Suite 3000, P.O. Box 53, Toronto, Ontario M5K 1E7, Canada. The Company’s common shares are listed on both the Toronto Stock Exchange and on the NASDAQ Capital Market. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Basis of presentation (a) Statement of compliance These consolidated financial statements as of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). These consolidated financial statements were approved by the Company’s Board of Directors, subject to confirmation by the Audit Committee of the Board of Directors, which confirmation was received on March 28, 2022 . The preparation of financial statements in accordance with IFRS requires the use of certain critical accounting estimates and the exercise of management’s judgment in applying the Company’s accounting policies. Areas involving a high degree of judgment or complexity and areas where assumptions and estimates are significant to the Company’s consolidated financial statements are discussed in note 3 - Critical accounting estimates and judgments. Certain comparative figures for the year ended December 31, 2020 were reclassified to conform to the presentation adopted for December 31, 2021. (b) Basis of measurement The consolidated financial statements have been prepared under a historical cost convention. (c) Principles of consolidation These consolidated financial statements include any entity in which the Company directly or indirectly holds more than 50% of the voting rights or over which the Company exercises control. The Company controls an entity when the Company is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. An entity is included in the consolidation from the date that control is transferred to the Company, while any entities that are sold are excluded from the consolidation from the date that control ceases. All inter-company balances and transactions are eliminated on consolidation. (d) Foreign currency Items included in the financial statements of the Group’s entities are measured using the currency of the primary economic environment in which the entities operate (the “functional currency”) which is the US dollar for the Company and its US subsidiary, Aeterna Zentaris, Inc., and the Euro (“EUR” or “€”) for its German subsidiaries. Assets and liabilities of the German subsidiaries are translated from EUR balances at the period-end exchange rates, and the results of operations are translated from EUR amounts at average rates of exchange for the period. The resulting translation adjustments are included in accumulated other comprehensive loss within shareholders’ equity (deficiency). Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the underlying transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities not denominated in the functional currency are recognized in the consolidated statements of comprehensive loss.

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Dec. 31, 2021
Summary of significant accounting policies	2. Summary of significant accounting policies The accounting policies set out below have been applied consistently to all years presented in these consolidated financial statements and have been applied consistently by all Group entities. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Cash and cash equivalents Cash and cash equivalents consist of unrestricted cash on hand and balances with banks, as well as short-term interest-bearing deposits, such as money market accounts, that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value, with a maturity of three months or less from the date of acquisition. Inventories Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company’s policy is to write down inventory that has become obsolete and inventory that has a cost basis in excess of its expected net realizable value. Increases in the reserve are recorded as charges in cost of sales. For product candidates that have not been approved by the FDA, inventory used in clinical trials is written down at the time of production and recorded as research and development (“R&D”) costs. For products that have been approved by the FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the clinical trial. All direct manufacturing costs incurred after approval are capitalized into inventory. Restricted cash equivalents Restricted cash equivalents are comprised of bank deposits, which are related to a guarantee for a long-term operating lease obligation, and for corporate credit card programs that cannot be used for current purposes. Property, plant and equipment and depreciation Items of property, plant and equipment are recorded at cost, net of accumulated depreciation and impairment charges. Depreciation is calculated using the following methods, annual rates and period: Summary of Depreciation Using Methods, Annual Rates and Period Methods Annual rates and period Equipment Declining balance and straight-line 20% Furniture and fixtures Declining balance and straight-line 10% to 20% Computer equipment Straight-line 25% to 33 1 Leasehold improvements Straight-line Remaining lease term Depreciation expense, which is recorded in the consolidated statement of comprehensive loss, is allocated to the appropriate functional expense categories to which the underlying items of property, plant and equipment relate. Identifiable intangible assets and amortization Identifiable intangible assets with finite useful lives consist of in-process R&D acquired in business combinations, patents, trademarks, in-licensed technology and rights to serialization equipment located at the Company’s third-party macimorelin manufacturer. In-process R&D acquired in business combinations is recognized at fair value at the acquisition date. Patents and trademarks are comprised of costs, including professional fees incurred in connection with the filing of patents and the registration of trademarks for product marketing and manufacturing purposes, net of related government grants, impairment losses and accumulated amortization. Identifiable intangible assets with finite useful lives are amortized beginning at the time at which the assets are available for use, on a straight-line basis over the assets’ estimated useful lives, which range from seven to 15 years for in-process R&D and patents and are ten years for trademarks. Amortization expense, which is recorded in the consolidated statement of comprehensive loss, is allocated to the appropriate functional expense categories to which the underlying identifiable intangible assets relate. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Contingent payments The Company accounts for contingent variable payments for separately acquired intangible assets, such as in-licensed technology, under the cost accumulation approach. Contingent consideration is not considered on initial recognition of the asset but instead is added to the cost of the asset initially recorded, when incurred. Goodwill Goodwill is recognized as the fair value of the consideration transferred, including the recognized amount of any non-controlling interest in the acquiree, less the fair value of the net identifiable assets acquired, and liabilities assumed, as of the acquisition date. Subsequent to initial recognition, goodwill is measured at cost less accumulated impairment losses. Goodwill acquired in business combinations is allocated to groups of cash generating units (“CGU”) that are expected to benefit from the synergies of the combination. Impairment of long-lived assets Items of property, plant and equipment, right of use assets and identifiable intangible assets with finite lives that are subject to depreciation or amortization, respectively, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Intangible assets that are not subject to amortization are tested when there are indications that their carrying value may not be recoverable, or, at a minimum, annually. Management is required to assess at each reporting date whether there is any indication that an asset may be impaired. Where such an indication exists, the asset’s recoverable amount is compared to its carrying value, and an impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and value in use. For purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows, or CGU. In determining value in use of a given asset or CGU, estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Items of property, plant and equipment and identifiable intangible assets with finite lives that have suffered impairment are reviewed for possible reversal of the impairment if there has been a change, since the date of the most recent impairment test, in the estimates used to determine the impaired asset’s recoverable amount. However, an asset’s carrying amount, increased due to the reversal of a prior impairment loss, must not exceed the carrying amount that would have been determined, net of depreciation or amortization, had the original impairment not occurred. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Goodwill is not subject to amortization, but instead is tested for impairment annually or more often if there is an indication that the CGU to which the goodwill has been allocated may be impaired. Impairment is determined for goodwill by assessing whether the carrying value of a CGU, including the allocated goodwill, exceeds the CGU’s recoverable amount, which is the higher of fair value less costs to sell and the CGU’s value in use. Fair value less costs of disposal is determined based on the Company’s market capitalization, as well as relevant market data, such as control premiums, and other assumptions. In the event that the carrying amount of goodwill exceeds its recoverable amount, an impairment loss is recognized in an amount equal to the excess. Impairment losses related to goodwill, which are recorded in the consolidated statement of comprehensive loss, are not subsequently reversed. Provisions Provisions represent liabilities to the Company for which the amount or timing is uncertain. Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events, such as organizational restructuring, when it is probable that an outflow of resources will be required to settle the obligation and where the amount can be reliably estimated. Provisions are not recognized for future operating losses. Provisions are made for any contracts which are deemed onerous. A contract is onerous if the unavoidable costs of meeting the obligations under the contract exceed the economic benefits expected to be received under it. Provisions for onerous contracts are measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Present value is determined based on expected future cash flows that are discounted at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized in finance costs. Leases At the inception of a contract, the Company assesses whether a contract is or contains a lease. A lease is a contract in which the right to control the use of an identified asset is granted for an agreed-upon period of time in exchange for consideration. The Company assesses whether a contract conveys the right to control the use of an identified asset when there is both the right to direct the use of the asset and obtain substantially all the economic benefits from that use. The Company recognizes a right of use asset and a lease liability at the lease commencement date. The lease liability is initially measured at the present value of the non-cancellable lease payments over the lease term and discounted at the rate implicit in the lease. If that rate cannot be determined, the Company’s incremental borrowing rate, or the rate that Company would have to pay to borrow the funds necessary to obtain an asset of similar value in a similar economic environment with similar terms and conditions, is used. Lease payments include fixed payments and such variable payments that depend on an index or a rate less any lease incentives receivable. The lease liability is subsequently measured at amortized cost using the effective interest method and is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Company’s estimate of the amount expected to be payable under a residual value guarantee or if the Company changes its assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right of use asset, with any difference recorded in the statement of comprehensive loss. Right of use assets are measured at cost, which comprises the initial lease liability, lease payments made at or before the lease commencement date, initial direct costs and restoration obligations, less lease incentives. Right of use assets are subsequently measured at amortized cost. The assets are depreciated over the shorter of the assets’ useful life and the lease terms on a straight-line basis, less any accumulated impairment losses, and adjusted for any remeasurement of the lease liability. The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) The Company accounts for a lease modification as a separate lease if both of the following conditions exist: (a) the modification increases the scope of the lease by adding the right to use one or more underlying assets; and (b) the consideration for the lease increases by an amount equivalent to the standalone price for the increase in scope and any appropriate adjustments to that stand-alone price to reflect the circumstances of the particular contract. Where the Company accounts for a lease modification as a new lease, the separate lease is accounted for in the same way as a new lease, as described above. Where the Company does not account for a lease modification as a separate lease, the lease liability is remeasured by: (a) decreasing the carrying amount of the right of use asset to reflect the partial or full termination of the lease for lease modifications that decrease the scope of the lease, with any gain or loss relating to the partial or full termination of the lease recorded in the consolidated statement of comprehensive loss; or (b) making a corresponding adjustment to the right of use asset for all other lease modifications. Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in the consolidated statement of comprehensive loss. Employee benefits Salaries and other short-term benefits Salaries and other short-term benefit obligations are measured on an undiscounted basis and are recognized in the consolidated statement of comprehensive loss over the related service period or when the Company has a present legal or constructive obligation to make payments as a result of past events and when the amount payable can be estimated reliably. Post-employment benefits AEZS Germany provides unfunded and partially funded defined benefit multi-employer pension plans, namely the DUPK pension plan and the RUK 1990 and 2006 pension plans, (the “Pension Benefit Plans”) and unfunded post-employment benefit plans for certain groups of employees. Provisions for pension obligations are established for benefits payable in the form of retirement, disability and surviving dependent pensions. The Company also provides a defined contribution plans to some of its employees. For defined benefit pension plans and other post-employment benefits, net periodic pension expense is actuarially determined on a quarterly basis using the projected unit credit method. The cost of pension and other benefits earned by employees is determined by applying certain assumptions, including discount rates, rate of pension benefit increases, the projected age of employees upon retirement and the expected rate of future compensation. The employee future benefits liability is recognized at its present value, which is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid and that have terms to maturity approximating the terms of the related future benefit liability. Actuarial gains and losses that arise in calculating the present value of the defined benefit obligation are recognized in other comprehensive loss, net of tax, and simultaneously reclassified in the deficit in the consolidated statement of financial position in the year in which the actuarial gains and losses arise and without recycling to the consolidated statement of comprehensive loss in subsequent periods. For defined contribution plans, expenses are recorded in the consolidated statement of comprehensive loss as incurred–namely, over the period that the related employee service is rendered. Termination benefits Termination benefits are recognized in the consolidated statement of comprehensive loss when the Company is demonstrably committed, without the realistic possibility of withdrawal, to a formal detailed plan to terminate employment earlier than originally expected. Termination benefit liabilities expected to be settled after 12 months from the end of a given reporting period are discounted to their present value, where material. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Financial instruments The Company classifies its financial instruments in the following categories: financial assets at fair value through profit or loss (“FVTPL”); financial liabilities at FVTPL; financial assets at amortized cost; financial liabilities at amortized cost and financial assets at fair value through other comprehensive income (“FVTOCI”). Financial assets at FVTPL Financial liabilities at FVTPL Financial assets at amortized cost Financial liabilities at amortized cost Financial assets at FVTOCI Impairment of financial assets at amortized cost Share capital Common shares are classified as equity. Incremental costs that are directly attributable to the issuance of common shares are recognized as a deduction from equity, net of any tax effects. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Where offerings result in the issuance of units (where each unit is comprised of a common share of the Company and a warrant, exercisable in order to purchase a common share or fraction thereof) and the Company does not have the unconditional right to avoid delivering cash to the holders in the future, proceeds received in connection with those offerings are allocated between share capital and warrants. Transaction costs in connection with such offerings are allocated to the liability and equity unit components in proportion to the allocation of proceeds. Where offerings result in the issuance of units (where each unit is comprised of a common share of the Company and a warrant, exercisable in order to purchase a common share or fraction thereof) and the warrants issued meet the fixed-for-fixed criteria, discussed below, proceeds received in connection with those offerings are allocated between share capital and warrants based on the relative fair value method. Transaction costs in connection with such offerings are allocated to share capital and warrant components within equity in proportion to the allocation of proceeds. Warrants Warrants are classified as liabilities when the Company does not have the unconditional right to avoid delivering cash to the holders in the future, or when they can be settled with a variable number of common shares. Each of the Company’s warrants contains a written put option, arising upon the occurrence of a fundamental transaction, as that term is defined in the warrants, including a change of control. The warrant liability is initially measured at fair value, and any subsequent changes in fair value are recognized as gains or losses through profit or loss. Any transaction costs related to the warrants are expensed as incurred. Fair value of such warrants is determined at the issue date using the Black-Scholes option pricing model. The warrant liability is classified as non-current, unless the underlying warrants will expire or be settled within 12 months from the end of a given reporting period. When issued warrants meet the fixed-for-fixed criteria under IAS 32, Financial Instruments Share-based compensation costs The Company operates an equity-settled share-based compensation plan under which the Company receives services from directors, senior executives, employees and other collaborators as consideration for equity instruments of the Company. The Company accounts for all forms of share-based compensation using the fair value-based method. Fair value of stock options is determined at the date of grant using the Black-Scholes option pricing model, which includes estimates of the number of awards that are expected to vest over the vesting period. Where granted share options vest in installments over the vesting period (defined as graded vesting), the Company treats each installment as a separate share option grant. Share-based compensation expense is recognized over the vesting period, or as specified vesting conditions are satisfied, and credited to other capital. Any consideration received by the Company in connection with the exercise of stock options is credited to share capital. Any other capital component of the share-based compensation is transferred to share capital upon the issuance of shares. The Company grants deferred share units (“DSUs”) to members of its Board of Directors who are not employees or officers of the Company. DSUs cannot be redeemed until the holder is no longer a director of the Company and are considered equity-settled instruments. Under the terms of the DSU agreement, the DSUs vest immediately upon grant. The value attributable to the DSUs is based on the market value of the share price at the time of grant and share based compensation expense is recognized in general and administrative expenses in the consolidated statement of comprehensive loss. At the time of redemption, each DSU may be exchanged for one common share of the Company. Any consideration received by the Company in connection with the exercise of DSUs is credited to share capital. Any other capital component of the share-based compensation is transferred to share capital upon the issuance of shares. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Revenue recognition The Company generates revenue from license and collaboration agreements with customers (license fees, milestone revenue, royalties), the provision of development services, the sale of certain active pharmaceutical ingredients (“API”) and semi-finished goods and finished goods, and from certain supply chain activities, which are comprised largely of oversight or supervisory support services related to stability studies or development activities carried out with respect to API batch production as specified in underlying contracts with customers. The Company applies the provisions of IFRS 15, Revenue from Contracts with Customers The transaction price is allocated among the performance obligations on a relative standalone selling price basis, and the applicable revenue recognition criteria are applied to each of the separate performance obligations. Standalone selling prices may be estimated via methods that include, but are not limited to, an adjusted market assessment approach, an expected cost-plus-margin approach or a residual approach. Determining the standalone selling price for performance obligations requires significant judgment. The Company applies judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, for performance obligations satisfied over time, in concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in the Company’s estimated measure of progress are accounted for on a cumulative catch-up basis as a change in accounting estimate and are recorded in the consolidated statement of comprehensive loss in the period of adjustment. License fees If the license to the Company’s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Development services Arrangements that include a promise for the Company to provide development services are assessed to determine whether the services are capable of being distinct, are not highly interdependent or do not significantly modify one another, and if so, the services are accounted for as a separate performance obligation as the services are provided to the customer. Otherwise, when development services are determined not to be capable of being distinct, such services are added to the performance obligation that includes the underlying license. For development services that are combined with other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. Milestone payments At the inception of any contracts with a customer that includes milestone payments, which are oftentimes payable upon the successful achievement of development or regulatory events, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If the Company concludes it is highly probable that a significant revenue reversal will not occur, the associated milestone payment is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company reassesses the probability of achievement of milestones and any related constraints, and, if necessary, adjusts the estimate of the overall transaction price on a cumulative catch-up basis. Royalty payments For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. Product sales The Company recognizes revenue from the sale of certain API and semi-finished goods, including Macrilen TM Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Supply chain revenue Supply chain services are contracted with fixed fees and are provided over a period of time. The Company recognizes revenue on a straight-line basis over time as it best represents the pattern of performance of the services. While providing services, the Company incurs certain direct costs for subcontractors and other expenses that are recoverable directly from its customers. The recoverable amounts of these direct costs are included in the Company’s operating expenses as the Company controls the services before they are transferred to the customer and acts as a principal in these arrangements. Contract costs The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered, and any capitalized contract costs are amortized on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that it otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer. Contract modifications Contract modifications are defined in IFRS 15 as changes in the scope or price (or both) of a contract that are approved by the parties to the contract, such as a contract amendment. Contract modifications exist when the parties to a contract approve a modification that either creates new or changes existing enforceable rights and obligations of the parties to the contract. Depending on facts and circumstances, the Company accounts for a contract modification in one of the following ways: (a) as a separate contract; (b) as a termination of the existing contract and a creation of a new contract; or (c) as a combination of the preceding treatments. A contract modification is accounted for as a separate contract if the scope of the contract increases because of the addition of promised goods or services that are distinct and the price of the contract increases by an amount of consideration that reflects the Company’s standalone selling prices of the additional promised goods or services. When a contract modification is not considered a separate contract and the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification, the Company accounts for the contract modification as a termination of the existing contract and a creation of a new contract. When a contract modification is not considered a separate contract and the remaining goods or services are not distinct, the Company accounts for the contract modification as an add-on to the existing contract and as an adjustment to revenue on a cumulative catch-up basis. Income tax Income tax on profit or loss comprises current and deferred tax. Tax is recognized in profit or loss, except that a change attributable to an item of income or expense recognized as other comprehensive loss or directly in equity is also recognized directly in other comprehensive loss or directly in equity. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. The current income tax charge is calculated in accordance with tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company’s subsidiaries operate and generate taxable income. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Deferred income tax is recognized on temporary differences (other than, where applicable, temporary differences associated with unremitted earnings from foreign subsidiaries and associates, to the extent that the investment is essentially permanent in duration, and temporary differences associated with the initial recognition of goodwill) arising between the tax bases of assets and liabilities and their carrying amoun

Critical accounting estimates a

Critical accounting estimates and judgments	12 Months Ended
	Dec. 31, 2021
Critical accounting estimates and judgments	3. Critical accounting estimates and judgments The preparation of consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgments, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s consolidated financial statements are prepared. Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgments in order to ensure that the consolidated financial statements are presented fairly and in accordance with IFRS. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Critical accounting estimates and assumptions are those that have a significant risk of causing material adjustment and are often applied to matters or outcomes that are inherently uncertain and subject to change. As such, management cautions that future events often vary from forecasts and expectations and that estimates routinely require adjustment. The following discusses the most significant accounting estimates and assumptions that the Company has made in the preparation of the consolidated financial statements. Accounting for a contract modification The Novo Amendment, as defined and discussed in note 5 – License, supply and distribution arrangements, and which was determined to be a modification pursuant to the provisions of IFRS 15, required management to apply significant judgments, including: assessment of any increases to the scope of the license agreement; assessment of whether the remaining goods or services are distinct from goods or services transferred before the modification; and assessment as to whether a portion of the changes in the transaction price was attributable to the amount of variable consideration promised before the modification. Any changes in the judgments or assumptions applied to account for this agreement could have a significant impact on the Company’s revenue and deferred revenue. License and collaboration arrangements with multiple elements The Company enters into licensing and supply agreements related to the licensing, development, supply and distribution for macimorelin in various territories. Each agreement may contain specific terms or clauses that require careful analysis by management under IFRS 15 in order to ensure the appropriate accounting treatment is reached. The agreements may include non-refundable upfront payments and licensing fees, the provision of development services, pre- and post-commercialization milestone payments, royalties on future product sales derived from such license agreements, and supply arrangements. Management analyzes each agreement and applies significant judgment to determine whether contracts entered into at or near the same time should be accounted for as a single arrangement, whether all parts of the contract are scoped within IFRS 15, to identify all performance obligations, determine whether a performance obligation is distinct or should be combined with other promised goods and services, determine and allocate the transaction price on a relative stand-alone selling price basis, determine whether a combined performance obligation is satisfied at a point in time or over time, and, for performance obligations satisfied over time, in concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. Any changes in the judgments or assumptions applied can give rise to a significant impact on the Company’s revenues and deferred revenues Impairment of goodwill The annual impairment assessment related to goodwill requires management to estimate the recoverable amount, which has been determined using fair value less cost of disposal. The Company has a single cash generating unit and reportable segment, and management monitors goodwill based on an overall entity basis. The carrying amount of its consolidated net assets is compared to its overall market capitalization less estimated cost of disposal. Based on this calculation, including a control premium, management determined that goodwill was not impaired. Future events could cause the assumptions utilized in the impairment tests to change, resulting in a potentially adverse effect on the Company’s future results due to increased impairment charges. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Employee future benefits The determination of expenses and obligations associated with employee future benefits requires the use of assumptions, such as the discount rate to measure obligations, rate of pension benefit increases, the projected age of employees upon retirement and the expected rate of future compensation. Because the determination of the costs and obligations associated with employee future benefits requires the use of various assumptions, there is measurement uncertainty inherent in the actuarial valuation process. Actual results will differ from results that are estimated based on the aforementioned assumptions. Additional information is included in note 18 - Employee future benefits. Research and development accrual As part of the process of preparing our financial statements, we are required to estimate accrued expenses including those pertaining to our research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrued or prepaid expense balance accordingly. Although the Company does not expect estimates to be materially different from amounts actually incurred, if those estimates of the status and timing of services performed differ from the actual status and timing of services performed, the Company may report amounts that are too high or too low in any particular period.

Recent accounting pronouncement

Recent accounting pronouncements	12 Months Ended
	Dec. 31, 2021
Recent accounting pronouncements	4. Recent accounting pronouncements IFRS Pronouncements issued but not yet effective (a) IAS 37, Provisions, Contingent Liabilities and Contingent Assets The amendment to IAS 37 clarifies the meaning of costs to fulfil a contract and that before a separate provision for an onerous contract is established, an entity recognizes any impairment loss that has occurred on assets used in fulfilling the contract, rather than on assets dedicated to the contract. This amendment will be effective for annual periods beginning on or after January 1, 2022. The Company is currently evaluating this guidance and the impacts that the amendments may have on the Company’s consolidated financial statements.

Cash and cash equivalents

Cash and cash equivalents	12 Months Ended
	Dec. 31, 2021
Cash and cash equivalents	5. License, supply and distribution arrangements License and supply agreements for Macrilen™ - United States and Canada On January 16, 2018, the Company, through AEZS Germany, entered into License Agreement with Strongbridge Ireland Limited (“Strongbridge”) to carry out development, manufacturing, registration, regulatory and supply chain services for the commercialization of Macrilen™ (macimorelin) in the U.S. and Canada, which provides for (i) a right to use license relating to the adult indication (the “Adult Indication”); (ii) a license for a future FDA-approved pediatric indication (the “Pediatric Indication”); (iii) the licensee to fund 70% of the costs of a pediatric clinical trial submitted for approval to the EMA and FDA to be run by the Company with oversight from a joint steering committee (the “PIP”); and (iv) for an Interim Supply Arrangement. In January 2018, the Company received a cash payment of $ 24,000 5,000 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) On November 16, 2020, the Company, through AEZS Germany, entered into an amendment (the “Novo Amendment”) of its existing License Agreement with Novo related to the development and commercialization of macimorelin. Under the Novo Amendment, Aeterna continues to retain all rights to macimorelin outside of the U.S. and Canada but Novo agreed to make an upfront payment to Aeterna of $ 6,109 5,000 40 40 5,000 9,000 10,980 9,000 Under the amended terms, Novo was also granted co-ownership of the U.S. and Canadian patents and trademarks owned by Aeterna on macimorelin but will be required to transfer co-ownership in those patents back to Aeterna on the occurrence of certain termination events. Management has determined that the modification that grants co-ownership of the U.S. and Canadian patents and trademarks that were previously licensed by the Company to Novo is not a distinct performance obligation as the related benefits are highly interdependent and interrelated with the licensed indications granted under the existing license contract prior to the modification. In addition, upon regulatory approval of macimorelin in the U.S. for the diagnosis of CGHD, if Novo determines not to commercialize macimorelin in Canada, then Aeterna has the option to exclusively license rights to macimorelin in Canada (but not in U.S.) to a third party. The Amendment also confirms that Aeterna has the right to use the results from Study P02, if successful, to support Aeterna seeking regulatory approval and ongoing efforts to seek partnering opportunities for macimorelin in other regions outside of the two countries licensed to Novo, the U.S. and Canada. Analysis prior to modification At contract inception, upon analysis of the total discounted cash flows of both the $ 24,000 5,000 23,600 400 5.4 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Under the License Agreement, the Company considered the funding arrangement under the PIP to be a collaboration arrangement under IFRS 11 and has accounted for the invoicing as a reduction of costs incurred. During 2020, the Company invoiced its licensee $ 1,099 979 Analysis post modification On November 16, 2020, the Company announced that it had entered into the Novo Amendment of its existing License Agreement and received an upfront payment of $ 6,109 (€ 5,000 ) in December 2020. Management determined that the remaining performance obligation under the contract which provides the customer with the license of a future FDA approved Pediatric Indication is a distinct performance obligation before and after the modification. Accordingly, the Company accounted for the modification to the License Agreement as an adjustment to the existing License Agreement with Novo, on a prospective basis. The portion of the changes in the transaction price that was attributable to the change in royalty rate was allocated to both the Adult Indication and the Pediatric Indication. Based on the change in future royalty rates, the Company determined that $ 550 of the additional upfront payment should be allocated to the Adult Indication. Accordingly, the Company allocated $ 550 (€ 470 ) to the Adult Indication which was recognized in revenues for the year ended December 31, 2020 and deferred $ 5,559 (€ 4,530 ). As required per IFRS 11, given changes in facts and circumstances with respect to the development activities associated with the pediatric indication—namely, the substantive changes to rights and responsibilities granted to Novo pursuant to the Novo Amendment—management reassessed whether the classification of those activities should change. Management concluded that the parties to the Novo Amendment no longer share joint control of the related activities. As such, the Pediatric Indication development activities are no longer accounted for under IFRS 11, and the incremental performance obligation associated with the Pediatric Indication development services has been combined with the pediatric license for revenue recognition purposes. No other additional performance obligations were identified in the Novo Amendment. Based on the preceding analysis, management determined that the total modified transaction price was $ 5,754 (€ 4.7 million), which is comprised of $ 195 (€ 0.2 million) pre-Novo Amendment unamortized pediatric license fee and $ 5,559 (€ 4.5 million) post-Novo Amendment Pediatric Indication and has been allocated to the remaining combined performance obligation. Revenue associated with this performance obligation is being recognized as pediatric development services using a cost-to-cost measure of progress method. The transfer of control to Novo occurs over time, and as such, in management’s judgment, this input method is the best measure of progress towards satisfying the performance obligation and reflects a faithful depiction of the transfer of goods and services. As of December 31, 2021, management expects that the remaining performance obligation will be recognized through December 31, 2022. Management reevaluates the transaction price at the end of each reporting period or as changes in circumstances occur and adjusts the transaction price and the timing of recognition thereof as necessary. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Supply Chain Arrangement The Company agreed, in the Interim Supply Arrangement to the License Agreement, to supply ingredients for the manufacture of Macrilen™ (macimorelin) during an interim period at a price that is set ‘at cost’ without any profit margin. The Company believes the stand-alone selling price of the manufacturing ingredients to be their cost, as that approximates the amount at which Novo would be able to procure those same goods with other suppliers. In November 2019, Novo contracted with AEZS Germany, to provide supply chain services including provision of supervision of stability studies (support services) as well as API batch production and delivery of certain API and semi-finished goods. License and supply agreements for macimorelin - European Union and United Kingdom Background On December 7, 2020, the Company entered into an exclusive licensing agreement with Consilient Health Limited (“CH”) for the commercialization of macimorelin (the “Licensed Product”) in the European Economic Area and the United Kingdom (the “CH License Agreement”). Under the terms of the CH License Agreement, CH agreed to make a non-refundable, non-creditable upfront payment to the Company of $ 1,209 1.0 The total transaction price associated with the CH Agreement is $ 1,209 1.0 that the achievement of the underlying milestones is uncertain and highly susceptible to factors outside of the Company’s control. The Company allocated the transaction price to the two combined performance obligation of the license agreement and the supply agreement for the adult and pediatric indication, using the application of an adjusted market assessment approach. Revenue will be recognized over time using an outputs method based on units of Licensed Product supplied to CH. The total units that the Company expects to supply to CH pursuant to the CH Agreement is an estimate, based on current projections and anticipated market demand, and therefore will be a significant judgment that will be relied upon when using the outputs method to recognize revenue. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) In December 2021, the Department of Health and Social Care in the United Kingdom approved a list price which triggered a $ 226 0.2 The aggregate amount of the transaction price allocated to the Company’s unsatisfied or partially unsatisfied performance obligations under the CH Agreement was $ 1,358 1.2 For the year ended December 31, 2021, the Company recognized $nil as license fee revenue associated with the CH Agreement. License and supply agreements for macimorelin - Korea The Company and NK Meditech Limited (“NK”) entered into a licensing agreement, effective November 30, 2021 and pursuant to which the Company granted to NK the exclusive right to commercialize (including marketing, selling and offering to sell) macimorelin in the Republic of Korea (the “ROK”) and as applicable, in the Democratic People’s Republic of Korea (“DPRK”) to the extent NK is allowed to use the aforementioned licensed rights in the latter (“NK License Agreement”). Under the terms of the NK License Agreement, NK agreed to make a non-refundable, non-creditable upfront payment to the Company of $ 136 (€ 0.1 million), which the Company received in December 2021. The Company also is eligible to receive additional consideration, including a regulatory milestone related to the approval of macimorelin in the Pediatric Indication in the ROK and/or DPRK. Additionally, NK has agreed to pay AEZS royalties of 12% of any sublicense income (i.e., royalties, upfront payments, license or option fees, lump sum payments, equity securities, milestone payments or other non-cash consideration) that may be received by NK from any future sublicensees (“Sublicense Income”). Also , effective November 30, 2021, the Company and NK entered into an exclusive supply agreement, pursuant to which the Company agreed to provide macimorelin to NK for a period of ten years, subject to renewal (the “NK Supply Agreement”). Management determined that the total transaction price associated with the NK License Agreement was $ 136 (€ 0.1 million), which consists of the upfront payment, discussed above, that was received by the Company in 2021. T 136 (€ 0.1 million) transaction price to the single combined performance using an outputs method based on units of macimorelin supplied to NK over a 10-year period. Distribution agreement for macimorelin - Israel and the Palestinian Authority In June 2020, the Company entered into an exclusive distribution and quality agreement with MegaPharm Ltd. (“MegaPharm”) for the commercialization in Israel and in the Palestinian Authority of Macrilen TM TM Summary of revenue recognized, deferred revenue and contract asset balances associated with license, supply and distribution arrangements The following table provides a summary of deferred revenue balances for the Novo Amendment, CH Agreement and NK License Agreement as of December 31: Summary of Deferred Revenue 2021 Current Non-Current Total $ $ $ Novo Amendment 4,791 23 4,814 CH Agreement 24 1,334 1,358 NK License Agreement — 136 136 Total 4,815 1,493 6,308 2020 Current Non-Current Total $ $ $ Novo Amendment 2,193 3,289 5,482 Total 2,193 3,289 5,482 The following table provides a summary of revenue recognized for the Strongbridge agreement and Novo Amendment: Summary of Products Supplied Under Agreement 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ License fee associated with the Strongbridge Agreement — 68 74 License fee associated with the Novo Amendment (of which $ 1,670 264 nil 1,670 843 — Development services associated with Novo Amendment 3,337 — — Product sales associated with Novo Supply Agreement (of which $ nil 852 nil — 2,370 129 Royalties associated with the Strongbridge Agreement — 56 45 Royalties associated with the Novo Amendment 68 11 — Supply chain revenue associated with the Novo Supply Agreement (of which $ nil 67 nil 185 304 284 Total 5,260 3,652 532 As of December 31, 2021, the Company had $ 132 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) 6. Cash and cash equivalents Summary of Cash and Cash Equivalents 2021 2020 December 31, 2021 2020 $ $ Cash on hand and balances with banks 55,600 23,920 Interest-bearing deposits with maturities of three months or less 9,700 351 Cash and cash equivalents 65,300 24,271

Trade and other receivables

Trade and other receivables	12 Months Ended
	Dec. 31, 2021
Trade and other receivables	7. Trade and other receivables Schedule of Trade and Other Receivables 2021 2020 December 31, 2021 2020 $ $ Trade accounts receivable (net of expected credit losses of $ 55 55 877 1,190 Value added tax 372 468 Other receivables 65 23 Trade and other receivables 1,314 1,681 See also note 24 - Financial instruments and financial risk management for discussion of credit losses.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2021
Inventory	8. Inventory Summary of Inventory 2021 2020 December 31, 2021 2020 $ $ Work in process 73 21 Inventory 73 21 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) The Company recognized $ nil nil 1,980 131 101 106

Prepaid expenses and other curr

Prepaid expenses and other current assets	12 Months Ended
	Dec. 31, 2021
Prepaid expenses and other current assets	9. Prepaid expenses and other current assets Summary of Prepaid Expenses and Other Current Assets 2021 2020 December 31, 2021 2020 $ $ Prepaid insurance 421 1,021 Prepaid research and development 1,329 — Other 22 19 Prepaid expenses and other current assets 1,772 1,040

Restricted cash equivalents

Restricted cash equivalents	12 Months Ended
	Dec. 31, 2021
Restricted cash equivalents	10. Restricted cash equivalents The Company had restricted cash equivalents amounting to $ 335 338

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2021
Property, plant and equipment	11. Property, plant and equipment Components of the Company’s property, plant and equipment are summarized below. Summary of Property, Plant and Equipment Equipment Furniture and fixtures Computer equipment Leasehold improvements Total Cost Equipment Furniture and fixtures Computer equipment Leasehold improvements Total $ $ $ $ $ At January 1, 2020 422 7 314 34 777 Property, plant and equipment, Cost Beginning 422 7 314 34 777 Disposals / Retirements (245 ) (7 ) (3 ) (38 ) (293 ) Impact of foreign exchange rate changes 38 — 24 4 66 At December 31, 2020 215 — 335 — 550 Additions 6 — 24 — 30 Disposals / Retirements (5 ) — (69 ) — (74 ) Impact of foreign exchange rate changes (17 ) — (22 ) — (39 ) At December 31, 2021 199 — 268 — 467 Property, plant and equipment, Cost Ending 199 — 268 — 467 Equipment Furniture and fixtures Computer equipment Leasehold improvements Total Accumulated Depreciation Equipment Furniture and fixtures Computer equipment Leasehold improvements Total $ $ $ $ $ At January 1, 2020 400 7 307 28 742 Property, plant and equipment, Accumulated depreciation Beginning 400 7 307 28 742 Disposals / Retirements (247 ) (7 ) (3 ) (38 ) (295 ) Depreciation expense 6 — 3 — 9 Impact of foreign exchange rate changes 40 — 22 10 72 At December 31, 2020 199 — 329 — 528 Disposals / Retirements (5 ) — (69 ) — (74 ) Depreciation expense 4 — 5 — 9 Impact of foreign exchange rate changes (17 ) — (21 ) — (38 ) At December 31, 2021 181 — 244 — 425 Property, plant and equipment, Accumulated depreciation Ending 181 — 244 — 425 Carrying amount Equipment Furniture and fixtures Computer equipment Leasehold improvements Total $ $ $ $ $ At December 31, 2020 16 — 6 — 22 At December 31, 2021 18 — 24 — 42 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted)

Right of use assets

Right of use assets	12 Months Ended
	Dec. 31, 2021
Right of use assets	12. Right of use assets Schedule of Right of Use Assets Building Vehicles and equipment Total $ $ $ Cost At January 1, 2020 757 106 863 Modification of building lease (259 ) — (259 ) Additions — 7 7 Disposals — (21 ) (21 ) Impact of foreign exchange rate changes 48 2 50 At December 31, 2020 546 94 640 Additions 16 — 16 Modification of building lease 109 — 109 Impact of foreign exchange rate changes (48 ) (7 ) (55 ) At December 31, 2021 623 87 710 Building Vehicles and equipment Total $ $ $ Accumulated Depreciation At January 1, 2020 242 39 281 Disposals — (21) (21) Depreciation 180 23 203 Impact of foreign exchange rate changes 15 5 20 At December 31, 2020 437 46 483 Depreciation 94 26 120 Impact of foreign exchange rate changes (38) (5) (43) At December 31, 2021 493 67 560 Building Vehicles and equipment Total $ $ $ Carrying amount As of December 31, 2020 109 48 157 As of December 31, 2021 130 20 150 Effective August 25, 2021, the Company and its landlord mutually agreed to a one-year extension to its existing building lease agreement for its German subsidiary, continuing such terms until March 31, 2023, resulting in a modification being recorded to the building right of use asset in the amount of $ 109 259

Identifiable intangible assets

Identifiable intangible assets	12 Months Ended
	Dec. 31, 2021
Identifiable intangible assets	13. Identifiable intangible assets Changes in the carrying value of the Company’s identifiable intangible assets are summarized below. Summary of Identifiable Intangible Assets with Finite Useful Lives Year ended December 31, 2021 Year ended December 31, 2020 Cost Accumulated amortization Carrying value Cost Accumulated amortization Carrying value $ $ $ $ $ $ Balances – Beginning of the year 35,020 (34,961 ) 59 31,422 (31,382 ) 40 Additions 609 — 609 34 — 34 Amortization expense — (16 ) (16 ) — (20 ) (20 ) Impact of foreign exchange rate changes (3,218 ) 3,191 (27 ) 3,564 (3,559 ) 5 Balances – End of the year 32,411 (31,786 ) 625 35,020 (34,961 ) 59 During 2021, the Company recorded additions of $ 609 400 471 100 138 16 20 20 Cetrotide On August 10, 2021, the Company entered into a trademark maintenance and assignment option agreement with ARES Trading SA, a subsidiary of Merck KGaA (“Merck”), with respect to the trademarks owned by the Company on Cetrotide® (cetrorelix acetate for injection), a luteinizing hormone-releasing hormone antagonist approved for therapeutic use as part of in vitro fertilization programs in women undergoing infertility treatment (the “Cetrotide Agreement”). The Company had transferred all Cetrotide activities to Merck in 2013 via a license and supply agreement (“LSA”). Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Pursuant to the Cetrotide Agreement, the Company has granted to Merck the exclusive option to acquire any and all rights in the Cetrotide trademarks at the end of the term of the LSA (the “Option”), which currently is May 2029 (the “Transfer Date”), when, as agreed, the Company will convey and assign to Merck all rights and interest in, as well as title to, the Cetrotide trademarks. The transfer of the trademarks on the Transfer Date shall constitute a sale, after which the Company will no longer have any ownership in or obligations related to the Cetrotide trademarks. As consideration for having been granted the Option, Merck has agreed to pay the Company a total of $ 566 0.5 The carrying value of the trademarks underlying Cetrotide is $nil and the Company received proceeds of $ 98

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2021
Goodwill	14. Goodwill Summary of Change in Carrying Value of Goodwill Cost Accumulated impairment loss Carrying amount $ $ $ Balances at January 1, 2020 8,050 — 8,050 Impact of foreign exchange rate changes 765 — 765 Balances at December 31, 2020 8,815 — 8,815 Impact of foreign exchange rate changes (685 ) — (685 ) Balances at December 31, 2021 8,130 — 8,130 Management’s evaluation of impairment in goodwill is based on fair value less costs of disposal based on the Company’s market capitalization at December 31, 2021, including a control premium, less estimated cost of disposal of approximately $ 1,774 no

Payables and accrued liabilitie

Payables and accrued liabilities	12 Months Ended
	Dec. 31, 2021
Payables and accrued liabilities	15. Payables and accrued liabilities Schedule of Payables and Accrued Liabilities 2021 2020 December 31, 2021 2020 $ $ Trade accounts payable 934 1,187 Accrued research and development costs 531 23 Salaries, employment taxes and benefits 596 474 Other accrued liabilities 611 515 Payables and accrued liabilities 2,672 2,199 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted)

Provisions

Provisions	12 Months Ended
	Dec. 31, 2021
Provisions	16. Provisions Schedule of Changes in Provisions for Onerous Contracts Cetrotide onerous contracts German restructuring: severance Total $ $ $ Balance at January 1, 2020 396 330 726 Utilization of provision (93 ) (323 ) (416 ) Change in the provision 33 — 33 Unwinding of discount and impact of foreign exchange rate changes 35 (7 ) 28 Balance at December 31, 2020 371 — 371 Utilization of provision (90 ) — (90 ) Change in the provision 23 — 23 Unwinding of discount and impact of foreign exchange rate changes (27 ) — (27 ) Balance at December 31, 2021 277 — 277 Less: current portion 34 — 34 Non-current portion 243 — 243 In 2013, the Company recognized a provision for certain non-cancellable contracts related to the Cetrotide activities, discussed in note 13 – Identifiable intangible assets, that were deemed onerous. The provisions for onerous contracts represent the present value of estimated unavoidable future royalty and patent costs associated with the intellectual property underlying Cetrotide. On June 6, 2019, the Company announced that it was reducing the size of its German workforce to more closely reflect the Company’s ongoing commercial activities. This restructuring was completed on January 31, 2020.

Employee future benefits

Employee future benefits	12 Months Ended
	Dec. 31, 2021
Employee future benefits	17. Lease liabilities Schedule of Operating Lease Liabilities Years Ended December 31, 2021 2020 $ $ Balance – Beginning of period 184 903 Additions 15 7 Interest paid as charged to comprehensive loss as other finance costs (7 ) (19 ) Payment against lease liabilities (127 ) (265 ) Modification of lease liability 103 (463 ) Impact of foreign exchange rate changes (7 ) 21 Balance – End of period 161 184 Current lease liabilities 130 135 Non-current lease liabilities 31 49 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Effective March 31, 2020, the Company and its landlord mutually agreed to modify its existing building lease agreement for its German subsidiary, extended the lease term for its portion of the reduced space from April 30, 2021 to March 31, 2022 and retained one sub-lessee until April 30, 2021. On May 5, 2020, the sub-lessee terminated its lease with the Company effective April 30, 2020. Concurrent with this termination, the Company was able to renegotiate a further reduction in leased square footage with the landlord, which resulted in a lease modification and a resulting gain of $ 34 nil 34 Future lease payments as of December 31, 2021 are as follows: Summary of Maturity Analysis of Operating Lease Liabilities $ Less than 1 year 130 1 – 3 years 31 Total 161 18. Employee future benefits AEZS Germany provides unfunded and partially funded defined benefit multi-employer pension plans, namely the DUPK pension plan and the RUK 1990 and 2006 pension plans, (the “Pension Benefit Plans”) and unfunded post-employment benefit plans for certain groups of employees. Provisions for pension obligations are established for benefits payable in the form of retirement, disability and surviving dependent pensions. The Company also provides a defined contribution plans to some of its employees. The Pension Benefit Plans are final salary pension plans, which provide benefits to members (or to their surviving dependents) in the form of a guaranteed level of pension payable for life. The level of benefits provided depends on the member’s length of service and on the member’s base salary in the final years leading up to retirement. Current pensions vary in accordance with applicable statutory requirements, which foresee an adjustment every three years on an individual basis that is based on inflationary increases or in relation to salaries of comparable groups of active employees in the Company. Generally, the Company has not authorized actual pension increases, given the economic situation of the Company, and any legally required increases have been funded from the related pension surpluses. In 2020, the Company became responsible for pension increases for one of its Pension Benefit Plans and, in 2021, the Company became additionally responsible for pension increases for two of its Pension Benefit Plans. An increase may be denied by the Company if the Company’s financial situation does not allow for an increase in pensions. As most German pension plans grant lifelong pension benefits, rising life expectancy could increase the Company’s benefit obligation. These plans are fully or partially unfunded and the Company meets benefit payment obligations as they fall due. In the past, certain Pension Benefit Plans were accounted for as defined contribution plans as sufficient information was not available for the Company to account for its proportionate share of the defined benefit obligation, plan assets and cost associated with such Pension Benefit Plans. During 2021, additional information became available to the Company, which began to account for its proportionate share of the defined benefit obligation and plan assets amounting to $ 16,137 11,963 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) The change in the Company’s accrued benefit obligations associated with the Employee future obligation is summarized for the year ended December 31, 2021: Disclosure of Net Defined Benefit Liability (Asset) Pension Benefit Plans Other benefit Total $ $ $ Change in benefit obligation: Balances – Beginning of the year 15,341 94 15,435 Current service cost 60 5 65 Interest cost 87 1 88 Actuarial loss (gain) arising from changes in financial assumptions (1,138 ) 8 (1,130 ) Past service cost associated with multi-employer plan 16,137 — 16,137 Actuarial loss arising from change in current assumptions on funding of future pension increases 556 — 556 Benefits paid (509 ) (2 ) (511 ) Impact of foreign exchange rate changes (1,221 ) (7 ) (1,228 ) Balances – End of the year 29,313 99 29,412 Obligation is attributable to: Active members 4,242 99 4,341 Vested terminees 13,799 — 13,799 Retirees 11,272 — 11,272 29,313 99 29,412 Change in plan assets Balances – Beginning of the year — — — Presentation of plan assets as of December 31, 2021 11,963 — 11,963 Impact of foreign exchange rate changes (36 ) — (36 ) Balances – End of the year 11,927 — 11,927 Net liability of the unfunded plans 12,650 99 12,749 Net liability of the funded plans 4,736 — 4,736 Net amount recognized as Employee future benefits 17,386 99 17,485 Amounts recognized: In net loss (147 ) (6 ) (153 ) In other comprehensive (loss) 2,407 1 2,408 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) The cumulative amount of actuarial net losses recognized in other comprehensive loss as of December 31, 2021 is $ 9,385 5,793 5,143 The change in the Company’s accrued benefit obligations associated with the Employee future benefits is summarized for the years ended December 31, 2020 and 2019: Pension Benefit Plans Other benefit plans 2020 2019 2020 2019 $ $ $ $ Balances – Beginning of the year 13,704 13,100 84 105 Current service cost 50 41 4 8 Interest cost 162 239 1 2 Actuarial loss (gain) arising from changes in financial assumptions 650 1,068 1 (28 ) Benefits paid (529 ) (483 ) (3 ) — Impact of foreign exchange rate changes 1,304 (261 ) 7 (3 ) Balances – End of the year 15,341 13,704 94 84 Amounts recognized: In net loss (212 ) (280 ) (6 ) 18 In other comprehensive loss (1,954 ) (807 ) (7 ) 3 The Company’s proportionate share of the multi-employer pension plan assets as of December 31, 2021 is as follows: Schedule of Employer Pension Plan Asset $ Quoted equities (Level 1) 826 Quoted bonds (Level 1) 7,445 Cash (Level 1) 67 Real estate (Level 3) 2,207 Other (Level 3) 1,382 Total 11,927 The significant actuarial assumptions applied to determine the Company’s accrued benefit obligations are as follows: Summary of Significant Actuarial Assumptions Applied to Determine Accrued Benefit Obligations Pension Benefit Plans Other benefit plans Years ended December 31, Years ended December 31, Actuarial assumptions 2021 2020 2019 2021 2020 2019 % % % % % % Discount rate 1.10 0.60 1.10 1.10 0.60 1.90 Pension benefits increase 0.50 0.50 1.50 0.50 0.50 1.50 Rate of compensation increase 2.50 2.00 2.00 2.50 2.00 2.00 During 2020, management expanded its assumptions of possible future compensation scenarios from its current three-year forecast to a thirty-year forecast and from using an expected average inflation rate to an expected inflation rate. Additionally, the Company included the potential claims of retirees within the thirty-year time horizon. The Company expects to invest in its R&D opportunities, which would not change its economic situation in the short term but, if successful, does allow for scenarios that such pension increases would be owing. Such potential future pension compensation obligations have been included in the revised forecast assumptions, at a rate of 0.50 1.75 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Assumptions regarding future mortality are set based on actuarial advice in accordance with published statistics and experience in Germany. These assumptions translate into an average remaining life expectancy in years for a pensioner retiring at age 65: Summary of Assumptions Translate into an Average Remaining Life Expectancy in Years 2021 2020 2019 Retiring at the end of the reporting period: Male 21 20 20 Female 24 24 24 Retiring 20 years after the end of the reporting period: Male 28 28 28 Female 31 31 31 The most recent actuarial reports give effect to the pension and post-employment benefit obligations as of December 31, 2021. The next actuarial reports are planned for December 31, 2022. In accordance with the assumptions used as of December 31, 2021, undiscounted defined pension benefits expected to be paid are as follows: Summary of Undiscounted Defined Pension Benefits Expected to be Paid Total $ 2022 801 2023 823 2024 853 2025 868 2026 894 Thereafter 32,685 36,924 The weighted average duration of the defined benefit obligation is 16.0 If variations in the following assumptions had occurred during 2021, the impact on the Company’s pension benefit obligation of $ 29,313 Summary of Impact on Pension Benefit Obligation Assumption Increase Decrease (1,252 ) 1,338 Change in discount rate of 0.25 (1,252 ) 1,338 Change in salary rate of 0.25 18 (18 ) Change in pension rate assumption by 0.25 905 (867 ) Change mortality by one year 968 (974 ) Total expenses for the defined benefit plan that the Company accounts for as a defined contribution plan amounted to approximately $ 45 38 54 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted)

Share capital, warrants and oth

Share capital, warrants and other capital	12 Months Ended
	Dec. 31, 2021
Share Capital Warrants And Other Capital
Share capital, warrants and other capital	19. Share capital, warrants and other capital (a) Share capital The Company has an unlimited number of authorized common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value. 2021 During the year ended December 31, 2021, certain warrant holders exercised outstanding warrants to purchase 35,111,187 20.1 On February 19, 2021, the Company completed an underwritten public offering of 20,509,746 1.45 29,739 2,837 3,076,461 1.45 1,435,682 1.8125 February 17, 2026 On February 22, 2021, the Underwriter exercised the Underwriter Option and received 3,076,461 4,461 215,352 Aggregate gross proceeds received in connection with the February 2021 Financing totaled $ 34,200 3,221 1,897 2020 On February 21, 2020, the Company closed a registered direct offering for 3,478,261 1.29 2,608,696 1.20 243,478 1.62 3,900 4,500 2,325 2,174 600 311 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) On July 7, 2020, the Company closed a public offering of 26,666,666 0.45 10,596 26,666,666 26,666,666 0.45 July 7, 2025 1,866,667 0.5625 July 1, 2025 Because the warrants were classified as equity, the gross proceeds of $ 12,000 6,308 5,691 1,420 754 666 On August 5, 2020, the Company closed a securities purchase agreement of 12,427,876 0.56325 7,000 9,320,907 five and one-half years 0.47 869,952 0.7040625 August 3, 2025 7,000 3,944 3,056 748 327 421 2019 On September 20, 2019, the Company entered into a securities purchase agreement with US institutional investors to purchase $ 4,988 795 The combined purchase price for one common share and one warrant was $1.50 3,325,000 4,988 3,457 1,531 795 550 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Shareholder rights plan Effective May 8, 2019, the shareholders re-approved the Company’s shareholder rights plan (the “Rights Plan”) that provides the board of directors and the Company’s shareholders with additional time to assess any unsolicited take-over bid for the Company and, where appropriate, to pursue other alternatives for maximizing shareholder value. Under the Rights Plan, one right has been issued for each currently issued common share, and one right will be issued with each additional common share that may be issued from time to time. (b) Warrants Schedule of Warrants Activity Reclassified into Equity Weighted average exercise price Number ($) $ Balance – January 1, 2020 — — — Warrant liability reclassified to equity 16,368,033 0.8556 7,377 Warrants issued as equity 28,533,333 0.4574 5,025 Balance – December 31, 2020 44,901,366 0.6025 12,402 February 2021 Placement Agent Warrants 1,651,034 1.8125 1,897 Warrants exercised (35,111,187 ) 0.5725 (9,746 ) Allocation of transaction costs to share capital — — 532 Balance – December 31, 2021 11,441,213 0.8668 5,085 i) Warrants granted in 2021 The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of the February 2021 Placement Agent Warrants: Schedule of Fair Value of Warrants Assumptions Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield # $ $ (i) (ii) (iii) (iv) February 2021 Placement Agent Warrants issued on February 19, 2021 1,435,682 1.48 1.8125 0.58734 % 119.18 % 4.99 0.00 % February 2021 Placement Agent Warrants issued on February 22, 2021 215,352 1.48 1.8125 0.58544 % 119.57 % 4.98 0.00 % (i) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (ii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants. (iii) Based upon time to expiry from the issuance date. (iv) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) ii) Warrants exercised in 2021 During 2021, certain warrant holders exercised their warrants as follows: Summary of Warrants Exercise Transactions Warrants exercised (number of underlying common shares) Exercise Price Aggregate proceeds to the Company September 2019 Investor warrants 2,000,000 $ 1.65 $ 3,300 February 2020 Investor warrants 1,739,130 1.20 2,087 July 2020 Investor warrants 21,045,555 0.45 9,471 July 2020 Placement Agent warrants 1,866,667 0.5625 1,050 August 2020 Investor warrants 7,589,883 0.47 3,567 August 2020 Placement Agent warrants 869,952 0.7040625 612 35,111,187 $ 20,087 iii) Warrant liability reclassified to equity in 2020 The Company had issued 3,325,000 2,608,696 243,478 Effective June 16, 2020, the Company registered the common shares underlying these warrants by way of a registration statement which eliminated the cashless exercise option on the warrants, on a one-for-one basis. Accordingly, as of June 16, 2020, the warrant liability was remeasured at fair value using the Black-Scholes option pricing model, with the amount of the remeasurement loss recognized in the consolidated statement of comprehensive loss. The carrying value of the warrants was then reclassified from warrant liability to other capital within equity. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) The Company also issued 9,320,907 869,952 The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of such warrants as of the noted dates of reclassification: Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield ($) ($) (i) (ii) (iii) (iv) As of June 16, 2020: September 2019 Warrants 3,325,000 0.96 1.65 0.30 % 104.5 % 4.3 0.00 % February 2020 Investor Warrants 2,608,696 0.96 1.20 0.36 % 119.3 % 5.2 0.00 % February 2020 Placement Agent Warrants 243,478 0.96 1.62 0.32 % 113.3 % 4.7 0.00 % As of September 14, 2020: August 2020 Investor Warrants 9,320,907 0.38 0.47 0.31 % 120.5 % 5.4 0.00 % August 2020 Placement Agent Warrants 869,952 0.38 0.704063 0.26 % 114.6 % 4.9 0.00 % (i) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (ii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants, as well as on future expectations. (iii) Based upon time to expiry from the reporting period date. (iv) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) iv) Warrants issued as equity in 2020 On July 7, 2020, the Company closed a public offering of 26,666,666 0.45 10,596 26,666,666 26,666,666 1,866,667 The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of such warrants: Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield ($) ($) (i) (ii) (iii) (iv) July 2020 Investor Warrants 26,666,666 0.52 0.457 0.2879 % 123.1048 % 5 0.00 % July 2020 Placement Agent Warrants 1,866,667 0.52 0.5625 0.2879 % 123.1048 % 5 0.00 % (i) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (ii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants, as well as on future expectations. (iii) Based upon time to expiry from the reporting period date. (iv) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. (c) Other capital Long-term incentive plan At the 2018 annual and special meeting of shareholders, the Company’s shareholders approved the adoption of the 2018 long-term incentive plan (the “LTIP”), which allows the Board of Directors to issue up to 11.4 10 seven years Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) The Company settles stock options exercised through the issuance of new common shares as opposed to purchasing common shares on the market to settle stock option exercises. As of December 31, 2021, the total compensation cost related to unvested US dollar stock options not yet recognized amounted to $ 96 43 101 1.54 1.43 1.21 Disclosure of Change in Stock Options Issued Year ended December 31, 2021 Stock options Weighted average exercise price DSUs (Number) ($) (Number) Balance – January 1, 2021 506,400 1.44 173,000 Granted 580,000 0.42 280,000 Expired (32 ) 590.25 — Exercised — — (30,000 ) Balance – December 31, 2021 1,086,368 0.88 423,000 Year ended December 31, 2019 US$ Stock options Weighted average DSUs CAN$ Stock options Weighted average (Number) (US$) (Number) (Number) (CAN$) Balance – Beginning of year 727,816 4.07 161,000 869 743.56 Granted 185,000 1.07 150,000 — — Exercised (64,850 ) 2.75 (99,000 ) — — Canceled/Forfeited (6,000 ) 13.39 — — — Expired (100,850 ) 2.24 — (428 ) 570.00 Balance – End of year 741,116 3.61 212,000 441 912.00 Year ended December 31, 2020 US$ Stock options Weighted average exercise price DSUs CAN$ Stock options Weighted average exercise price (Number) (US$) (Number) (Number) (CAN$) Balance – Beginning of year 741,116 3.61 212,000 441 912.00 Granted 180,000 0.37 120,000 — — Exercised — — (159,000 ) — — Canceled/Forfeited (330,350 ) 2.56 — — — Expired (84,366 ) 2.14 — (441 ) 912.00 Balance – End of year 506,400 1.44 173,000 — — Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Fair value input assumptions for US dollar stock option grants The table below shows the assumptions, or weighted average parameters, applied to the Black-Scholes option pricing model in order to determine share-based compensation costs over the life of the awards. Summary of Assumptions to Determine Share-Based Compensation Costs Over the Life of Awards 2021 2020 2019 Years ended December 31, 2021 2020 2019 Expected dividend yield (a) 0.00 % 0.00 % 0.00 % Expected volatility (b) 115.80 % 112.50 % 110.02 % Risk-free annual interest rate (c) 1.23 % 0.27 % 1.86 % Expected life (years) (d) 5.71 4.02 5.94 Weighted average share price $ 0.42 $ 0.37 $ 2.00 Weighted average exercise price $ 0.42 $ 0.37 $ 2.00 Weighted average grant date fair value $ 0.35 $ 0.27 $ 2.00 _________________________ (a) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. (b) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations. (c) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options. (d) Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior. Schedule of Stock Options Exercise Price Range Options outstanding Options exercisable Range of US dollar stock option exercise prices Number (#) Weighted average remaining contractual life (years) Weighted average exercise price ($) Number (#) Weighted average remaining contractual life (years) Weighted average exercise price ($) 0.37 0.50 760,000 6.72 0.41 60,006 5.95 0.37 0.51 1.78 160,000 4.91 0.91 106,672 4.91 0.90 1.79 3.14 85,000 3.21 2.08 76,667 3.06 2.07 3.15 217.00 81,368 1.70 3.95 81,368 1.70 3.95 1,086,368 5.81 0.88 324,713 3.86 1.84 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted)

Operating expenses

Operating expenses	12 Months Ended
	Dec. 31, 2021
Operating expenses	20. Operating expenses The nature of the Company’s operating expenses includes the following: Schedule of Operating Expenses 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Key management personnel compensation (1) Salaries and short-term employee benefits (1) 1,646 1,540 1,705 Consultant’s fees (1) 163 167 194 Termination benefits (1) — — 503 Post-employment benefits, including defined contribution plan benefits of $ 33 33 195 (1) 70 86 257 Share-based compensation costs (1) 295 160 784 Key management personnel compensation (1) 2,174 1,953 3,443 Other employees compensation: Salaries and short-term employee benefits 1,160 1,004 1,257 Post-employment benefits, including defined contribution plan benefits of $ 15 9 25 139 159 78 Share-based compensation costs 16 (99 ) 9 Other employees compensation 1,315 1,064 1,344 Cost of inventory used and services provided 90 2,186 309 Professional fees 2,749 1,969 2,599 Insurance 1,077 861 890 Third-party research and development 5,047 414 322 Consulting fees 553 587 144 Restructuring costs — — 507 Travel 130 66 154 Marketing services 222 39 18 Laboratory supplies 114 36 23 Other goods and services 162 72 137 Leasing costs, net of sublease receipts of $ nil nil 214 112 218 247 Modification of building lease — (219 ) — (Reversal) impairment of other asset and inventory — (8 ) 270 Depreciation and amortization of property, equipment and intangibles 25 29 37 Depreciation - right to use assets 120 203 278 Impairment of right of use asset — — 22 Operating foreign exchange losses (gains) 41 (112 ) 30 Operating expenses excluding management and Employee compensation 10,442 6,341 5,987 Total operating expenses 13,931 9,358 10,774 ______________________ (1) Key management includes the Company’s executive management team and directors. Most of the employment agreements entered into between the Company and its executive officers include termination provisions, whereby the executive officers would be entitled to receive benefits that would be payable if the Company were to terminate the executive officers’ employment without cause or if their employment is terminated following a change of control. Separation benefits generally are calculated based on an agreed-upon multiple of applicable base salary and incentive compensation and, in certain cases, other benefit amounts. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted)

Supplemental disclosure of cash

Supplemental disclosure of cash flow information	12 Months Ended
	Dec. 31, 2021
Supplemental disclosure of cash flow information	21. Supplemental disclosure of cash flow information Disclosure of Changes in Operating Assets and Liabilities 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Changes in operating assets and liabilities: Trade and other receivables 120 (1,023 ) (371 ) Inventory (56 ) 1,182 (971 ) Prepaid expenses and other current assets (750 ) (702 ) (170 ) Payables and accrued liabilities 634 51 (615 ) Income taxes payable (109 ) 395 (188 ) Deferred revenues 3,010 3,031 743 Provision for restructuring and other costs — — (389 ) Employee future benefits (note 18) (349 ) (532 ) (483 ) Increase (decrease) in operating assets and liabilities 2,500 2,402 (2,444 )

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2021
Income Taxes
Income taxes	22. Income taxes Significant components of the current and deferred income tax recovery (expense) for the years ended December 31, 2021, 2020 and 2019 are as follows: Summary of Significant Components of Current and Deferred Income Tax Recovery (Expense) 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Current income tax recovery (expense) 109 (395 ) 188 Deferred tax: Origination and reversal of temporary differences 1,291 1,509 2,755 Change in unrecognized tax assets (1,291 ) (1,509 ) (2,755 ) Total income tax recovery (expense) 109 (395 ) 188 From time to time, the Company is subject to tax audits. While the Company believes that its filing positions are appropriate and supportable, periodically, certain matters are challenged by tax authorities. Although the Company believes its tax provisions are adequate, the final determination of tax audits and any related disputes could be materially different from historical income tax provisions and accruals. In 2020, AEZS Germany underwent a tax audit regarding the taxation years 2013 to 2016. As of December 31, 2021, the tax authorities concluded the audit for those years. The subsequent years remain unaudited, and the Company has accrued $ 115 1,605 1,448 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) The reconciliation of the combined Canadian federal and provincial corporate income tax rate to the income tax expense is provided below: Summary of Reconciliation of Combined Canadian Federal and Provincial Income Tax Rate to Income Tax Expense 2021 2020 2019 Years ended December 31, 2021 2020 2019 Combined Canadian federal and provincial statutory income tax rate 26.5 % 26.5 % 26.5 % 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Income tax (expense) recovery based on combined statutory income tax rate 2,246 1,252 1,615 Change in unrecognized tax assets (1,291 ) (1,872 ) (2,820 ) Share issuance costs 367 363 65 Permanent difference attributable to the use of local currency for tax reporting — — 35 Change in enacted rates used — — (27 ) Impact of expiring tax credits (1,724 ) (481 ) — Provision to filed return adjustments 151 — — Permanent difference attributable to net change in fair value of warrant liability — 304 1,197 Share-based compensation costs (82 ) (16 ) (210 ) Difference in statutory income tax rate of foreign subsidiaries 226 99 321 Uncertain tax position — (123 ) — Other 216 79 12 Total income tax (expense) recovery 109 (395 ) 188 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) (Loss) income before income taxes (Loss) income before income taxes is attributable to the Company’s tax jurisdictions as follows: Summary of (Loss) Income Before Income Taxes 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Germany (4,383 ) (2,042 ) (6,010 ) Canada (3,860 ) (2,463 ) 812 United States (234 ) (218 ) (1,032 ) Loss before income taxes (8,477 ) (4,723 ) (6,230 ) Significant components of deferred tax assets and liabilities are as follows: Summary of Significant Components of Deferred Tax Assets and Liabilities 2021 2020 December 31, 2021 2020 $ $ Deferred tax assets Operating losses carried forward 205 46 Intangible assets 776 1,318 Deferred tax assets 981 1,364 Deferred tax liabilities Accounts receivable 375 — Payables and accrued liabilities 7 126 Property, plant and equipment 47 49 Deferred revenues 492 1,073 Other 60 116 Deferred tax liabilities 981 1,364 Deferred tax liabilities, net 981 1,364 Deferred tax assets (liabilities), net — — Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Significant components of deferred tax assets and losses are as follows: Summary of Significant Components of Unrecognized Deferred Tax Assets 2021 2020 December 31, 2021 2020 $ $ Unrecognized deferred tax assets Deferred revenues and other provisions 1,680 1,494 Operating losses carried forward 87,734 89,144 Capital losses carried forward 105 — SR&ED Pool 9,138 9,138 Unused tax credits 2,945 4,668 Employee future benefits 3,396 2,570 Property, plant and equipment 523 495 Intangible assets — 541 Share issuance expenses 1,110 623 Other 84 — Unrecognized deferred tax assets, gross 106,715 108,673 Unrecognized deferred tax assets 106,715 108,673 Deferred income tax assets are recognized to the extent that the realization of the related tax benefit through reversal of temporary differences and future taxable profits is probable. Based on the current forecasted future taxable profits and reversal of temporary differences, the company does not believe it will have sufficient future earnings to offset the deferred tax assets and has an unrecognized deferred tax asset balance of $ 106,715 As at December 31, 2021, the Corporation has total accumulated non-capital losses of $ 77,867 76,545 Summary of Disclosure of Federal Tax Losses Federal Provincial Canada Federal Provincial $ $ 2028 8,054 6,668 2029 4,791 4,773 2030 4,104 4,089 2031 1,753 1,737 2032 4,250 4,250 2033 3,721 3,721 2034 4,153 4,153 2035 10,418 10,452 2036 10,592 10,592 2037 7,343 7,343 2038 6,557 6,557 2039 3,501 3,580 2040 3,808 3,808 2041 4,822 4,822 Tax attributes to be deferred for which no deferred tax asset was recognized 77,867 76,545 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) The Company has non-refundable R&D investment tax credits of approximately $ 4,006 210,709 185,271 4,793 United States $ 2028 369 2029 178 2034 151 2035 447 2036 195 2037 709 2038 1,224 2039 771 2040 515 2041 234 Unused tax losses for which no deferred tax asset recognized 4,793 The operating loss carryforwards and the tax credits claimed are subject to review, and potential adjustment, by tax authorities. Other deductible temporary differences for which tax assets have not been booked are not subject to a time limit, except for share issuance expenses which are amortizable over five years.

Capital disclosures

Capital disclosures	12 Months Ended
	Dec. 31, 2021
Capital disclosures	23. Capital disclosures The Company’s objective in managing capital, consisting of shareholders’ equity, with cash and cash equivalents and restricted cash equivalents being its primary components, is to ensure sufficient liquidity to fund R&D costs, selling expenses, general and administrative expenses and working capital requirements. Over the past several years, the Company has raised capital via public and private equity offerings and issuances as its primary source of liquidity, as discussed in note 19 - share capital, warrants and other capital. The capital management objective of the Company remains the same as that in previous periods. The policy on dividends is to retain cash to keep funds available to finance the activities required to advance the Company’s product development portfolio and to pursue appropriate commercial opportunities as they may arise. The Company is not subject to any capital requirements imposed by any regulators or by any other external source. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted)

Financial instruments and finan

Financial instruments and financial risk management	12 Months Ended
	Dec. 31, 2021
Financial instruments and financial risk management	24. Financial instruments and financial risk management Financial assets and liabilities as of December 31, 2021 and December 31, 2020 are presented below. Disclosure of Fair Value Measurement of Assets December 31, 2021 Financial assets at amortized cost Financial liabilities at amortized cost $ $ Cash and cash equivalents (note 6) 65,300 — Trade and other receivables (note 7) 1,314 — Restricted cash equivalents (note 10) 335 — Payables and accrued liabilities (note 15) — 1,530 Lease liability (note 17) — 161  66,949 1,691 December 31, 2020 Financial assets at amortized cost Financial liabilities at amortized cost $ $ Cash and cash equivalents (note 6) 24,271 — Trade and other receivables (note 7) 1,681 — Restricted cash equivalents (note 10) 338 — Payables and accrued liabilities (note 15) — 2,176 Lease liability (note 17) — 184 26,290 2,360 Fair value IFRS 13, Fair Value Measurement The input levels discussed in IFRS 13 are: Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than quoted prices included within Level 1 that are observable for an asset or liability, either directly (i.e. prices) or indirectly (i.e. derived from prices). Level 3 – Inputs for an asset or liability that are not based on observable market data (unobservable inputs). The carrying values of the Company’s cash and cash equivalents, trade and other receivables, restricted cash equivalents, payables and accrued liabilities and provision for restructuring and other costs approximate their fair values due to their short-term maturities or to the prevailing interest rates of the related instruments, which are comparable to those of the market. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Financial risk factors The following provides disclosures relating to the nature and extent of the Company’s exposure to risks arising from financial instruments, including credit risk, liquidity risk and foreign exchange risk and how the Company manages those risks. (a) Credit risk Credit risk is the risk of an unexpected loss if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company regularly monitors credit risk exposure and takes steps to mitigate the likelihood of this exposure resulting in losses. The Company’s exposure to credit risk currently relates to the financial assets at amortized cost in the table above. The Company holds its available cash in amounts that are readily convertible to known amounts of cash and deposits its cash balances with financial institutions that have an investment grade rating of at least “P-2” or the equivalent. This information is supplied by independent rating agencies where available and, if not available, the Company uses publicly available financial information to ensure that it invests its cash in creditworthy and reputable financial institutions. Once there are indicators that there is no reasonable expectation of recovery, such financial assets are written off but are still subject to enforcement activity. As of December 31, 2021, trade accounts receivable for an amount of approximately $ 932 55 1,245 55 Generally, the Company does not require collateral or other security from customers for trade accounts receivable; however, credit is extended following an evaluation of creditworthiness. In addition, the Company performs ongoing credit reviews of all of its customers and determines expected credit losses. On this basis, as of December 31, 2021, the Company has provided for all outstanding and unpaid amounts relating to its operations before its licensing of Macrilen TM The maximum exposure to credit risk approximates the amount recognized in the Company’s consolidated statement of financial position. (b) Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. As indicated in note 24, the Company manages this risk through the management of its capital structure. It also manages liquidity risk by continuously monitoring actual and projected cash flows. A portion of the Company’s cash is held in AEZS Germany, which is the counter-party to various license and distribution agreements for the Company’s only approved product. In September 2019 and February, July and August of 2020 and February of 2021 the Company completed financings resulting in total funding (net of transaction costs) of $ 55,905 5,000 6,109 1,000 1,209 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) The Board of Directors reviews and approves the Company’s operating and capital budgets, as well as any material transactions occurring outside of the ordinary course of business. The Company has adopted an investment policy in respect of the safety and preservation of its capital to ensure the Company’s liquidity needs are met. The instruments are selected with regard to the expected timing of expenditures and prevailing interest rates. All of the Company’s financial liabilities except lease liabilities are current liabilities with expected settlement dates within one year. The maturity analysis for lease liabilities is disclosed in note 17. (c) Foreign exchange risk Entities using the Euro as their functional currency The Company is exposed to foreign exchange risk due to its investments in foreign operations whose functional currency is the Euro. As of December 31, 2021, if the US dollar had increased or decreased by 10% against the Euro 300 110 841

Segment information

Segment information	12 Months Ended
	Dec. 31, 2021
Segment Information
Segment information	25. Segment information The Company operates in a single Geographical information Revenues by geographical area have been allocated to geographic regions based on the country of residence of the Company’s external customers or licensees and are detailed as follows: Summary of Revenues by Geographical Area 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Switzerland 5,075 905 — Ireland — 73 74 Denmark 185 2,655 413 Other — 19 45 Revenue 5,260 3,652 532 Non-current assets include restricted cash equivalents, right of use assets, property, plant and equipment, identifiable intangible assets, other asset and goodwill and are detailed by geographical area as follows: Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Summary of Non-current Assets by Geographical Area 2021 2020 December 31, 2021 2020 $ $ Germany 9,212 9,341 United States 70 50 Non-current assets 9,282 9,391 Major customers representing 10% or more of the Company’s revenues in each of the last three years are as follows: Summary of Major Customers 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Company 1 5,260 3,634 532

Net loss per share

Net loss per share	12 Months Ended
	Dec. 31, 2021
Net loss per share	26. Net loss per share The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Summary of Pertinent Data Relating to Computation of Basic and Diluted Net Loss Per Share 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Net loss (8,368 ) (5,118 ) (6,042 ) Basic weighted average number of shares outstanding 114,924,497 41,083,163 17,494,472 Diluted weighted average number of shares outstanding 114,924,497 41,083,163 17,494,472 Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect Stock options and DSUs 1,509,368 679,400 953,557 Share purchase warrants 11,441,213 44,901,366 6,629,144 Anti-dilutive shares Net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during the relevant period. Diluted weighted average number of shares reflects the dilutive effect of equity instruments, such as any “in the money” stock options, DSUs and warrants. In periods with reported net losses, all stock options and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal, and thus “in the money” stock options and warrants have not been included in the computation of net loss per share because to do so would be anti-dilutive. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted)

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and contingencies	27. Commitments and contingencies Contractual obligations and commitments as of December 31, 2021 Schedule of Expected Future Minimum Lease Payments Service and manufacturing R&D contracts TOTAL $ $ $ Less than 1 year 1,085 2,252 3,337 1 – 3 years 6 1,049 1,055 4 – 5 years — — — More than 5 years — — — Total 1,091 3,301 4,392 During 2021, the Company executed various agreements including in-licensing and similar arrangements with development partners (note 13). Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty. The Company recognizes research and development milestones as an intangible asset once it is committed to the payment, which is generally when the Company reaches a set point in the development cycle. Based on the closing exchange rates at December 31, 2021, the Company expects to pay $ 3,301 8,937 32,942 Schedule of R&D and Revenue Related Milestone Payments Future potential R&D milestone payments Future potential revenue milestone payments Total $ $ $ Less than 1 year 28 — 28 1 – 3 years 113 — 113 4 – 5 years 927 — 927 More than 5 years 7,869 32,942 40,811 Total 8,937 32,942 41,879 The table excludes any payments already capitalized in the consolidated statement of financial position. The future payments that are disclosed represent contract payments and are not discounted and are not risk-adjusted. The development of any pharmaceutical product candidates is a complex and risky process that may fail at any stage in the development process due to a number of factors. The timing of the payments is based on the Company’s current best estimate of achievement of the relevant milestone. Securities class action lawsuit On March 9, 2020, the Company settled the previously disclosed class-action lawsuit against it pending in the US District Court for the District of New Jersey. This settlement was approved by the US District Court for the District of New Jersey on June 3, 2021. The settlement payment was funded entirely by the Company’s insurers. As no appeals were filed within the 30-day appeal period, this matter is fully and finally settled.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
	Dec. 31, 2021
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents consist of unrestricted cash on hand and balances with banks, as well as short-term interest-bearing deposits, such as money market accounts, that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value, with a maturity of three months or less from the date of acquisition.
Inventories	Inventories Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company’s policy is to write down inventory that has become obsolete and inventory that has a cost basis in excess of its expected net realizable value. Increases in the reserve are recorded as charges in cost of sales. For product candidates that have not been approved by the FDA, inventory used in clinical trials is written down at the time of production and recorded as research and development (“R&D”) costs. For products that have been approved by the FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the clinical trial. All direct manufacturing costs incurred after approval are capitalized into inventory.
Restricted cash equivalents	Restricted cash equivalents Restricted cash equivalents are comprised of bank deposits, which are related to a guarantee for a long-term operating lease obligation, and for corporate credit card programs that cannot be used for current purposes.
Property, plant and equipment and depreciation	Property, plant and equipment and depreciation Items of property, plant and equipment are recorded at cost, net of accumulated depreciation and impairment charges. Depreciation is calculated using the following methods, annual rates and period: Summary of Depreciation Using Methods, Annual Rates and Period Methods Annual rates and period Equipment Declining balance and straight-line 20% Furniture and fixtures Declining balance and straight-line 10% to 20% Computer equipment Straight-line 25% to 33 1 Leasehold improvements Straight-line Remaining lease term Depreciation expense, which is recorded in the consolidated statement of comprehensive loss, is allocated to the appropriate functional expense categories to which the underlying items of property, plant and equipment relate.
Identifiable intangible assets and amortization	Identifiable intangible assets and amortization Identifiable intangible assets with finite useful lives consist of in-process R&D acquired in business combinations, patents, trademarks, in-licensed technology and rights to serialization equipment located at the Company’s third-party macimorelin manufacturer. In-process R&D acquired in business combinations is recognized at fair value at the acquisition date. Patents and trademarks are comprised of costs, including professional fees incurred in connection with the filing of patents and the registration of trademarks for product marketing and manufacturing purposes, net of related government grants, impairment losses and accumulated amortization. Identifiable intangible assets with finite useful lives are amortized beginning at the time at which the assets are available for use, on a straight-line basis over the assets’ estimated useful lives, which range from seven to 15 years for in-process R&D and patents and are ten years for trademarks. Amortization expense, which is recorded in the consolidated statement of comprehensive loss, is allocated to the appropriate functional expense categories to which the underlying identifiable intangible assets relate. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Contingent payments The Company accounts for contingent variable payments for separately acquired intangible assets, such as in-licensed technology, under the cost accumulation approach. Contingent consideration is not considered on initial recognition of the asset but instead is added to the cost of the asset initially recorded, when incurred.
Goodwill	Goodwill Goodwill is recognized as the fair value of the consideration transferred, including the recognized amount of any non-controlling interest in the acquiree, less the fair value of the net identifiable assets acquired, and liabilities assumed, as of the acquisition date. Subsequent to initial recognition, goodwill is measured at cost less accumulated impairment losses. Goodwill acquired in business combinations is allocated to groups of cash generating units (“CGU”) that are expected to benefit from the synergies of the combination.
Impairment of long-lived assets	Impairment of long-lived assets Items of property, plant and equipment, right of use assets and identifiable intangible assets with finite lives that are subject to depreciation or amortization, respectively, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Intangible assets that are not subject to amortization are tested when there are indications that their carrying value may not be recoverable, or, at a minimum, annually. Management is required to assess at each reporting date whether there is any indication that an asset may be impaired. Where such an indication exists, the asset’s recoverable amount is compared to its carrying value, and an impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs to sell and value in use. For purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows, or CGU. In determining value in use of a given asset or CGU, estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. Items of property, plant and equipment and identifiable intangible assets with finite lives that have suffered impairment are reviewed for possible reversal of the impairment if there has been a change, since the date of the most recent impairment test, in the estimates used to determine the impaired asset’s recoverable amount. However, an asset’s carrying amount, increased due to the reversal of a prior impairment loss, must not exceed the carrying amount that would have been determined, net of depreciation or amortization, had the original impairment not occurred. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Goodwill is not subject to amortization, but instead is tested for impairment annually or more often if there is an indication that the CGU to which the goodwill has been allocated may be impaired. Impairment is determined for goodwill by assessing whether the carrying value of a CGU, including the allocated goodwill, exceeds the CGU’s recoverable amount, which is the higher of fair value less costs to sell and the CGU’s value in use. Fair value less costs of disposal is determined based on the Company’s market capitalization, as well as relevant market data, such as control premiums, and other assumptions. In the event that the carrying amount of goodwill exceeds its recoverable amount, an impairment loss is recognized in an amount equal to the excess. Impairment losses related to goodwill, which are recorded in the consolidated statement of comprehensive loss, are not subsequently reversed.
Provisions	Provisions Provisions represent liabilities to the Company for which the amount or timing is uncertain. Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events, such as organizational restructuring, when it is probable that an outflow of resources will be required to settle the obligation and where the amount can be reliably estimated. Provisions are not recognized for future operating losses. Provisions are made for any contracts which are deemed onerous. A contract is onerous if the unavoidable costs of meeting the obligations under the contract exceed the economic benefits expected to be received under it. Provisions for onerous contracts are measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Present value is determined based on expected future cash flows that are discounted at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized in finance costs.
Leases	Leases At the inception of a contract, the Company assesses whether a contract is or contains a lease. A lease is a contract in which the right to control the use of an identified asset is granted for an agreed-upon period of time in exchange for consideration. The Company assesses whether a contract conveys the right to control the use of an identified asset when there is both the right to direct the use of the asset and obtain substantially all the economic benefits from that use. The Company recognizes a right of use asset and a lease liability at the lease commencement date. The lease liability is initially measured at the present value of the non-cancellable lease payments over the lease term and discounted at the rate implicit in the lease. If that rate cannot be determined, the Company’s incremental borrowing rate, or the rate that Company would have to pay to borrow the funds necessary to obtain an asset of similar value in a similar economic environment with similar terms and conditions, is used. Lease payments include fixed payments and such variable payments that depend on an index or a rate less any lease incentives receivable. The lease liability is subsequently measured at amortized cost using the effective interest method and is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Company’s estimate of the amount expected to be payable under a residual value guarantee or if the Company changes its assessment of whether it will exercise a purchase, extension or termination option. When the lease liability is remeasured, a corresponding adjustment is made to the carrying amount of the right of use asset, with any difference recorded in the statement of comprehensive loss. Right of use assets are measured at cost, which comprises the initial lease liability, lease payments made at or before the lease commencement date, initial direct costs and restoration obligations, less lease incentives. Right of use assets are subsequently measured at amortized cost. The assets are depreciated over the shorter of the assets’ useful life and the lease terms on a straight-line basis, less any accumulated impairment losses, and adjusted for any remeasurement of the lease liability. The lease term includes periods covered by an option to extend if the Company is reasonably certain to exercise that option. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) The Company accounts for a lease modification as a separate lease if both of the following conditions exist: (a) the modification increases the scope of the lease by adding the right to use one or more underlying assets; and (b) the consideration for the lease increases by an amount equivalent to the standalone price for the increase in scope and any appropriate adjustments to that stand-alone price to reflect the circumstances of the particular contract. Where the Company accounts for a lease modification as a new lease, the separate lease is accounted for in the same way as a new lease, as described above. Where the Company does not account for a lease modification as a separate lease, the lease liability is remeasured by: (a) decreasing the carrying amount of the right of use asset to reflect the partial or full termination of the lease for lease modifications that decrease the scope of the lease, with any gain or loss relating to the partial or full termination of the lease recorded in the consolidated statement of comprehensive loss; or (b) making a corresponding adjustment to the right of use asset for all other lease modifications. Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in the consolidated statement of comprehensive loss.
Employee benefits	Employee benefits Salaries and other short-term benefits Salaries and other short-term benefit obligations are measured on an undiscounted basis and are recognized in the consolidated statement of comprehensive loss over the related service period or when the Company has a present legal or constructive obligation to make payments as a result of past events and when the amount payable can be estimated reliably. Post-employment benefits AEZS Germany provides unfunded and partially funded defined benefit multi-employer pension plans, namely the DUPK pension plan and the RUK 1990 and 2006 pension plans, (the “Pension Benefit Plans”) and unfunded post-employment benefit plans for certain groups of employees. Provisions for pension obligations are established for benefits payable in the form of retirement, disability and surviving dependent pensions. The Company also provides a defined contribution plans to some of its employees. For defined benefit pension plans and other post-employment benefits, net periodic pension expense is actuarially determined on a quarterly basis using the projected unit credit method. The cost of pension and other benefits earned by employees is determined by applying certain assumptions, including discount rates, rate of pension benefit increases, the projected age of employees upon retirement and the expected rate of future compensation. The employee future benefits liability is recognized at its present value, which is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid and that have terms to maturity approximating the terms of the related future benefit liability. Actuarial gains and losses that arise in calculating the present value of the defined benefit obligation are recognized in other comprehensive loss, net of tax, and simultaneously reclassified in the deficit in the consolidated statement of financial position in the year in which the actuarial gains and losses arise and without recycling to the consolidated statement of comprehensive loss in subsequent periods. For defined contribution plans, expenses are recorded in the consolidated statement of comprehensive loss as incurred–namely, over the period that the related employee service is rendered. Termination benefits Termination benefits are recognized in the consolidated statement of comprehensive loss when the Company is demonstrably committed, without the realistic possibility of withdrawal, to a formal detailed plan to terminate employment earlier than originally expected. Termination benefit liabilities expected to be settled after 12 months from the end of a given reporting period are discounted to their present value, where material. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted)
Financial instruments	Financial instruments The Company classifies its financial instruments in the following categories: financial assets at fair value through profit or loss (“FVTPL”); financial liabilities at FVTPL; financial assets at amortized cost; financial liabilities at amortized cost and financial assets at fair value through other comprehensive income (“FVTOCI”). Financial assets at FVTPL Financial liabilities at FVTPL Financial assets at amortized cost Financial liabilities at amortized cost Financial assets at FVTOCI Impairment of financial assets at amortized cost
Share capital	Share capital Common shares are classified as equity. Incremental costs that are directly attributable to the issuance of common shares are recognized as a deduction from equity, net of any tax effects. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Where offerings result in the issuance of units (where each unit is comprised of a common share of the Company and a warrant, exercisable in order to purchase a common share or fraction thereof) and the Company does not have the unconditional right to avoid delivering cash to the holders in the future, proceeds received in connection with those offerings are allocated between share capital and warrants. Transaction costs in connection with such offerings are allocated to the liability and equity unit components in proportion to the allocation of proceeds. Where offerings result in the issuance of units (where each unit is comprised of a common share of the Company and a warrant, exercisable in order to purchase a common share or fraction thereof) and the warrants issued meet the fixed-for-fixed criteria, discussed below, proceeds received in connection with those offerings are allocated between share capital and warrants based on the relative fair value method. Transaction costs in connection with such offerings are allocated to share capital and warrant components within equity in proportion to the allocation of proceeds. Warrants Warrants are classified as liabilities when the Company does not have the unconditional right to avoid delivering cash to the holders in the future, or when they can be settled with a variable number of common shares. Each of the Company’s warrants contains a written put option, arising upon the occurrence of a fundamental transaction, as that term is defined in the warrants, including a change of control. The warrant liability is initially measured at fair value, and any subsequent changes in fair value are recognized as gains or losses through profit or loss. Any transaction costs related to the warrants are expensed as incurred. Fair value of such warrants is determined at the issue date using the Black-Scholes option pricing model. The warrant liability is classified as non-current, unless the underlying warrants will expire or be settled within 12 months from the end of a given reporting period. When issued warrants meet the fixed-for-fixed criteria under IAS 32, Financial Instruments Share-based compensation costs The Company operates an equity-settled share-based compensation plan under which the Company receives services from directors, senior executives, employees and other collaborators as consideration for equity instruments of the Company. The Company accounts for all forms of share-based compensation using the fair value-based method. Fair value of stock options is determined at the date of grant using the Black-Scholes option pricing model, which includes estimates of the number of awards that are expected to vest over the vesting period. Where granted share options vest in installments over the vesting period (defined as graded vesting), the Company treats each installment as a separate share option grant. Share-based compensation expense is recognized over the vesting period, or as specified vesting conditions are satisfied, and credited to other capital. Any consideration received by the Company in connection with the exercise of stock options is credited to share capital. Any other capital component of the share-based compensation is transferred to share capital upon the issuance of shares. The Company grants deferred share units (“DSUs”) to members of its Board of Directors who are not employees or officers of the Company. DSUs cannot be redeemed until the holder is no longer a director of the Company and are considered equity-settled instruments. Under the terms of the DSU agreement, the DSUs vest immediately upon grant. The value attributable to the DSUs is based on the market value of the share price at the time of grant and share based compensation expense is recognized in general and administrative expenses in the consolidated statement of comprehensive loss. At the time of redemption, each DSU may be exchanged for one common share of the Company. Any consideration received by the Company in connection with the exercise of DSUs is credited to share capital. Any other capital component of the share-based compensation is transferred to share capital upon the issuance of shares. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted)
Revenue recognition	Revenue recognition The Company generates revenue from license and collaboration agreements with customers (license fees, milestone revenue, royalties), the provision of development services, the sale of certain active pharmaceutical ingredients (“API”) and semi-finished goods and finished goods, and from certain supply chain activities, which are comprised largely of oversight or supervisory support services related to stability studies or development activities carried out with respect to API batch production as specified in underlying contracts with customers. The Company applies the provisions of IFRS 15, Revenue from Contracts with Customers The transaction price is allocated among the performance obligations on a relative standalone selling price basis, and the applicable revenue recognition criteria are applied to each of the separate performance obligations. Standalone selling prices may be estimated via methods that include, but are not limited to, an adjusted market assessment approach, an expected cost-plus-margin approach or a residual approach. Determining the standalone selling price for performance obligations requires significant judgment. The Company applies judgment in determining whether a combined performance obligation is satisfied at a point in time or over time, and, for performance obligations satisfied over time, in concluding upon the appropriate method of measuring progress to be applied for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, as estimates related to the measure of progress change, related revenue recognition is adjusted accordingly. Changes in the Company’s estimated measure of progress are accounted for on a cumulative catch-up basis as a change in accounting estimate and are recorded in the consolidated statement of comprehensive loss in the period of adjustment. License fees If the license to the Company’s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Development services Arrangements that include a promise for the Company to provide development services are assessed to determine whether the services are capable of being distinct, are not highly interdependent or do not significantly modify one another, and if so, the services are accounted for as a separate performance obligation as the services are provided to the customer. Otherwise, when development services are determined not to be capable of being distinct, such services are added to the performance obligation that includes the underlying license. For development services that are combined with other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. Milestone payments At the inception of any contracts with a customer that includes milestone payments, which are oftentimes payable upon the successful achievement of development or regulatory events, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If the Company concludes it is highly probable that a significant revenue reversal will not occur, the associated milestone payment is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company reassesses the probability of achievement of milestones and any related constraints, and, if necessary, adjusts the estimate of the overall transaction price on a cumulative catch-up basis. Royalty payments For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and when the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied. Product sales The Company recognizes revenue from the sale of certain API and semi-finished goods, including Macrilen TM Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Supply chain revenue Supply chain services are contracted with fixed fees and are provided over a period of time. The Company recognizes revenue on a straight-line basis over time as it best represents the pattern of performance of the services. While providing services, the Company incurs certain direct costs for subcontractors and other expenses that are recoverable directly from its customers. The recoverable amounts of these direct costs are included in the Company’s operating expenses as the Company controls the services before they are transferred to the customer and acts as a principal in these arrangements. Contract costs The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be recovered, and any capitalized contract costs are amortized on a systematic basis that is consistent with the transfer to the customer of the goods or services to which the asset relates. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that it otherwise would have recognized is one year or less. To date, the Company has not incurred any incremental costs of obtaining a contract with a customer. Contract modifications Contract modifications are defined in IFRS 15 as changes in the scope or price (or both) of a contract that are approved by the parties to the contract, such as a contract amendment. Contract modifications exist when the parties to a contract approve a modification that either creates new or changes existing enforceable rights and obligations of the parties to the contract. Depending on facts and circumstances, the Company accounts for a contract modification in one of the following ways: (a) as a separate contract; (b) as a termination of the existing contract and a creation of a new contract; or (c) as a combination of the preceding treatments. A contract modification is accounted for as a separate contract if the scope of the contract increases because of the addition of promised goods or services that are distinct and the price of the contract increases by an amount of consideration that reflects the Company’s standalone selling prices of the additional promised goods or services. When a contract modification is not considered a separate contract and the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification, the Company accounts for the contract modification as a termination of the existing contract and a creation of a new contract. When a contract modification is not considered a separate contract and the remaining goods or services are not distinct, the Company accounts for the contract modification as an add-on to the existing contract and as an adjustment to revenue on a cumulative catch-up basis.
Income tax	Income tax Income tax on profit or loss comprises current and deferred tax. Tax is recognized in profit or loss, except that a change attributable to an item of income or expense recognized as other comprehensive loss or directly in equity is also recognized directly in other comprehensive loss or directly in equity. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities. The current income tax charge is calculated in accordance with tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company’s subsidiaries operate and generate taxable income. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) Deferred income tax is recognized on temporary differences (other than, where applicable, temporary differences associated with unremitted earnings from foreign subsidiaries and associates, to the extent that the investment is essentially permanent in duration, and temporary differences associated with the initial recognition of goodwill) arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements and on unused tax losses or R&D non-refundable tax credits in the Group. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date. Deferred income tax assets are recognized only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when the deferred income taxes assets and liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities where there is an intention to settle the balances on a net basis. The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions and other issues. Reserves are based on a determination of whether and how much of a tax benefit taken by the Company in its tax filing is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit.
Research and development expenses	Research and development expenses Research costs are expensed as incurred. Development costs are expensed as incurred, except for those that meet the criteria for deferral, in which case the costs are capitalized and amortized to operations over the estimated period of benefit. No development costs have been capitalized during any of the periods presented.
Net loss per share	Net loss per share Basic net loss per share is calculated using the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated based on the weighted average number of common shares outstanding during the year, plus the effects of dilutive common share equivalents, such as stock options and warrants. This method requires that diluted net loss per share be calculated using the treasury stock method, as if all common share equivalents had been exercised at the beginning of the reporting period, or period of issuance, as the case may be, and that the funds obtained thereby were used to purchase common shares of the Company at the average trading price of the common shares during the period. Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted)

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Depreciation Using Methods, Annual Rates and Period	Items of property, plant and equipment are recorded at cost, net of accumulated depreciation and impairment charges. Depreciation is calculated using the following methods, annual rates and period: Summary of Depreciation Using Methods, Annual Rates and Period Methods Annual rates and period Equipment Declining balance and straight-line 20% Furniture and fixtures Declining balance and straight-line 10% to 20% Computer equipment Straight-line 25% to 33 1 Leasehold improvements Straight-line Remaining lease term

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Products Supplied Under Agreement	The following table provides a summary of deferred revenue balances for the Novo Amendment, CH Agreement and NK License Agreement as of December 31: Summary of Deferred Revenue 2021 Current Non-Current Total $ $ $ Novo Amendment 4,791 23 4,814 CH Agreement 24 1,334 1,358 NK License Agreement — 136 136 Total 4,815 1,493 6,308 2020 Current Non-Current Total $ $ $ Novo Amendment 2,193 3,289 5,482 Total 2,193 3,289 5,482 The following table provides a summary of revenue recognized for the Strongbridge agreement and Novo Amendment: Summary of Products Supplied Under Agreement 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ License fee associated with the Strongbridge Agreement — 68 74 License fee associated with the Novo Amendment (of which $ 1,670 264 nil 1,670 843 — Development services associated with Novo Amendment 3,337 — — Product sales associated with Novo Supply Agreement (of which $ nil 852 nil — 2,370 129 Royalties associated with the Strongbridge Agreement — 56 45 Royalties associated with the Novo Amendment 68 11 — Supply chain revenue associated with the Novo Supply Agreement (of which $ nil 67 nil 185 304 284 Total 5,260 3,652 532
Summary of Products Supplied Under Agreement	Summary of Products Supplied Under Agreement 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ License fee associated with the Strongbridge Agreement — 68 74 License fee associated with the Novo Amendment (of which $ 1,670 264 nil 1,670 843 — Development services associated with Novo Amendment 3,337 — — Product sales associated with Novo Supply Agreement (of which $ nil 852 nil — 2,370 129 Royalties associated with the Strongbridge Agreement — 56 45 Royalties associated with the Novo Amendment 68 11 — Supply chain revenue associated with the Novo Supply Agreement (of which $ nil 67 nil 185 304 284 Total 5,260 3,652 532
Summary of Cash and Cash Equivalents	Summary of Cash and Cash Equivalents 2021 2020 December 31, 2021 2020 $ $ Cash on hand and balances with banks 55,600 23,920 Interest-bearing deposits with maturities of three months or less 9,700 351 Cash and cash equivalents 65,300 24,271

Trade and other receivables (Ta

Trade and other receivables (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Trade and Other Receivables	Schedule of Trade and Other Receivables 2021 2020 December 31, 2021 2020 $ $ Trade accounts receivable (net of expected credit losses of $ 55 55 877 1,190 Value added tax 372 468 Other receivables 65 23 Trade and other receivables 1,314 1,681

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Inventory	Summary of Inventory 2021 2020 December 31, 2021 2020 $ $ Work in process 73 21 Inventory 73 21 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted) The Company recognized $ nil nil 1,980 131 101 106

Prepaid expenses and other cu_2

Prepaid expenses and other current assets (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Prepaid Expenses and Other Current Assets	Summary of Prepaid Expenses and Other Current Assets 2021 2020 December 31, 2021 2020 $ $ Prepaid insurance 421 1,021 Prepaid research and development 1,329 — Other 22 19 Prepaid expenses and other current assets 1,772 1,040

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Property, Plant and Equipment	Components of the Company’s property, plant and equipment are summarized below. Summary of Property, Plant and Equipment Equipment Furniture and fixtures Computer equipment Leasehold improvements Total Cost Equipment Furniture and fixtures Computer equipment Leasehold improvements Total $ $ $ $ $ At January 1, 2020 422 7 314 34 777 Property, plant and equipment, Cost Beginning 422 7 314 34 777 Disposals / Retirements (245 ) (7 ) (3 ) (38 ) (293 ) Impact of foreign exchange rate changes 38 — 24 4 66 At December 31, 2020 215 — 335 — 550 Additions 6 — 24 — 30 Disposals / Retirements (5 ) — (69 ) — (74 ) Impact of foreign exchange rate changes (17 ) — (22 ) — (39 ) At December 31, 2021 199 — 268 — 467 Property, plant and equipment, Cost Ending 199 — 268 — 467 Equipment Furniture and fixtures Computer equipment Leasehold improvements Total Accumulated Depreciation Equipment Furniture and fixtures Computer equipment Leasehold improvements Total $ $ $ $ $ At January 1, 2020 400 7 307 28 742 Property, plant and equipment, Accumulated depreciation Beginning 400 7 307 28 742 Disposals / Retirements (247 ) (7 ) (3 ) (38 ) (295 ) Depreciation expense 6 — 3 — 9 Impact of foreign exchange rate changes 40 — 22 10 72 At December 31, 2020 199 — 329 — 528 Disposals / Retirements (5 ) — (69 ) — (74 ) Depreciation expense 4 — 5 — 9 Impact of foreign exchange rate changes (17 ) — (21 ) — (38 ) At December 31, 2021 181 — 244 — 425 Property, plant and equipment, Accumulated depreciation Ending 181 — 244 — 425 Carrying amount Equipment Furniture and fixtures Computer equipment Leasehold improvements Total $ $ $ $ $ At December 31, 2020 16 — 6 — 22 At December 31, 2021 18 — 24 — 42 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted)

Right of use assets (Tables)

Right of use assets (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Right of Use Assets	Schedule of Right of Use Assets Building Vehicles and equipment Total $ $ $ Cost At January 1, 2020 757 106 863 Modification of building lease (259 ) — (259 ) Additions — 7 7 Disposals — (21 ) (21 ) Impact of foreign exchange rate changes 48 2 50 At December 31, 2020 546 94 640 Additions 16 — 16 Modification of building lease 109 — 109 Impact of foreign exchange rate changes (48 ) (7 ) (55 ) At December 31, 2021 623 87 710 Building Vehicles and equipment Total $ $ $ Accumulated Depreciation At January 1, 2020 242 39 281 Disposals — (21) (21) Depreciation 180 23 203 Impact of foreign exchange rate changes 15 5 20 At December 31, 2020 437 46 483 Depreciation 94 26 120 Impact of foreign exchange rate changes (38) (5) (43) At December 31, 2021 493 67 560 Building Vehicles and equipment Total $ $ $ Carrying amount As of December 31, 2020 109 48 157 As of December 31, 2021 130 20 150

Identifiable intangible assets

Identifiable intangible assets (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Identifiable Intangible Assets with Finite Useful Lives	Changes in the carrying value of the Company’s identifiable intangible assets are summarized below. Summary of Identifiable Intangible Assets with Finite Useful Lives Year ended December 31, 2021 Year ended December 31, 2020 Cost Accumulated amortization Carrying value Cost Accumulated amortization Carrying value $ $ $ $ $ $ Balances – Beginning of the year 35,020 (34,961 ) 59 31,422 (31,382 ) 40 Additions 609 — 609 34 — 34 Amortization expense — (16 ) (16 ) — (20 ) (20 ) Impact of foreign exchange rate changes (3,218 ) 3,191 (27 ) 3,564 (3,559 ) 5 Balances – End of the year 32,411 (31,786 ) 625 35,020 (34,961 ) 59

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Change in Carrying Value of Goodwill	Summary of Change in Carrying Value of Goodwill Cost Accumulated impairment loss Carrying amount $ $ $ Balances at January 1, 2020 8,050 — 8,050 Impact of foreign exchange rate changes 765 — 765 Balances at December 31, 2020 8,815 — 8,815 Impact of foreign exchange rate changes (685 ) — (685 ) Balances at December 31, 2021 8,130 — 8,130

Payables and accrued liabilit_2

Payables and accrued liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Payables and Accrued Liabilities	Schedule of Payables and Accrued Liabilities 2021 2020 December 31, 2021 2020 $ $ Trade accounts payable 934 1,187 Accrued research and development costs 531 23 Salaries, employment taxes and benefits 596 474 Other accrued liabilities 611 515 Payables and accrued liabilities 2,672 2,199 Aeterna Zentaris Inc. Notes to Consolidated Financial Statements As of December 31, 2021 and December 31, 2020 and for the years ended December 31, 2021, 2020 and 2019 (in thousands of US dollars, except share and per share data and where otherwise noted)

Provisions (Tables)

Provisions (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Changes in Provisions for Onerous Contracts	Schedule of Changes in Provisions for Onerous Contracts Cetrotide onerous contracts German restructuring: severance Total $ $ $ Balance at January 1, 2020 396 330 726 Utilization of provision (93 ) (323 ) (416 ) Change in the provision 33 — 33 Unwinding of discount and impact of foreign exchange rate changes 35 (7 ) 28 Balance at December 31, 2020 371 — 371 Utilization of provision (90 ) — (90 ) Change in the provision 23 — 23 Unwinding of discount and impact of foreign exchange rate changes (27 ) — (27 ) Balance at December 31, 2021 277 — 277 Less: current portion 34 — 34 Non-current portion 243 — 243

Employee future benefits (Table

Employee future benefits (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Operating Lease Liabilities	Schedule of Operating Lease Liabilities Years Ended December 31, 2021 2020 $ $ Balance – Beginning of period 184 903 Additions 15 7 Interest paid as charged to comprehensive loss as other finance costs (7 ) (19 ) Payment against lease liabilities (127 ) (265 ) Modification of lease liability 103 (463 ) Impact of foreign exchange rate changes (7 ) 21 Balance – End of period 161 184 Current lease liabilities 130 135 Non-current lease liabilities 31 49
Summary of Maturity Analysis of Operating Lease Liabilities	Future lease payments as of December 31, 2021 are as follows: Summary of Maturity Analysis of Operating Lease Liabilities $ Less than 1 year 130 1 – 3 years 31 Total 161
Disclosure of Net Defined Benefit Liability (Asset)	The change in the Company’s accrued benefit obligations associated with the Employee future obligation is summarized for the year ended December 31, 2021: Disclosure of Net Defined Benefit Liability (Asset) Pension Benefit Plans Other benefit Total $ $ $ Change in benefit obligation: Balances – Beginning of the year 15,341 94 15,435 Current service cost 60 5 65 Interest cost 87 1 88 Actuarial loss (gain) arising from changes in financial assumptions (1,138 ) 8 (1,130 ) Past service cost associated with multi-employer plan 16,137 — 16,137 Actuarial loss arising from change in current assumptions on funding of future pension increases 556 — 556 Benefits paid (509 ) (2 ) (511 ) Impact of foreign exchange rate changes (1,221 ) (7 ) (1,228 ) Balances – End of the year 29,313 99 29,412 Obligation is attributable to: Active members 4,242 99 4,341 Vested terminees 13,799 — 13,799 Retirees 11,272 — 11,272 29,313 99 29,412 Change in plan assets Balances – Beginning of the year — — — Presentation of plan assets as of December 31, 2021 11,963 — 11,963 Impact of foreign exchange rate changes (36 ) — (36 ) Balances – End of the year 11,927 — 11,927 Net liability of the unfunded plans 12,650 99 12,749 Net liability of the funded plans 4,736 — 4,736 Net amount recognized as Employee future benefits 17,386 99 17,485 Amounts recognized: In net loss (147 ) (6 ) (153 ) In other comprehensive (loss) 2,407 1 2,408 The change in the Company’s accrued benefit obligations associated with the Employee future benefits is summarized for the years ended December 31, 2020 and 2019: Pension Benefit Plans Other benefit plans 2020 2019 2020 2019 $ $ $ $ Balances – Beginning of the year 13,704 13,100 84 105 Current service cost 50 41 4 8 Interest cost 162 239 1 2 Actuarial loss (gain) arising from changes in financial assumptions 650 1,068 1 (28 ) Benefits paid (529 ) (483 ) (3 ) — Impact of foreign exchange rate changes 1,304 (261 ) 7 (3 ) Balances – End of the year 15,341 13,704 94 84 Amounts recognized: In net loss (212 ) (280 ) (6 ) 18 In other comprehensive loss (1,954 ) (807 ) (7 ) 3
Schedule of Employer Pension Plan Asset	The Company’s proportionate share of the multi-employer pension plan assets as of December 31, 2021 is as follows: Schedule of Employer Pension Plan Asset $ Quoted equities (Level 1) 826 Quoted bonds (Level 1) 7,445 Cash (Level 1) 67 Real estate (Level 3) 2,207 Other (Level 3) 1,382 Total 11,927
Summary of Significant Actuarial Assumptions Applied to Determine Accrued Benefit Obligations	The significant actuarial assumptions applied to determine the Company’s accrued benefit obligations are as follows: Summary of Significant Actuarial Assumptions Applied to Determine Accrued Benefit Obligations Pension Benefit Plans Other benefit plans Years ended December 31, Years ended December 31, Actuarial assumptions 2021 2020 2019 2021 2020 2019 % % % % % % Discount rate 1.10 0.60 1.10 1.10 0.60 1.90 Pension benefits increase 0.50 0.50 1.50 0.50 0.50 1.50 Rate of compensation increase 2.50 2.00 2.00 2.50 2.00 2.00
Summary of Assumptions Translate into an Average Remaining Life Expectancy in Years	Assumptions regarding future mortality are set based on actuarial advice in accordance with published statistics and experience in Germany. These assumptions translate into an average remaining life expectancy in years for a pensioner retiring at age 65: Summary of Assumptions Translate into an Average Remaining Life Expectancy in Years 2021 2020 2019 Retiring at the end of the reporting period: Male 21 20 20 Female 24 24 24 Retiring 20 years after the end of the reporting period: Male 28 28 28 Female 31 31 31
Summary of Undiscounted Defined Pension Benefits Expected to be Paid	In accordance with the assumptions used as of December 31, 2021, undiscounted defined pension benefits expected to be paid are as follows: Summary of Undiscounted Defined Pension Benefits Expected to be Paid Total $ 2022 801 2023 823 2024 853 2025 868 2026 894 Thereafter 32,685 36,924
Summary of Impact on Pension Benefit Obligation	Summary of Impact on Pension Benefit Obligation Assumption Increase Decrease (1,252 ) 1,338 Change in discount rate of 0.25 (1,252 ) 1,338 Change in salary rate of 0.25 18 (18 ) Change in pension rate assumption by 0.25 905 (867 ) Change mortality by one year 968 (974 )

Share capital, warrants and o_2

Share capital, warrants and other capital (Tables)	12 Months Ended
	Dec. 31, 2021
Share Capital Warrants And Other Capital
Schedule of Warrants Activity Reclassified into Equity	Schedule of Warrants Activity Reclassified into Equity Weighted average exercise price Number ($) $ Balance – January 1, 2020 — — — Warrant liability reclassified to equity 16,368,033 0.8556 7,377 Warrants issued as equity 28,533,333 0.4574 5,025 Balance – December 31, 2020 44,901,366 0.6025 12,402 February 2021 Placement Agent Warrants 1,651,034 1.8125 1,897 Warrants exercised (35,111,187 ) 0.5725 (9,746 ) Allocation of transaction costs to share capital — — 532 Balance – December 31, 2021 11,441,213 0.8668 5,085
Schedule of Fair Value of Warrants Assumptions	The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of the February 2021 Placement Agent Warrants: Schedule of Fair Value of Warrants Assumptions Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield # $ $ (i) (ii) (iii) (iv) February 2021 Placement Agent Warrants issued on February 19, 2021 1,435,682 1.48 1.8125 0.58734 % 119.18 % 4.99 0.00 % February 2021 Placement Agent Warrants issued on February 22, 2021 215,352 1.48 1.8125 0.58544 % 119.57 % 4.98 0.00 % (i) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (ii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants. (iii) Based upon time to expiry from the issuance date. (iv) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of such warrants as of the noted dates of reclassification: Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield ($) ($) (i) (ii) (iii) (iv) As of June 16, 2020: September 2019 Warrants 3,325,000 0.96 1.65 0.30 % 104.5 % 4.3 0.00 % February 2020 Investor Warrants 2,608,696 0.96 1.20 0.36 % 119.3 % 5.2 0.00 % February 2020 Placement Agent Warrants 243,478 0.96 1.62 0.32 % 113.3 % 4.7 0.00 % As of September 14, 2020: August 2020 Investor Warrants 9,320,907 0.38 0.47 0.31 % 120.5 % 5.4 0.00 % August 2020 Placement Agent Warrants 869,952 0.38 0.704063 0.26 % 114.6 % 4.9 0.00 % (i) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (ii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants, as well as on future expectations. (iii) Based upon time to expiry from the reporting period date. (iv) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of such warrants: Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield ($) ($) (i) (ii) (iii) (iv) July 2020 Investor Warrants 26,666,666 0.52 0.457 0.2879 % 123.1048 % 5 0.00 % July 2020 Placement Agent Warrants 1,866,667 0.52 0.5625 0.2879 % 123.1048 % 5 0.00 % (i) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (ii) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants, as well as on future expectations. (iii) Based upon time to expiry from the reporting period date. (iv) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
Summary of Warrants Exercise Transactions	During 2021, certain warrant holders exercised their warrants as follows: Summary of Warrants Exercise Transactions Warrants exercised (number of underlying common shares) Exercise Price Aggregate proceeds to the Company September 2019 Investor warrants 2,000,000 $ 1.65 $ 3,300 February 2020 Investor warrants 1,739,130 1.20 2,087 July 2020 Investor warrants 21,045,555 0.45 9,471 July 2020 Placement Agent warrants 1,866,667 0.5625 1,050 August 2020 Investor warrants 7,589,883 0.47 3,567 August 2020 Placement Agent warrants 869,952 0.7040625 612 35,111,187 $ 20,087
Disclosure of Change in Stock Options Issued	Disclosure of Change in Stock Options Issued Year ended December 31, 2021 Stock options Weighted average exercise price DSUs (Number) ($) (Number) Balance – January 1, 2021 506,400 1.44 173,000 Granted 580,000 0.42 280,000 Expired (32 ) 590.25 — Exercised — — (30,000 ) Balance – December 31, 2021 1,086,368 0.88 423,000 Year ended December 31, 2019 US$ Stock options Weighted average DSUs CAN$ Stock options Weighted average (Number) (US$) (Number) (Number) (CAN$) Balance – Beginning of year 727,816 4.07 161,000 869 743.56 Granted 185,000 1.07 150,000 — — Exercised (64,850 ) 2.75 (99,000 ) — — Canceled/Forfeited (6,000 ) 13.39 — — — Expired (100,850 ) 2.24 — (428 ) 570.00 Balance – End of year 741,116 3.61 212,000 441 912.00 Year ended December 31, 2020 US$ Stock options Weighted average exercise price DSUs CAN$ Stock options Weighted average exercise price (Number) (US$) (Number) (Number) (CAN$) Balance – Beginning of year 741,116 3.61 212,000 441 912.00 Granted 180,000 0.37 120,000 — — Exercised — — (159,000 ) — — Canceled/Forfeited (330,350 ) 2.56 — — — Expired (84,366 ) 2.14 — (441 ) 912.00 Balance – End of year 506,400 1.44 173,000 — —
Summary of Assumptions to Determine Share-Based Compensation Costs Over the Life of Awards	The table below shows the assumptions, or weighted average parameters, applied to the Black-Scholes option pricing model in order to determine share-based compensation costs over the life of the awards. Summary of Assumptions to Determine Share-Based Compensation Costs Over the Life of Awards 2021 2020 2019 Years ended December 31, 2021 2020 2019 Expected dividend yield (a) 0.00 % 0.00 % 0.00 % Expected volatility (b) 115.80 % 112.50 % 110.02 % Risk-free annual interest rate (c) 1.23 % 0.27 % 1.86 % Expected life (years) (d) 5.71 4.02 5.94 Weighted average share price $ 0.42 $ 0.37 $ 2.00 Weighted average exercise price $ 0.42 $ 0.37 $ 2.00 Weighted average grant date fair value $ 0.35 $ 0.27 $ 2.00 _________________________ (a) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. (b) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations. (c) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options. (d) Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.
Schedule of Stock Options Exercise Price Range	Schedule of Stock Options Exercise Price Range Options outstanding Options exercisable Range of US dollar stock option exercise prices Number (#) Weighted average remaining contractual life (years) Weighted average exercise price ($) Number (#) Weighted average remaining contractual life (years) Weighted average exercise price ($) 0.37 0.50 760,000 6.72 0.41 60,006 5.95 0.37 0.51 1.78 160,000 4.91 0.91 106,672 4.91 0.90 1.79 3.14 85,000 3.21 2.08 76,667 3.06 2.07 3.15 217.00 81,368 1.70 3.95 81,368 1.70 3.95 1,086,368 5.81 0.88 324,713 3.86 1.84

Operating expenses (Tables)

Operating expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Operating Expenses	The nature of the Company’s operating expenses includes the following: Schedule of Operating Expenses 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Key management personnel compensation (1) Salaries and short-term employee benefits (1) 1,646 1,540 1,705 Consultant’s fees (1) 163 167 194 Termination benefits (1) — — 503 Post-employment benefits, including defined contribution plan benefits of $ 33 33 195 (1) 70 86 257 Share-based compensation costs (1) 295 160 784 Key management personnel compensation (1) 2,174 1,953 3,443 Other employees compensation: Salaries and short-term employee benefits 1,160 1,004 1,257 Post-employment benefits, including defined contribution plan benefits of $ 15 9 25 139 159 78 Share-based compensation costs 16 (99 ) 9 Other employees compensation 1,315 1,064 1,344 Cost of inventory used and services provided 90 2,186 309 Professional fees 2,749 1,969 2,599 Insurance 1,077 861 890 Third-party research and development 5,047 414 322 Consulting fees 553 587 144 Restructuring costs — — 507 Travel 130 66 154 Marketing services 222 39 18 Laboratory supplies 114 36 23 Other goods and services 162 72 137 Leasing costs, net of sublease receipts of $ nil nil 214 112 218 247 Modification of building lease — (219 ) — (Reversal) impairment of other asset and inventory — (8 ) 270 Depreciation and amortization of property, equipment and intangibles 25 29 37 Depreciation - right to use assets 120 203 278 Impairment of right of use asset — — 22 Operating foreign exchange losses (gains) 41 (112 ) 30 Operating expenses excluding management and Employee compensation 10,442 6,341 5,987 Total operating expenses 13,931 9,358 10,774 ______________________ (1) Key management includes the Company’s executive management team and directors.

Supplemental disclosure of ca_2

Supplemental disclosure of cash flow information (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of Changes in Operating Assets and Liabilities	Disclosure of Changes in Operating Assets and Liabilities 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Changes in operating assets and liabilities: Trade and other receivables 120 (1,023 ) (371 ) Inventory (56 ) 1,182 (971 ) Prepaid expenses and other current assets (750 ) (702 ) (170 ) Payables and accrued liabilities 634 51 (615 ) Income taxes payable (109 ) 395 (188 ) Deferred revenues 3,010 3,031 743 Provision for restructuring and other costs — — (389 ) Employee future benefits (note 18) (349 ) (532 ) (483 ) Increase (decrease) in operating assets and liabilities 2,500 2,402 (2,444 )

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Taxes
Summary of Significant Components of Current and Deferred Income Tax Recovery (Expense)	Significant components of the current and deferred income tax recovery (expense) for the years ended December 31, 2021, 2020 and 2019 are as follows: Summary of Significant Components of Current and Deferred Income Tax Recovery (Expense) 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Current income tax recovery (expense) 109 (395 ) 188 Deferred tax: Origination and reversal of temporary differences 1,291 1,509 2,755 Change in unrecognized tax assets (1,291 ) (1,509 ) (2,755 ) Total income tax recovery (expense) 109 (395 ) 188
Summary of Reconciliation of Combined Canadian Federal and Provincial Income Tax Rate to Income Tax Expense	The reconciliation of the combined Canadian federal and provincial corporate income tax rate to the income tax expense is provided below: Summary of Reconciliation of Combined Canadian Federal and Provincial Income Tax Rate to Income Tax Expense 2021 2020 2019 Years ended December 31, 2021 2020 2019 Combined Canadian federal and provincial statutory income tax rate 26.5 % 26.5 % 26.5 % 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Income tax (expense) recovery based on combined statutory income tax rate 2,246 1,252 1,615 Change in unrecognized tax assets (1,291 ) (1,872 ) (2,820 ) Share issuance costs 367 363 65 Permanent difference attributable to the use of local currency for tax reporting — — 35 Change in enacted rates used — — (27 ) Impact of expiring tax credits (1,724 ) (481 ) — Provision to filed return adjustments 151 — — Permanent difference attributable to net change in fair value of warrant liability — 304 1,197 Share-based compensation costs (82 ) (16 ) (210 ) Difference in statutory income tax rate of foreign subsidiaries 226 99 321 Uncertain tax position — (123 ) — Other 216 79 12 Total income tax (expense) recovery 109 (395 ) 188
Summary of (Loss) Income Before Income Taxes	(Loss) income before income taxes is attributable to the Company’s tax jurisdictions as follows: Summary of (Loss) Income Before Income Taxes 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Germany (4,383 ) (2,042 ) (6,010 ) Canada (3,860 ) (2,463 ) 812 United States (234 ) (218 ) (1,032 ) Loss before income taxes (8,477 ) (4,723 ) (6,230 )
Summary of Significant Components of Deferred Tax Assets and Liabilities	Significant components of deferred tax assets and liabilities are as follows: Summary of Significant Components of Deferred Tax Assets and Liabilities 2021 2020 December 31, 2021 2020 $ $ Deferred tax assets Operating losses carried forward 205 46 Intangible assets 776 1,318 Deferred tax assets 981 1,364 Deferred tax liabilities Accounts receivable 375 — Payables and accrued liabilities 7 126 Property, plant and equipment 47 49 Deferred revenues 492 1,073 Other 60 116 Deferred tax liabilities 981 1,364 Deferred tax liabilities, net 981 1,364 Deferred tax assets (liabilities), net — —
Summary of Significant Components of Unrecognized Deferred Tax Assets	Significant components of deferred tax assets and losses are as follows: Summary of Significant Components of Unrecognized Deferred Tax Assets 2021 2020 December 31, 2021 2020 $ $ Unrecognized deferred tax assets Deferred revenues and other provisions 1,680 1,494 Operating losses carried forward 87,734 89,144 Capital losses carried forward 105 — SR&ED Pool 9,138 9,138 Unused tax credits 2,945 4,668 Employee future benefits 3,396 2,570 Property, plant and equipment 523 495 Intangible assets — 541 Share issuance expenses 1,110 623 Other 84 — Unrecognized deferred tax assets, gross 106,715 108,673 Unrecognized deferred tax assets 106,715 108,673
Summary of Disclosure of Federal Tax Losses	Summary of Disclosure of Federal Tax Losses Federal Provincial Canada Federal Provincial $ $ 2028 8,054 6,668 2029 4,791 4,773 2030 4,104 4,089 2031 1,753 1,737 2032 4,250 4,250 2033 3,721 3,721 2034 4,153 4,153 2035 10,418 10,452 2036 10,592 10,592 2037 7,343 7,343 2038 6,557 6,557 2039 3,501 3,580 2040 3,808 3,808 2041 4,822 4,822 Tax attributes to be deferred for which no deferred tax asset was recognized 77,867 76,545 United States $ 2028 369 2029 178 2034 151 2035 447 2036 195 2037 709 2038 1,224 2039 771 2040 515 2041 234 Unused tax losses for which no deferred tax asset recognized 4,793

Financial instruments and fin_2

Financial instruments and financial risk management (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of Fair Value Measurement of Assets	Financial assets and liabilities as of December 31, 2021 and December 31, 2020 are presented below. Disclosure of Fair Value Measurement of Assets December 31, 2021 Financial assets at amortized cost Financial liabilities at amortized cost $ $ Cash and cash equivalents (note 6) 65,300 — Trade and other receivables (note 7) 1,314 — Restricted cash equivalents (note 10) 335 — Payables and accrued liabilities (note 15) — 1,530 Lease liability (note 17) — 161  66,949 1,691 December 31, 2020 Financial assets at amortized cost Financial liabilities at amortized cost $ $ Cash and cash equivalents (note 6) 24,271 — Trade and other receivables (note 7) 1,681 — Restricted cash equivalents (note 10) 338 — Payables and accrued liabilities (note 15) — 2,176 Lease liability (note 17) — 184 26,290 2,360

Segment information (Tables)

Segment information (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Information
Summary of Revenues by Geographical Area	Revenues by geographical area have been allocated to geographic regions based on the country of residence of the Company’s external customers or licensees and are detailed as follows: Summary of Revenues by Geographical Area 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Switzerland 5,075 905 — Ireland — 73 74 Denmark 185 2,655 413 Other — 19 45 Revenue 5,260 3,652 532
Summary of Non-current Assets by Geographical Area	Summary of Non-current Assets by Geographical Area 2021 2020 December 31, 2021 2020 $ $ Germany 9,212 9,341 United States 70 50 Non-current assets 9,282 9,391
Summary of Major Customers	Major customers representing 10% or more of the Company’s revenues in each of the last three years are as follows: Summary of Major Customers 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Company 1 5,260 3,634 532

Net loss per share (Tables)

Net loss per share (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Pertinent Data Relating to Computation of Basic and Diluted Net Loss Per Share	The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Summary of Pertinent Data Relating to Computation of Basic and Diluted Net Loss Per Share 2021 2020 2019 Years ended December 31, 2021 2020 2019 $ $ $ Net loss (8,368 ) (5,118 ) (6,042 ) Basic weighted average number of shares outstanding 114,924,497 41,083,163 17,494,472 Diluted weighted average number of shares outstanding 114,924,497 41,083,163 17,494,472 Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect Stock options and DSUs 1,509,368 679,400 953,557 Share purchase warrants 11,441,213 44,901,366 6,629,144 Anti-dilutive shares

Commitments and contingencies (

Commitments and contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Schedule of Expected Future Minimum Lease Payments	Contractual obligations and commitments as of December 31, 2021 Schedule of Expected Future Minimum Lease Payments Service and manufacturing R&D contracts TOTAL $ $ $ Less than 1 year 1,085 2,252 3,337 1 – 3 years 6 1,049 1,055 4 – 5 years — — — More than 5 years — — — Total 1,091 3,301 4,392
Schedule of R&D and Revenue Related Milestone Payments	Schedule of R&D and Revenue Related Milestone Payments Future potential R&D milestone payments Future potential revenue milestone payments Total $ $ $ Less than 1 year 28 — 28 1 – 3 years 113 — 113 4 – 5 years 927 — 927 More than 5 years 7,869 32,942 40,811 Total 8,937 32,942 41,879

Summary of Depreciation Using M

Summary of Depreciation Using Methods, Annual Rates and Period (Details)	12 Months Ended
	Dec. 31, 2021
Machinery [member]
IfrsStatementLineItems [Line Items]
Property, plant and equipment and depreciation, Methods	Declining balance and straight-line
Property, plant and equipment and depreciation, Annual rates and period, percentage	20.00%
Fixtures and fittings [member]
IfrsStatementLineItems [Line Items]
Property, plant and equipment and depreciation, Methods	Declining balance and straight-line
Property, plant and equipment and depreciation, Annual rates and period, Percentage description	10% to 20%
Computer equipment [member]
IfrsStatementLineItems [Line Items]
Property, plant and equipment and depreciation, Methods	Straight-line
Property, plant and equipment and depreciation, Annual rates and period, Percentage description	25% to 331/3%
Leasehold improvements [member]
IfrsStatementLineItems [Line Items]
Property, plant and equipment and depreciation, Methods	Straight-line
Property, plant and equipment and depreciation, Annual rates and period, period description	Remaining lease term

Summary of Products Supplied Un

Summary of Products Supplied Under Agreement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues	$ 4,815	$ 2,193
Total Deferred Revenues Non Current	1,493	3,289
Total Deferred Revenues	6,308	5,482
Total	5,260	3,652	$ 532
License Strongbridge Agreement [Member]
IfrsStatementLineItems [Line Items]
Total		68	74
License Novo Amendment [Member]
IfrsStatementLineItems [Line Items]
Total	1,670	843
Development Services Novo Amendment [Member]
IfrsStatementLineItems [Line Items]
Total	3,337
Novo Supply Agreement [Member]
IfrsStatementLineItems [Line Items]
Total		2,370	129
Royalties Strongbridge Agreement [Member]
IfrsStatementLineItems [Line Items]
Total		56	45
Royalties Novo Amendement [Member]
IfrsStatementLineItems [Line Items]
Total	68	11
Novo Supply Agreements [Member]
IfrsStatementLineItems [Line Items]
Total	185	304	$ 284
Novo Amendment [Member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues	4,791	2,193
Total Deferred Revenues Non Current	23	3,289
Total Deferred Revenues	4,814	$ 5,482
CH Agreement [Member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues	24
Total Deferred Revenues Non Current	1,334
Total Deferred Revenues	1,358
NK License Agreement [Member]
IfrsStatementLineItems [Line Items]
Total Current Deferred Revenues
Total Deferred Revenues Non Current	136
Total Deferred Revenues	$ 136

Summary of Products Supplied _2

Summary of Products Supplied Under Agreement (Details) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Deferred tax liabilities	$ 981	$ 1,364
Supply Agreement [Member]
IfrsStatementLineItems [Line Items]
Deferred tax liabilities		67
License Novo Amendment [Member]
IfrsStatementLineItems [Line Items]
License fee	1,670	264	0
Novo Supply Agreement [Member]
IfrsStatementLineItems [Line Items]
Deferred revenue		$ 852

Summary of Cash and Cash Equiva

Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash on hand and balances with banks	$ 55,600	$ 23,920
Interest-bearing deposits with maturities of three months or less	9,700	351
Cash and cash equivalents	$ 65,300	$ 24,271	$ 7,838	$ 14,512

Schedule of Trade and Other Rec

Schedule of Trade and Other Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Trade accounts receivable (net of expected credit losses of $55 (2020 - $55))	$ 877	$ 1,190
Value added tax	372	468
Other receivables	65	23
Trade and other receivables	$ 1,314	$ 1,681

Schedule of Trade and Other R_2

Schedule of Trade and Other Receivables (Details) (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Trade accounts receivable, expected credit losses	$ 55	$ 55

Summary of Inventory (Details)

Summary of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Work in process	$ 73	$ 21
Inventory	$ 73	$ 21

Cash and cash equivalents (Deta

Cash and cash equivalents (Details Narrative) € in Thousands, $ in Thousands

Dec. 07, 2020USD ($)

Dec. 07, 2020EUR (€)

Nov. 16, 2020USD ($)

Nov. 16, 2020USD ($)

Nov. 16, 2020EUR (€)

Dec. 31, 2021USD ($)

Dec. 31, 2021EUR (€)

Dec. 31, 2020USD ($)

Dec. 31, 2020EUR (€)

Dec. 31, 2019USD ($)

Dec. 31, 2021EUR (€)

Dec. 31, 2020EUR (€)

Dec. 31, 2018USD ($)

Jan. 31, 2018USD ($)

IfrsStatementLineItems [Line Items]

Revenue

$ 5,260

$ 3,652

$ 532

Performance obligation and deferred

226

€ 200

Contract assets

132

License Agreement [Member]

IfrsStatementLineItems [Line Items]

Annual net sales

$ 40,000

Post Nova Amendement [Member]

IfrsStatementLineItems [Line Items]

Licensee costs

5,559

€ 4,500

Transaction Price Prior to Modification [Member]

IfrsStatementLineItems [Line Items]

Transaction costs

$ 5,754

€ 4,700

Amortization period

5 years 4 months 24 days

5 years 4 months 24 days

Transaction Price Prior to Modification [Member] | Adult Indication [Member]

IfrsStatementLineItems [Line Items]

Transaction costs

$ 23,600

Transaction Price Prior to Modification [Member] | Pediatric Indication [Member]

IfrsStatementLineItems [Line Items]

Transaction costs

$ 400

Transaction Price Prior to Modification [Member] | Discounted cash flow [member]

IfrsStatementLineItems [Line Items]

Transaction costs

24,000

$ 24,000

Transaction Price Prior to Modification [Member] | FDA Approval [Member]

IfrsStatementLineItems [Line Items]

Transaction costs

5,000

$ 5,000

License Agreement [Member] | Novo Nordisk A/S [Member]

IfrsStatementLineItems [Line Items]

Upfront payment received

$ 6,109

6,109

€ 5,000

[custom:RevenueDeferred-0]

5,559

License Agreement [Member] | Novo Nordisk A/S [Member] | Euro [Member]

IfrsStatementLineItems [Line Items]

Upfront payment received

$ 5,000

[custom:RevenueDeferred-0] | €

€ 4,530

License Agreement [Member] | Consilient Health Limited [Member]

IfrsStatementLineItems [Line Items]

Transaction costs

$ 1,209

Upfront payment received

1,209

PIP Study [Member]

IfrsStatementLineItems [Line Items]

Clinical trial costs

10,980

Licensee costs

1,099

$ 979

PIP Study [Member] | Novo Nordisk A/S [Member]

IfrsStatementLineItems [Line Items]

Additional clinical trial costs | €

€ 9,000

Transaction Price Adjusted Post Modification [Member] | Adult Indication [Member]

IfrsStatementLineItems [Line Items]

Revenue

$ 550

$ 550

€ 470

Pre Nova Amendement [Member]

IfrsStatementLineItems [Line Items]

Transaction costs

195

200

CH License Agreement [Member] | Consilient Health Limited [Member]

IfrsStatementLineItems [Line Items]

Transaction costs

$ 1,000

Upfront payment received | €

€ 1,000

CH Agreement [Member]

IfrsStatementLineItems [Line Items]

Performance obligation and deferred

1,358

€ 1,200

NK License Agreement [Member]

IfrsStatementLineItems [Line Items]

Transaction costs

136

€ 100

Upfront payment received

$ 136

€ 100

Summary of Prepaid Expenses and

Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Prepaid insurance	$ 421	$ 1,021
Prepaid research and development	1,329
Other	22	19
Prepaid expenses and other current assets	$ 1,772	$ 1,040

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventory costs		$ 1,980	$ 101
Impairment of inventory		$ 131	$ 106

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
At December 31, 2020	$ 550	$ 777
Disposals / Retirements	(74)	(293)
Impact of foreign exchange rate changes	(39)	66
Additions	30
Property, plant and equipment, Cost Ending	467	550
At December 31, 2020	528	742
Disposals / Retirements	(74)	(295)
Depreciation expense	9	9
Impact of foreign exchange rate changes	(38)	72
Property, plant and equipment, Accumulated depreciation Ending	425	528
Property, plant and equipment, Carrying amount	42	22
Machinery [member]
IfrsStatementLineItems [Line Items]
At December 31, 2020	215	422
Disposals / Retirements	(5)	(245)
Impact of foreign exchange rate changes	(17)	38
Additions	6
Property, plant and equipment, Cost Ending	199	215
At December 31, 2020	199	400
Disposals / Retirements	(5)	(247)
Depreciation expense	4	6
Impact of foreign exchange rate changes	(17)	40
Property, plant and equipment, Accumulated depreciation Ending	181	199
Property, plant and equipment, Carrying amount	18	16
Fixtures and fittings [member]
IfrsStatementLineItems [Line Items]
At December 31, 2020		7
Disposals / Retirements		(7)
Impact of foreign exchange rate changes
Additions
Property, plant and equipment, Cost Ending
At December 31, 2020		7
Disposals / Retirements		(7)
Depreciation expense
Impact of foreign exchange rate changes
Property, plant and equipment, Accumulated depreciation Ending
Property, plant and equipment, Carrying amount
Computer equipment [member]
IfrsStatementLineItems [Line Items]
At December 31, 2020	335	314
Disposals / Retirements	(69)	(3)
Impact of foreign exchange rate changes	(22)	24
Additions	24
Property, plant and equipment, Cost Ending	268	335
At December 31, 2020	329	307
Disposals / Retirements	(69)	(3)
Depreciation expense	5	3
Impact of foreign exchange rate changes	(21)	22
Property, plant and equipment, Accumulated depreciation Ending	244	329
Property, plant and equipment, Carrying amount	24	6
Leasehold improvements [member]
IfrsStatementLineItems [Line Items]
At December 31, 2020		34
Disposals / Retirements		(38)
Impact of foreign exchange rate changes		4
Additions
Property, plant and equipment, Cost Ending
At December 31, 2020		28
Disposals / Retirements		(38)
Depreciation expense
Impact of foreign exchange rate changes		10
Property, plant and equipment, Accumulated depreciation Ending
Property, plant and equipment, Carrying amount

Restricted cash equivalents (De

Restricted cash equivalents (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Restricted cash and cash equivalents	$ 335	$ 338

Schedule of Right of Use Assets

Schedule of Right of Use Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
At December 31, 2020	$ 157
At December 31, 2021	150	$ 157
IFRS Sixteen Leases [Member]
IfrsStatementLineItems [Line Items]
At December 31, 2020	640	863
Modification of building lease	109	259
Additions	16	7
Disposals		(21)
Impact of foreign exchange rate changes	(55)	50
At December 31, 2021	710	640
At December 31, 2020	483	281
Disposals		(21)
Depreciation	120	203
Impact of foreign exchange rate changes	(43)	20
At December 31, 2021	560	483
Right of use assets, carrying amount	150	157
IFRS Sixteen Leases [Member] | Buildings [member]
IfrsStatementLineItems [Line Items]
At December 31, 2020	546	757
Modification of building lease	109	259
Additions	16
Disposals
Impact of foreign exchange rate changes	(48)	48
At December 31, 2021	623	546
At December 31, 2020	437	242
Disposals
Depreciation	94	180
Impact of foreign exchange rate changes	(38)	15
At December 31, 2021	493	437
Right of use assets, carrying amount	130	109
IFRS Sixteen Leases [Member] | Vehicles and Equipment [Member]
IfrsStatementLineItems [Line Items]
At December 31, 2020	94	106
Modification of building lease
Additions		7
Disposals		(21)
Impact of foreign exchange rate changes	(7)	2
At December 31, 2021	87	94
At December 31, 2020	46	39
Disposals		(21)
Depreciation	26	23
Impact of foreign exchange rate changes	(5)	5
At December 31, 2021	67	46
Right of use assets, carrying amount	$ 20	$ 48

Right of use assets (Details Na

Right of use assets (Details Narrative) - USD ($) $ in Thousands	Aug. 25, 2021	Dec. 31, 2021
Building Lease Agreement [Member]
IfrsStatementLineItems [Line Items]
Modification of building lease	$ 109	$ 259

Summary of Identifiable Intangi

Summary of Identifiable Intangible Assets with Finite Useful Lives (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Identifiable intangible assets, Cost Balances - Beginning of the year	$ 35,020	$ 31,422
Accumulated amortization Balances - Beginning of the year	(34,961)	31,382
Carrying value Balances - Beginning of the year	59	40
Accumulated amortization Balances - Beginning of the year	34,961	(31,382)
Additions	609	34
Additions
Additions	609	34
Additions
Recurring amortization expense
Recurring amortization expense	(16)	(20)	$ (20)
Recurring amortization expense	(16)	(20)
Impact of foreign exchange rate changes	(3,218)	3,564
Impact of foreign exchange rate changes	3,191	(3,559)
Impact of foreign exchange rate changes	(27)	5
Accumulated amortization Balances - End of the year	32,411	35,020	31,422
Accumulated amortization Balances - End of the year	(31,786)	(34,961)	31,382
Carrying value Balances - End of the year	$ 625	$ 59	$ 40

Summary of Change in Carrying V

Summary of Change in Carrying Value of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill Cost, Beginning	$ 8,815	$ 8,050
Accumulated impairment loss, Beginning
Goodwill Carrying amount, Beginning	8,815	8,050
Impact of foreign exchange rate changes	(685)	765
Impact of foreign exchange rate changes
Impact of foreign exchange rate changes	(685)	765
Goodwill Cost, Ending	8,130	8,815
Accumulated impairment loss, Ending
Goodwill Carrying amount, Ending	$ 8,130	$ 8,815

Identifiable intangible asset_2

Identifiable intangible assets (Details Narrative) € in Thousands, $ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2021CAD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
IfrsStatementLineItems [Line Items]
Addition to identifiable intangible assets	$ 609			$ 34
Amortization expense	16			$ 20	$ 20
Reimbursement pay	566		€ 500
Proceeds from trademarks	98
License Agreement [Member]
IfrsStatementLineItems [Line Items]
Addition to identifiable intangible assets	609
License Agreement [Member] | University of Wuerzburg [Member]
IfrsStatementLineItems [Line Items]
Addition to identifiable intangible assets	471		€ 400
License Agreement [Member] | University of Sheffield [Member]
IfrsStatementLineItems [Line Items]
Addition to identifiable intangible assets	$ 138	$ 100

Schedule of Payables and Accrue

Schedule of Payables and Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Trade accounts payable	$ 934	$ 1,187
Accrued research and development costs	531	23
Salaries, employment taxes and benefits	596	474
Other accrued liabilities	611	515
Payables and accrued liabilities	$ 2,672	$ 2,199

Schedule of Changes in Provisio

Schedule of Changes in Provisions for Onerous Contracts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Balance at December 31, 2020	$ 371	$ 726
Utilization of provision	(90)	(416)
Change in the provision	23	33
Unwinding of discount and impact of foreign exchange rate changes	(27)	28
Balance at December 31, 2021	277	371
Less: current portion	34	92
Non-current portion	243
Cetrotide Onerous Contracts [Member]
IfrsStatementLineItems [Line Items]
Balance at December 31, 2020	371	396
Utilization of provision	(90)	(93)
Change in the provision	23	33
Unwinding of discount and impact of foreign exchange rate changes	(27)	35
Balance at December 31, 2021	277	371
Less: current portion	34
Non-current portion	243
German Restructuring Severance [Member]
IfrsStatementLineItems [Line Items]
Balance at December 31, 2020		330
Utilization of provision		(323)
Change in the provision
Unwinding of discount and impact of foreign exchange rate changes		(7)
Balance at December 31, 2021
Less: current portion
Non-current portion

Schedule of Operating Lease Lia

Schedule of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Operating Lease Liabilities
Balance - Beginning of period	$ 184	$ 903
Additions	15	7
Interest paid as charged to comprehensive loss as other finance costs	(7)	(19)
Payment against lease liabilities	(127)	(265)	$ (614)
Modification of lease liability	103	(463)
Impact of foreign exchange rate changes	(7)	21
Balance - End of period	161	184	$ 903
Current lease liabilities	130	135
Non-current lease liabilities	$ 31	$ 49

Goodwill (Details Narrative)

Goodwill (Details Narrative) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Cost of disposal of goodwill	$ 1,774
Impairment of goodwill	$ 0

Summary of Maturity Analysis of

Summary of Maturity Analysis of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Lease liabilities	$ 161	$ 184	$ 903
Not later than one year [member]
IfrsStatementLineItems [Line Items]
Lease liabilities	130
Later than two years and not later than three years [member]
IfrsStatementLineItems [Line Items]
Lease liabilities	$ 31

Disclosure of Net Defined Benef

Disclosure of Net Defined Benefit Liability (Asset) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Balances - Beginning of the year	$ 11,963
Balances - End of the year	11,927	$ 11,963
Unfunded Plan [Member]
IfrsStatementLineItems [Line Items]
Balances - Beginning of the period	15,435
Current service cost	65
Interest cost	88
Actuarial loss (gain) arising from changes in financial assumptions	(1,130)
Past service cost associated with multi-employer plan	16,137
Actuarial loss arising from change in current assumptions on funding of future pension increases	556
Benefits paid	(511)
Impact of foreign exchange rate changes	(1,228)
Balances - End of the period	29,412	15,435
Balances - Beginning of the year
Presentation of plan assets as of December 31, 2021	11,963
Impact of foreign exchange rate changes	(36)
Balances - End of the year	11,927
Net liability of the unfunded plans	12,749
Net liability of the funded plans	4,736
Net amount recognized as Employee future benefits	17,485
Amounts recognized: In net loss	(153)
Amounts recognized: In other comprehensive loss	2,408
Unfunded Plan [Member] | Active Members [Member]
IfrsStatementLineItems [Line Items]
Balances - End of the period	4,341
Unfunded Plan [Member] | Vested Terminees [Member]
IfrsStatementLineItems [Line Items]
Balances - End of the period	13,799
Unfunded Plan [Member] | Retirees [Member]
IfrsStatementLineItems [Line Items]
Balances - End of the period	11,272
Unfunded Plan [Member] | Pension defined benefit plans [member]
IfrsStatementLineItems [Line Items]
Balances - Beginning of the period	15,341	13,704	13,100
Current service cost	60	50	41
Interest cost	87	162	239
Actuarial loss (gain) arising from changes in financial assumptions	(1,138)	650	1,068
Past service cost associated with multi-employer plan	16,137
Actuarial loss arising from change in current assumptions on funding of future pension increases	556
Benefits paid	(509)	(529)	(483)
Impact of foreign exchange rate changes	(1,221)	1,304	(261)
Balances - End of the period	29,313	15,341	13,704
Balances - Beginning of the year
Presentation of plan assets as of December 31, 2021	11,963
Impact of foreign exchange rate changes	(36)
Balances - End of the year	11,927
Net liability of the unfunded plans	12,650
Net liability of the funded plans	4,736
Net amount recognized as Employee future benefits	17,386
Amounts recognized: In net loss	(147)	(212)	(280)
Amounts recognized: In other comprehensive loss	2,407	(1,954)	(807)
Unfunded Plan [Member] | Pension defined benefit plans [member] | Active Members [Member]
IfrsStatementLineItems [Line Items]
Balances - End of the period	4,242
Unfunded Plan [Member] | Pension defined benefit plans [member] | Vested Terminees [Member]
IfrsStatementLineItems [Line Items]
Balances - End of the period	13,799
Unfunded Plan [Member] | Pension defined benefit plans [member] | Retirees [Member]
IfrsStatementLineItems [Line Items]
Balances - End of the period	11,272
Unfunded Plan [Member] | Other Benefit Plans [Member]
IfrsStatementLineItems [Line Items]
Balances - Beginning of the period	94	84	105
Current service cost	5	4	8
Interest cost	1	1	2
Actuarial loss (gain) arising from changes in financial assumptions	8	1	(28)
Past service cost associated with multi-employer plan
Actuarial loss arising from change in current assumptions on funding of future pension increases
Benefits paid	(2)	(3)
Impact of foreign exchange rate changes	(7)	7	(3)
Balances - End of the period	99	94	84
Balances - Beginning of the year
Presentation of plan assets as of December 31, 2021
Impact of foreign exchange rate changes
Balances - End of the year
Net liability of the unfunded plans	99
Net liability of the funded plans
Net amount recognized as Employee future benefits	99
Amounts recognized: In net loss	(6)	(6)	18
Amounts recognized: In other comprehensive loss	1	$ (7)	$ 3
Unfunded Plan [Member] | Other Benefit Plans [Member] | Active Members [Member]
IfrsStatementLineItems [Line Items]
Balances - End of the period	99
Unfunded Plan [Member] | Other Benefit Plans [Member] | Vested Terminees [Member]
IfrsStatementLineItems [Line Items]
Balances - End of the period
Unfunded Plan [Member] | Other Benefit Plans [Member] | Retirees [Member]
IfrsStatementLineItems [Line Items]
Balances - End of the period

Schedule of Employer Pension Pl

Schedule of Employer Pension Plan Asset (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Total	$ 11,927	$ 11,963
Multi Employer Pension Plan [Member] | Quoted Equities Level 1 [Member]
IfrsStatementLineItems [Line Items]
Total	826
Multi Employer Pension Plan [Member] | Quoted Bonds Level 1 [Member]
IfrsStatementLineItems [Line Items]
Total	7,445
Multi Employer Pension Plan [Member] | Cash Level 1 [Member]
IfrsStatementLineItems [Line Items]
Total	67
Multi Employer Pension Plan [Member] | Real Estate Level 3 [Member]
IfrsStatementLineItems [Line Items]
Total	2,207
Multi Employer Pension Plan [Member] | Other Level 3 [Member]
IfrsStatementLineItems [Line Items]
Total	$ 1,382

Summary of Significant Actuaria

Summary of Significant Actuarial Assumptions Applied to Determine Accrued Benefit Obligations (Details)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Pension defined benefit plans [member]
IfrsStatementLineItems [Line Items]
Discount rate		0.50%
Pension defined benefit plans [member] | Actuarial Assumptions [Member]
IfrsStatementLineItems [Line Items]
Discount rate	1.10%	0.60%	1.10%
Pension benefits increase	0.50%	0.50%	1.50%
Rate of compensation increase	2.50%	2.00%	2.00%
Other Benefit Plans [Member] | Actuarial Assumptions [Member]
IfrsStatementLineItems [Line Items]
Discount rate	1.10%	0.60%	1.90%
Pension benefits increase	0.50%	0.50%	1.50%
Rate of compensation increase	2.50%	2.00%	2.00%

Summary of Assumptions Translat

Summary of Assumptions Translate into an Average Remaining Life Expectancy in Years (Details) - Pension defined benefit plans [member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Male [Member]
IfrsStatementLineItems [Line Items]
Average remaining life expectancy at the end of the reporting period	21 years	20 years	20 years
Average remaining life expectancy of those retiring twenty years after the end of the reporting period	28 years	28 years	28 years
Female [Member]
IfrsStatementLineItems [Line Items]
Average remaining life expectancy at the end of the reporting period	24 years	24 years	24 years
Average remaining life expectancy of those retiring twenty years after the end of the reporting period	31 years	31 years	31 years

Summary of Undiscounted Defined

Summary of Undiscounted Defined Pension Benefits Expected to be Paid (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Total undiscounted defined pension benefits expected to be paid		$ 16,137
Pension defined benefit plans [member]
IfrsStatementLineItems [Line Items]
Total undiscounted defined pension benefits expected to be paid	$ 36,924
Pension defined benefit plans [member] | Not later than one year [member]
IfrsStatementLineItems [Line Items]
Total undiscounted defined pension benefits expected to be paid	801
Pension defined benefit plans [member] | Later than one year and not later than two years [member]
IfrsStatementLineItems [Line Items]
Total undiscounted defined pension benefits expected to be paid	823
Pension defined benefit plans [member] | Later than two years and not later than three years [member]
IfrsStatementLineItems [Line Items]
Total undiscounted defined pension benefits expected to be paid	853
Pension defined benefit plans [member] | Later than three years and not later than four years [member]
IfrsStatementLineItems [Line Items]
Total undiscounted defined pension benefits expected to be paid	868
Pension defined benefit plans [member] | Later than five years [member]
IfrsStatementLineItems [Line Items]
Total undiscounted defined pension benefits expected to be paid	894
Pension defined benefit plans [member] | Later than four years and not later than five years [member]
IfrsStatementLineItems [Line Items]
Total undiscounted defined pension benefits expected to be paid	$ 32,685

Summary of Impact on Pension Be

Summary of Impact on Pension Benefit Obligation (Details) - Pension defined benefit plans [member] $ in Thousands	Dec. 31, 2021USD ($)
Actuarial assumption of discount rates [member]
IfrsStatementLineItems [Line Items]
Increase	$ (1,252)
Decrease	1,338
Actuarial assumption of expected rates of pension increases [member]
IfrsStatementLineItems [Line Items]
Increase	18
Decrease	(18)
Actuarial assumption of expected rates of salary increases [member]
IfrsStatementLineItems [Line Items]
Increase	905
Decrease	(867)
Actuarial assumption of mortality rates [member]
IfrsStatementLineItems [Line Items]
Increase	968
Decrease	$ (974)

Summary of Impact on Pension _2

Summary of Impact on Pension Benefit Obligation (Details) (Parenthetical) - Pension defined benefit plans [member]	12 Months Ended
	Dec. 31, 2021
Actuarial assumption of discount rates [member]
IfrsStatementLineItems [Line Items]
Change in percentage, increase	0.25%
Change in percentage, decrease	0.25%
Actuarial assumption of expected rates of pension increases [member]
IfrsStatementLineItems [Line Items]
Change in percentage, increase	0.25%
Change in percentage, decrease	0.25%
Actuarial assumption of expected rates of salary increases [member]
IfrsStatementLineItems [Line Items]
Change in percentage, increase	0.25%
Change in percentage, decrease	0.25%
Actuarial assumption of mortality rates [member]
IfrsStatementLineItems [Line Items]
Change in mortality, increase	1 year
Change in mortality, decrease	1 year

Employee future benefits (Detai

Employee future benefits (Details Narrative) - USD ($) $ in Thousands	May 05, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
IfrsStatementLineItems [Line Items]
Gain on modification of building lease	$ 34
Defined benefit obligation, at present value			$ 16,137
Assets of benefit plan		$ 11,927	11,963
Cumulative amount of actuarial net losses		$ 9,385	5,793	$ 5,143
Weighted average duration of defined benefit obligation		16 years
German Subsidiary [Member]
IfrsStatementLineItems [Line Items]
Defined contribution plan, expenses		$ 45	38	54
Unfunded Plan [Member]
IfrsStatementLineItems [Line Items]
Assets of benefit plan		11,927
Liability asset of defined benefit plans		29,412	$ 15,435
Pension defined benefit plans [member]
IfrsStatementLineItems [Line Items]
Defined benefit obligation, at present value		36,924
Discount rate			0.50%
Pension defined benefit plans [member] | Unfunded Plan [Member]
IfrsStatementLineItems [Line Items]
Assets of benefit plan		11,927
Liability asset of defined benefit plans		29,313	$ 15,341	$ 13,704	$ 13,100
Pension defined benefit plans [member] | Addition Expected Inflation [Member]
IfrsStatementLineItems [Line Items]
Discount rate			1.75%
German Subsidiary [Member]
IfrsStatementLineItems [Line Items]
Gain on modification of building lease			$ 34

Schedule of Warrants Activity R

Schedule of Warrants Activity Reclassified into Equity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share Capital Warrants And Other Capital
Warrants Outstanding, Beginning of year	44,901,366
Weighted Average Exercise Price, Beginning of year	$ 0.6025
Warrants Outstanding, Beginning of year, value	$ 12,402
Warrant liability reclassified to equity		16,368,033
Weighted Average Exercise Price, Warrant liability reclassified to equity		$ 0.8556
Warrant liability reclassified to equity, value		$ 7,377
Warrants issued as equity		28,533,333
Weighted Average Exercise Price, Warrants issued as equity (July 2020)		$ 0.4574
Warrants issued as equity (July 2020), value		$ 5,025
February 2021 Placement Agent Warrants	1,651,034
Weighted Average Exercise Price, February 2021 Placement Agent Warrants	$ 1.8125
February 2021 Placement Agent Warrants, value	$ 1,897
Warrants exercised	(35,111,187)
Warrants exercised	$ 0.5725
Warrants exercised, value	$ (9,746)
Allocation of transaction costs to share capital, value	$ 532
Warrants Outstanding, End of year	11,441,213	44,901,366
Weighted Average Exercise Price, End of year	$ 0.8668	$ 0.6025
Warrants Outstanding, End of year, value	$ 5,085	$ 12,402

Schedule of Fair Value of Warra

Schedule of Fair Value of Warrants Assumptions (Details) - $ / shares		Sep. 14, 2020	Jun. 16, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Market value per share price				$ 0.42	$ 0.37	$ 2
Risk-free annual interest rate	[1]			123.00%	27.00%	186.00%
Expected volatility	[2]			115.80%	112.50%	110.02%
Expected dividend yield	[3]			0.00%	0.00%	0.00%
February 2021 Placement Agent Warrants issued on February 19, 2021 [Member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares				1,435,682
Market value per share price				$ 1.48
Weighted average exercise price				$ 1.8125
Risk-free annual interest rate	[4]			0.58734%
Expected volatility	[5]			119.18%
Expected life (years)	[6]			4 years 11 months 26 days
Expected dividend yield	[7]			0.00%
February 2021 Placement Agent Warrants issued on February 22, 2021 [Member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares				215,352
Market value per share price				$ 1.48
Weighted average exercise price				$ 1.8125
Risk-free annual interest rate	[4]			0.58544%
Expected volatility	[5]			119.57%
Expected life (years)	[6]			4 years 11 months 23 days
Expected dividend yield	[7]			0.00%
September 2019 Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares			3,325,000
Market value per share price			$ 0.96
Weighted average exercise price			$ 1.65
Risk-free annual interest rate	[8]		0.30%
Expected volatility	[9]		104.50%
Expected life (years)	[10]		4 years 3 months 18 days
Expected dividend yield	[11]		0.00%
February 2020 Investor Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares			2,608,696
Market value per share price			$ 0.96
Weighted average exercise price			$ 1.20
Risk-free annual interest rate	[8]		0.36%
Expected volatility	[9]		119.30%
Expected life (years)	[10]		5 years 2 months 12 days
Expected dividend yield	[11]		0.00%
February 2020 Placement Agent Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares			243,478
Market value per share price			$ 0.96
Weighted average exercise price			$ 1.62
Risk-free annual interest rate	[8]		0.32%
Expected volatility	[9]		113.30%
Expected life (years)	[10]		4 years 8 months 12 days
Expected dividend yield	[11]		0.00%
August 2020 Placement Agent Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares		9,320,907
Market value per share price		$ 0.38
Weighted average exercise price		$ 0.47
Risk-free annual interest rate	[8]	0.31%
Expected volatility	[9]	120.50%
Expected life (years)	[10]	5 years 4 months 24 days
Expected dividend yield	[11]	0.00%
August 2020 Investor Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares		869,952
Market value per share price		$ 0.38
Weighted average exercise price		$ 0.704063
Risk-free annual interest rate	[8]	0.26%
Expected volatility	[9]	114.60%
Expected life (years)	[10]	4 years 10 months 24 days
Expected dividend yield	[11]	0.00%
June Two Thousand Twenty Investor Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares				26,666,666
Market value per share price				$ 0.52
Weighted average exercise price				$ 0.457
Risk-free annual interest rate	[12]			0.2879%
Expected volatility	[13]			123.1048%
Expected life (years)	[14]			5 years
Expected dividend yield	[15]			0.00%
June 2020 Placement Agent Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of equivalent shares				1,866,667
Market value per share price				$ 0.52
Weighted average exercise price				$ 0.5625
Risk-free annual interest rate	[12]			0.2879%
Expected volatility	[13]			123.1048%
Expected life (years)	[14]			5 years
Expected dividend yield	[15]			0.00%
[1]	Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options.
[2]	Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations.
[3]	The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
[4]	Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants.
[5]	Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants.
[6]	Based upon time to expiry from the issuance date.
[7]	The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
[8]	Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants.
[9]	Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants, as well as on future expectations.
[10]	Based upon time to expiry from the reporting period date.
[11]	The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
[12]	Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants.
[13]	Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants, as well as on future expectations.
[14]	Based upon time to expiry from the reporting period date.
[15]	The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.

Summary of Warrants Exercise Tr

Summary of Warrants Exercise Transactions (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)shares$ / shares
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	35,111,187
Proceeds from exercise of options | $	$ 20,087
September 2019 Investor Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	2,000,000
Exercise Price | $ / shares	$ 1.65
Proceeds from exercise of options | $	$ 3,300
February 2020 Investor Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	1,739,130
Exercise Price | $ / shares	$ 1.20
Proceeds from exercise of options | $	$ 2,087
July 2020 Investor Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	21,045,555
Exercise Price | $ / shares	$ 0.45
Proceeds from exercise of options | $	$ 9,471
July 2020 Placement Agent Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	1,866,667
Exercise Price | $ / shares	$ 0.5625
Proceeds from exercise of options | $	$ 1,050
August 2020 Investor Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	7,589,883
Exercise Price | $ / shares	$ 0.47
Proceeds from exercise of options | $	$ 3,567
August 2020 Placement Agent Warrants [Member]
IfrsStatementLineItems [Line Items]
Number of share options exercised in share-based payment arrangement | shares	869,952
Exercise Price | $ / shares	$ 0.7040625
Proceeds from exercise of options | $	$ 612

Disclosure of Change in Stock O

Disclosure of Change in Stock Options Issued (Details)	12 Months Ended
	Dec. 31, 2021shares$ / shares	Dec. 31, 2020shares$ / shares	Dec. 31, 2019shares$ / shares
IfrsStatementLineItems [Line Items]
Balance - Beginning of year, Number (in shares)	(35,111,187)
Exercised, Number (in shares)	35,111,187
Employee Stock Option, USD [Member]
IfrsStatementLineItems [Line Items]
Balance - Beginning of year, Number (in shares)	506,400	741,116	727,816
Balance - Beginning of year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares	$ 1.44	$ 3.61	$ 4.07
Balance - Beginning of year, Number (in shares)	580,000	180,000	185,000
Balance - Beginning of year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares	$ 0.42	$ 0.37	$ 1.07
Balance - Beginning of year, Number (in shares)	(32)	(84,366)	(100,850)
Balance - Beginning of year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares	$ 590.25	$ 2.14	$ 2.24
Balance - Beginning of year, Number (in shares)	32	84,366	100,850
Balance - Beginning of year, Number (in shares)			(64,850)
Balance - Beginning of year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares			$ (2.75)
Balance - Beginning of year, Number (in shares)	1,086,368	506,400	741,116
Balance - Beginning of year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares	$ 0.88	$ 1.44	$ 3.61
Exercised, Weighted average exercise price (in US and CAN dollars per share) | $ / shares			$ 2.75
Exercised, Number (in shares)			64,850
Balance - Beginning of year, Number (in shares)		(330,350)	(6,000)
Balance - Beginning of year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares		$ 2.56	$ 13.39
Balance - Beginning of year, Number (in shares)		330,350	6,000
Deferred Stock Units DSU's [Member]
IfrsStatementLineItems [Line Items]
Balance - Beginning of year, Number (in shares)	173,000	212,000	161,000
Balance - Beginning of year, Number (in shares)	280,000	120,000	150,000
Balance - Beginning of year, Number (in shares)
Balance - Beginning of year, Number (in shares)
Balance - Beginning of year, Number (in shares)	(30,000)	(159,000)	(99,000)
Balance - Beginning of year, Number (in shares)	423,000	173,000	212,000
Exercised, Number (in shares)	30,000	159,000	99,000
Balance - Beginning of year, Number (in shares)
Balance - Beginning of year, Number (in shares)
Employee Stock Option, CAD [Member]
IfrsStatementLineItems [Line Items]
Balance - Beginning of year, Number (in shares)		441	869
Balance - Beginning of year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares		$ 912	$ 743.56
Balance - Beginning of year, Number (in shares)
Balance - Beginning of year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares
Balance - Beginning of year, Number (in shares)		(441)	(428)
Balance - Beginning of year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares		$ 912	$ 570
Balance - Beginning of year, Number (in shares)		441	428
Balance - Beginning of year, Number (in shares)
Balance - Beginning of year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares
Balance - Beginning of year, Number (in shares)			441
Balance - Beginning of year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares			$ 912
Exercised, Weighted average exercise price (in US and CAN dollars per share) | $ / shares
Exercised, Number (in shares)
Balance - Beginning of year, Number (in shares)
Balance - Beginning of year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares
Balance - Beginning of year, Number (in shares)

Summary of Assumptions to Deter

Summary of Assumptions to Determine Share-Based Compensation Costs Over the Life of Awards (Details) - $ / shares		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Capital Warrants And Other Capital
Expected dividend yield	[1]	0.00%	0.00%	0.00%
Expected volatility	[2]	115.80%	112.50%	110.02%
Risk-free annual interest rate	[3]	123.00%	27.00%	186.00%
Expected life (years)	[4]	5 years 8 months 15 days	4 years 7 days	5 years 11 months 8 days
Weighted average share price		$ 0.42	$ 0.37	$ 2
Weighted average exercise price		0.42	0.37	2
Weighted average grant date fair value		$ 0.35	$ 0.27	$ 2
[1]	The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
[2]	Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the stock options, as well as on future expectations.
[3]	Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the stock options.
[4]	Based upon historical data related to the exercise of stock options, on post-vesting employment terminations and on future expectations related to exercise behavior.

Schedule of Stock Options Exerc

Schedule of Stock Options Exercise Price Range (Details)	12 Months Ended
	Dec. 31, 2021shares$ / shares
IfrsStatementLineItems [Line Items]
Options outstanding, Number (in shares) | shares	1,086,368
Options outstanding, Weighted average remaining contractual life (years)	5 years 9 months 21 days
Options outstanding, Weighted average exercise price (in US dollars per share)	$ 0.88
Options exercisable, Number (in shares) | shares	324,713
Options exercisable, Weighted average remaining contractual life (years)	3 years 10 months 9 days
Options exercisable, Weighted average exercise price (in US dollars per share)	$ 1.84
Range One [Member]
IfrsStatementLineItems [Line Items]
Range of US/CAN dollar-denominated options exercise price, lower limit	0.37
Range of US/CAN dollar-denominated options exercise price, upper limit	$ 0.50
Options outstanding, Number (in shares) | shares	760,000
Options outstanding, Weighted average remaining contractual life (years)	6 years 8 months 19 days
Options outstanding, Weighted average exercise price (in US dollars per share)	$ 0.41
Options exercisable, Number (in shares) | shares	60,006
Options exercisable, Weighted average remaining contractual life (years)	5 years 11 months 12 days
Options exercisable, Weighted average exercise price (in US dollars per share)	$ 0.37
Range Two [Member]
IfrsStatementLineItems [Line Items]
Range of US/CAN dollar-denominated options exercise price, lower limit	0.51
Range of US/CAN dollar-denominated options exercise price, upper limit	$ 1.78
Options outstanding, Number (in shares) | shares	160,000
Options outstanding, Weighted average remaining contractual life (years)	4 years 10 months 28 days
Options outstanding, Weighted average exercise price (in US dollars per share)	$ 0.91
Options exercisable, Number (in shares) | shares	106,672
Options exercisable, Weighted average remaining contractual life (years)	4 years 10 months 28 days
Options exercisable, Weighted average exercise price (in US dollars per share)	$ 0.90
Range Three [Member]
IfrsStatementLineItems [Line Items]
Range of US/CAN dollar-denominated options exercise price, lower limit	1.79
Range of US/CAN dollar-denominated options exercise price, upper limit	$ 3.14
Options outstanding, Number (in shares) | shares	85,000
Options outstanding, Weighted average remaining contractual life (years)	3 years 2 months 15 days
Options outstanding, Weighted average exercise price (in US dollars per share)	$ 2.08
Options exercisable, Number (in shares) | shares	76,667
Options exercisable, Weighted average remaining contractual life (years)	3 years 21 days
Options exercisable, Weighted average exercise price (in US dollars per share)	$ 2.07
Range Four [Member]
IfrsStatementLineItems [Line Items]
Range of US/CAN dollar-denominated options exercise price, lower limit	3.15
Range of US/CAN dollar-denominated options exercise price, upper limit	$ 217
Options outstanding, Number (in shares) | shares	81,368
Options outstanding, Weighted average remaining contractual life (years)	1 year 8 months 12 days
Options outstanding, Weighted average exercise price (in US dollars per share)	$ 3.95
Options exercisable, Number (in shares) | shares	81,368
Options exercisable, Weighted average remaining contractual life (years)	1 year 8 months 12 days
Options exercisable, Weighted average exercise price (in US dollars per share)	$ 3.95

Share capital, warrants and o_3

Share capital, warrants and other capital (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

Feb. 22, 2021

Feb. 21, 2021

Feb. 19, 2021

Aug. 05, 2020

Jul. 07, 2020

Sep. 20, 2019

May 10, 2017

Feb. 28, 2021

Aug. 31, 2020

Aug. 31, 2020

Jul. 31, 2020

Feb. 28, 2020

Sep. 30, 2019

Sep. 30, 2019

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

IfrsStatementLineItems [Line Items]

Number of common shares issued, shares

26,666,666

35,111,187

Proceeds from issuing common shares

$ 754

$ 20,100

Share price

$ 0.45

Warrant liability

$ 5,691

Transaction costs

1,420

$ 55,905

$ 55,905

$ 55,905

$ 55,905

$ 55,905

3,221

$ 2,767

$ 795

Gross proceeds from Issuance of common shares and warrants

12,000

34,200

Share capital

6,308

Warrants issued value

666

Stock Options [Member]

IfrsStatementLineItems [Line Items]

Unrecognized compensation cost

$ 96

$ 43

$ 101

Unrecognized compensation cost expected to be recognized over weighted average period

1 year 6 months 14 days

1 year 5 months 4 days

1 year 2 months 15 days

Registered Direct Offering [Member]

IfrsStatementLineItems [Line Items]

Number of common shares issued, shares

3,478,261

Proceeds from issuing common shares

$ 4,500

Share price

$ 1.29

Registered Direct Offering [Member] | September 2019 Warrants [Member]

IfrsStatementLineItems [Line Items]

Warrants Issued

3,325,000

Public Offering [Member]

IfrsStatementLineItems [Line Items]

Proceeds from issuing common shares

$ 10,596

Securities Purchase Agreement [Member]

IfrsStatementLineItems [Line Items]

Number of common shares issued, shares

12,427,876

3,325,000

Share price

$ 0.56325

Warrant liability

$ 3,944

$ 550

Gross proceeds from Issuance of common shares and warrants

$ 7,000

$ 4,988

Combined purchase price, description

The combined purchase price for one common share and one warrant was $1.50

Securities Purchase Agreement [Member] | Investors [Member]

IfrsStatementLineItems [Line Items]

Gross proceeds from Issuance of common shares and warrants

$ 4,988

Securities Purchase Agreement [Member] | Unregistered Warrants [Member]

IfrsStatementLineItems [Line Items]

Warrants Issued

9,320,907

Warrants exercise price

$ 0.47

Warrant exercisable term description

five and one-half years

Securities Purchase Agreement [Member] | Unregistered Warrants [Member] | Placement Agent [Member]

IfrsStatementLineItems [Line Items]

Warrants Issued

869,952

Warrants exercise price

$ 0.7040625

Warrants expiry date

Aug. 3, 2025

Transaction costs

$ 327

Gross proceeds from Issuance of common shares and warrants

7,000

Share capital

3,056

Securities Purchase Agreement [Member] | Warrant Liability [Member] | Nonadjusting Event [Member]

IfrsStatementLineItems [Line Items]

Transaction costs

421

Gross proceeds from Issuance of common shares and warrants

$ 748

2018 Long-Term Incentive Plan [Member]

IfrsStatementLineItems [Line Items]

Percentage of issued and outstanding common shares

11.40%

Warrants [Member]

IfrsStatementLineItems [Line Items]

Number of common shares issued, shares

243,478

Proceeds from issuing common shares

$ 34,200

Non-cash transaction costs

3,221

Warrant liability

$ 1,897

Exercise price

$ 1.62

Warrants [Member] | Registered Direct Offering [Member]

IfrsStatementLineItems [Line Items]

Number of common shares issued, shares

2,608,696

Proceeds from issuing common shares

$ 3,900

Warrant liability

$ 311

Exercise price

$ 1.20

Warrants [Member] | Securities Purchase Agreement [Member]

IfrsStatementLineItems [Line Items]

Transaction costs

795

Gross proceeds from Issuance of common shares and warrants

3,457

Placement Agent Warrants [Member]

IfrsStatementLineItems [Line Items]

Number of common shares issued, shares

215,352

1,866,667

Proceeds from issuing common shares

$ 4,461

Share price

$ 0.5625

Option to purchase common stock

3,076,461

Warrants expiry date

Jul. 1, 2025

Warrants Liability [Member]

IfrsStatementLineItems [Line Items]

Proceeds from issuing common shares

$ 2,325

Share Capital [Member]

IfrsStatementLineItems [Line Items]

Proceeds from issuing common shares

2,174

Share Capital [Member] | Securities Purchase Agreement [Member]

IfrsStatementLineItems [Line Items]

Transaction costs

795

Gross proceeds from Issuance of common shares and warrants

$ 1,531

Share Capital and Warrants [Member]

IfrsStatementLineItems [Line Items]

Transaction costs

$ 600

Common Stock [Member]

IfrsStatementLineItems [Line Items]

Number of common shares issued, shares

26,666,666

Investor Share Purchase Warrants [Member]

IfrsStatementLineItems [Line Items]

Number of common shares issued, shares

26,666,666

Share price

$ 0.45

Warrants expiry date

Jul. 7, 2025

February 2020 Investor Warrants [Member] | Registered Direct Offering [Member]

IfrsStatementLineItems [Line Items]

Warrants Issued

2,608,696

February 2020 Placement Agent Warrants [Member] | Registered Direct Offering [Member]

IfrsStatementLineItems [Line Items]

Warrants Issued

243,478

August 2020 Investor Warrants [Member] | Registered Direct Offering [Member]

IfrsStatementLineItems [Line Items]

Warrants Issued

9,320,907

August 2020 Placement Agent Warrants [Member] | Registered Direct Offering [Member]

IfrsStatementLineItems [Line Items]

Warrants Issued

869,952

Top of range [member] | Stock Option Plan Prior to 2014 Amendment [Member]

IfrsStatementLineItems [Line Items]

Expected life of options granted

10 years

Top of range [member] | Stock Option Plan After to 2014 Amendment [Member]

IfrsStatementLineItems [Line Items]

Expected life of options granted

7 years

Public Offering [Member]

IfrsStatementLineItems [Line Items]

Number of common shares issued, shares

20,509,746

Proceeds from issuing common shares

$ 29,739

Share price

$ 1.45

Placement agent fees and other offering expenses

$ 2,837

Warrants Issued

1,435,682

Public Offering [Member] | Warrants [Member]

IfrsStatementLineItems [Line Items]

Warrants exercise price

$ 1.8125

Warrants expiry date

Feb. 17, 2026

Public Offering [Member] | Top of range [member]

IfrsStatementLineItems [Line Items]

Option to purchase common stock

3,076,461

Schedule of Operating Expenses

Schedule of Operating Expenses (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Cost of inventory used and services provided		$ 90	$ 2,317	$ 410
Restructuring costs				507
Modification of building lease			(219)
Impairment of right of use asset			131	106
Total operating expenses		13,931	9,358	10,774
Unfunded Plan [Member] | Other Benefit Plans [Member]
IfrsStatementLineItems [Line Items]
Salaries and short-term employee benefits	[1]	1,646	1,540	1,705
Consultant’s fees	[1]	163	167	194
Termination benefits	[1]			503
Post-employment benefits, including defined contribution plan benefits of $33 in 2021, $33 in 2020 and $195 in 2019		70	86	257
Share-based compensation costs	[1]	295	160	784
Key management personnel compensation	[1]	2,174	1,953	3,443
Salaries and short-term employee benefits		1,160	1,004	1,257
Post-employment benefits, including defined contribution plan benefits of $15 in 2021, $9 in 2020 and $25 in 2019		139	159	78
Share-based compensation costs		16	(99)	9
Other employees compensation		1,315	1,064	1,344
Cost of inventory used and services provided		90	2,186	309
Professional fees		2,749	1,969	2,599
Insurance		1,077	861	890
Third-party research and development		5,047	414	322
Consulting fees		553	587	144
Restructuring costs				507
Travel		130	66	154
Marketing services		222	39	18
Laboratory supplies		114	36	23
Other goods and services		162	72	137
Leasing costs, net of sublease receipts of $nil in 2021, $nil in 2020 and $214 in 2019		112	218	247
Modification of building lease			(219)
(Reversal) impairment of other asset and inventory			(8)	270
Depreciation and amortization of property, equipment and intangibles		25	29	37
Depreciation - right to use assets		120	203	278
Impairment of right of use asset				22
Operating foreign exchange losses (gains)		41	(112)	30
Operating expenses excluding management and Employee compensation		10,442	6,341	5,987
Total operating expenses		$ 13,931	$ 9,358	$ 10,774
[1]	Key management includes the Company’s executive management team and directors.

Schedule of Operating Expense_2

Schedule of Operating Expenses (Details) (Parenthetical) - Unfunded Plan [Member] - Other Benefit Plans [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Sublease			$ 214
Key management personnel of entity or parent [member]
IfrsStatementLineItems [Line Items]
Post-employment benefits, including defined contribution plan benefits	33	33	195
Other Employees Compensation [Member]
IfrsStatementLineItems [Line Items]
Post-employment benefits, including defined contribution plan benefits	$ 15	$ 9	$ 25

Disclosure of Changes in Operat

Disclosure of Changes in Operating Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Trade and other receivables	$ 120	$ (1,023)	$ (371)
Inventory	(56)	1,182	(971)
Prepaid expenses and other current assets	(750)	(702)	(170)
Payables and accrued liabilities	634	51	(615)
Income taxes payable	(109)	395	(188)
Deferred revenues	3,010	3,031	743
Provision for restructuring and other costs			(389)
Employee future benefits (note 18)	(349)	(532)	(483)
Increase (decrease) in operating assets and liabilities	$ 2,500	$ 2,402	$ (2,444)

Summary of Significant Componen

Summary of Significant Components of Current and Deferred Income Tax Recovery (Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes
Current income tax recovery (expense)	$ 109	$ (395)	$ 188
Origination and reversal of temporary differences	1,291	1,509	2,755
Change in unrecognized tax assets	(1,291)	(1,509)	(2,755)
Total income tax recovery (expense)	$ 109	$ (395)	$ 188

Summary of Reconciliation of Co

Summary of Reconciliation of Combined Canadian Federal and Provincial Income Tax Rate to Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Taxes
Combined Canadian federal and provincial statutory income tax rate	26.50%	26.50%	26.50%
Income tax (expense) recovery based on combined statutory income tax rate	$ 2,246	$ 1,252	$ 1,615
Change in unrecognized tax assets	(1,291)	(1,872)	(2,820)
Share issuance costs	367	363	65
Permanent difference attributable to the use of local currency for tax reporting			35
Change in enacted rates used			(27)
Impact of expiring tax credits	(1,724)	(481)
Provision to filed return adjustments	151
Permanent difference attributable to net change in fair value of warrant liability		304	1,197
Share-based compensation costs	(82)	(16)	(210)
Difference in statutory income tax rate of foreign subsidiaries	226	99	321
Uncertain tax position		(123)
Other	216	79	12
Total income tax recovery (expense)	$ 109	$ (395)	$ 188

Summary of (Loss) Income Before

Summary of (Loss) Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Loss before income taxes	$ (8,477)	$ (4,723)	$ (6,230)
Germany [Member]
IfrsStatementLineItems [Line Items]
Loss before income taxes	(4,383)	(2,042)	(6,010)
Canada [Member]
IfrsStatementLineItems [Line Items]
Loss before income taxes	(3,860)	(2,463)	812
United States [Member]
IfrsStatementLineItems [Line Items]
Loss before income taxes	$ (234)	$ (218)	$ (1,032)

Summary of Significant Compon_2

Summary of Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Deferred tax assets	$ 981	$ 1,364
Deferred tax liabilities	981	1,364
Deferred tax liabilities, net	981	1,364
Deferred tax assets (liabilities), net
Operating Losses Carried Forward [Member]
IfrsStatementLineItems [Line Items]
Deferred tax assets	205	46
Intangible Asset [Member]
IfrsStatementLineItems [Line Items]
Deferred tax assets	776	1,318
Accounts Receivable Related Temporary Differences [Member]
IfrsStatementLineItems [Line Items]
Deferred tax liabilities	375	0
Payable and Accrued Liabilities [Member]
IfrsStatementLineItems [Line Items]
Deferred tax liabilities	7	126
Property, Plant and Equipment [Member]
IfrsStatementLineItems [Line Items]
Deferred tax liabilities	47	49
Deferred Revenues [Member]
IfrsStatementLineItems [Line Items]
Deferred tax liabilities	492	1,073
Other temporary differences [member]
IfrsStatementLineItems [Line Items]
Deferred tax liabilities	$ 60	$ 116

Summary of Significant Compon_3

Summary of Significant Components of Unrecognized Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Unrecognized deferred tax assets, gross	$ 106,715	$ 108,673
Unrecognized deferred tax assets	106,715	108,673
Deferred Revenues and Other Provisions [Member]
IfrsStatementLineItems [Line Items]
Unrecognized deferred tax assets, gross	1,680	1,494
Operating Losses Carried Forward [Member]
IfrsStatementLineItems [Line Items]
Unrecognized deferred tax assets, gross	87,734	89,144
Capital Losses Carried Forward Temporary Differences [Member]
IfrsStatementLineItems [Line Items]
Unrecognized deferred tax assets, gross	105
Scientific Research and Experimental Development [Member]
IfrsStatementLineItems [Line Items]
Unrecognized deferred tax assets, gross	9,138	9,138
Unused tax credits [member]
IfrsStatementLineItems [Line Items]
Unrecognized deferred tax assets, gross	2,945	4,668
Employee Future Benefits [Member]
IfrsStatementLineItems [Line Items]
Unrecognized deferred tax assets, gross	3,396	2,570
Property, Plant and Equipment [Member]
IfrsStatementLineItems [Line Items]
Unrecognized deferred tax assets, gross	523	495
Intangible Assets [Member]
IfrsStatementLineItems [Line Items]
Unrecognized deferred tax assets, gross		541
Share Issuance Expenses [Member]
IfrsStatementLineItems [Line Items]
Unrecognized deferred tax assets, gross	1,110	623
Other temporary differences [member]
IfrsStatementLineItems [Line Items]
Unrecognized deferred tax assets, gross	$ 84

Summary of Disclosure of Federa

Summary of Disclosure of Federal Tax Losses (Details) $ in Thousands, $ in Thousands	Dec. 31, 2021USD ($)	Dec. 31, 2021CAD ($)	Dec. 31, 2020USD ($)
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized	$ 106,715		$ 108,673
United State [Member]
IfrsStatementLineItems [Line Items]
Unused tax losses for which no deferred tax asset recognized	4,793
United State [Member] | 2028 [Member]
IfrsStatementLineItems [Line Items]
Unused tax losses for which no deferred tax asset recognized	369
United State [Member] | 2029 [Member]
IfrsStatementLineItems [Line Items]
Unused tax losses for which no deferred tax asset recognized	178
United State [Member] | 2034 [Member]
IfrsStatementLineItems [Line Items]
Unused tax losses for which no deferred tax asset recognized	151
United State [Member] | 2035 [Member]
IfrsStatementLineItems [Line Items]
Unused tax losses for which no deferred tax asset recognized	447
United State [Member] | 2036 [Member]
IfrsStatementLineItems [Line Items]
Unused tax losses for which no deferred tax asset recognized	195
United State [Member] | 2037 [Member]
IfrsStatementLineItems [Line Items]
Unused tax losses for which no deferred tax asset recognized	709
United State [Member] | 2038 [Member]
IfrsStatementLineItems [Line Items]
Unused tax losses for which no deferred tax asset recognized	1,224
United State [Member] | 2039 [Member]
IfrsStatementLineItems [Line Items]
Unused tax losses for which no deferred tax asset recognized	771
United State [Member] | 2040 [Member]
IfrsStatementLineItems [Line Items]
Unused tax losses for which no deferred tax asset recognized	515
United State [Member] | 2041 [Member]
IfrsStatementLineItems [Line Items]
Unused tax losses for which no deferred tax asset recognized	$ 234
Domestic Tax Authority [Member] | Canada [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		$ 77,867
Domestic Tax Authority [Member] | Canada [Member] | 2028 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		8,054
Domestic Tax Authority [Member] | Canada [Member] | 2029 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		4,791
Domestic Tax Authority [Member] | Canada [Member] | 2030 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		4,104
Domestic Tax Authority [Member] | Canada [Member] | 2031 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		1,753
Domestic Tax Authority [Member] | Canada [Member] | 2032 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		4,250
Domestic Tax Authority [Member] | Canada [Member] | 2033 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		3,721
Domestic Tax Authority [Member] | Canada [Member] | 2034 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		4,153
Domestic Tax Authority [Member] | Canada [Member] | 2035 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		10,418
Domestic Tax Authority [Member] | Canada [Member] | 2036 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		10,592
Domestic Tax Authority [Member] | Canada [Member] | 2037 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		7,343
Domestic Tax Authority [Member] | Canada [Member] | 2038 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		6,557
Domestic Tax Authority [Member] | Canada [Member] | 2039 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		3,501
Domestic Tax Authority [Member] | Canada [Member] | 2040 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		3,808
Domestic Tax Authority [Member] | Canada [Member] | 2041 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		4,822
Provincial [Member] | Canada [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		76,545
Provincial [Member] | Canada [Member] | 2028 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		6,668
Provincial [Member] | Canada [Member] | 2029 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		4,773
Provincial [Member] | Canada [Member] | 2030 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		4,089
Provincial [Member] | Canada [Member] | 2031 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		1,737
Provincial [Member] | Canada [Member] | 2032 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		4,250
Provincial [Member] | Canada [Member] | 2033 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		3,721
Provincial [Member] | Canada [Member] | 2034 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		4,153
Provincial [Member] | Canada [Member] | 2035 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		10,452
Provincial [Member] | Canada [Member] | 2036 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		10,592
Provincial [Member] | Canada [Member] | 2037 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		7,343
Provincial [Member] | Canada [Member] | 2038 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		6,557
Provincial [Member] | Canada [Member] | 2039 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		3,580
Provincial [Member] | Canada [Member] | 2040 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		3,808
Provincial [Member] | Canada [Member] | 2041 [Member]
IfrsStatementLineItems [Line Items]
Tax attributes to be deferred for which no deferred tax asset was recognized		$ 4,822

Income taxes (Details Narrative

Income taxes (Details Narrative) € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2021EUR (€)	Dec. 31, 2020USD ($)
IfrsStatementLineItems [Line Items]
Uncertain tax provision accrued	$ 115
Unrecognized deferred tax asset	106,715		$ 108,673
R D Investment Tax Credits [Member]
IfrsStatementLineItems [Line Items]
Unused tax credits for which no deferred tax asset recognized	4,006
Domestic Tax Authority [Member]
IfrsStatementLineItems [Line Items]
Accumulated non-capital losses	77,867
Provincial [Member]
IfrsStatementLineItems [Line Items]
Accumulated non-capital losses	76,545
Germany [Member]
IfrsStatementLineItems [Line Items]
Prepaid taxes owned	1,605		$ 1,448
Unused tax losses for which no deferred tax asset recognized	210,709	€ 185,271
United State [Member]
IfrsStatementLineItems [Line Items]
Unused tax losses for which no deferred tax asset recognized	$ 4,793

Disclosure of Fair Value Measur

Disclosure of Fair Value Measurement of Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Financial liabilities at amortised cost, category [member]
IfrsStatementLineItems [Line Items]
Financial asset (liabilities)	$ 1,691	$ 2,360
Financial liabilities at amortised cost, category [member] | Lease liabilities [member]
IfrsStatementLineItems [Line Items]
Financial asset (liabilities)	161	184
Financial liabilities at amortised cost, category [member] | Payables and Accrued Liabilities [Member]
IfrsStatementLineItems [Line Items]
Financial asset (liabilities)	1,530	2,176
Cash and Cash Equivalent [Member] | Financial liabilities at amortised cost, category [member]
IfrsStatementLineItems [Line Items]
Financial asset (liabilities)
Trade and Other Receivables [Member] | Financial liabilities at amortised cost, category [member]
IfrsStatementLineItems [Line Items]
Financial asset (liabilities)
Restricted Cash [Member] | Financial liabilities at amortised cost, category [member]
IfrsStatementLineItems [Line Items]
Financial asset (liabilities)
Financial assets at amortised cost, category [member]
IfrsStatementLineItems [Line Items]
Financial asset (liabilities)	66,949	26,290
Financial assets at amortised cost, category [member] | Lease liabilities [member]
IfrsStatementLineItems [Line Items]
Financial asset (liabilities)
Financial assets at amortised cost, category [member] | Payables and Accrued Liabilities [Member]
IfrsStatementLineItems [Line Items]
Financial asset (liabilities)
Financial assets at amortised cost, category [member] | Cash and Cash Equivalent [Member]
IfrsStatementLineItems [Line Items]
Financial asset (liabilities)	65,300	24,271
Financial assets at amortised cost, category [member] | Trade and Other Receivables [Member]
IfrsStatementLineItems [Line Items]
Financial asset (liabilities)	1,314	1,681
Financial assets at amortised cost, category [member] | Restricted Cash [Member]
IfrsStatementLineItems [Line Items]
Financial asset (liabilities)	$ 335	$ 338

Financial instruments and fin_3

Financial instruments and financial risk management (Details Narrative) € in Thousands, $ in Thousands	Jul. 07, 2020USD ($)	Feb. 28, 2021USD ($)	Jan. 31, 2021USD ($)	Jan. 31, 2021EUR (€)	Aug. 31, 2020USD ($)	Jul. 31, 2020USD ($)	Feb. 28, 2020USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020EUR (€)	Dec. 31, 2019USD ($)
IfrsStatementLineItems [Line Items]
Transaction costs	$ 1,420	$ 55,905			$ 55,905	$ 55,905	$ 55,905	$ 55,905	$ 3,221	$ 2,767		$ 795
Foreign exchange risk, description									The Company is exposed to foreign exchange risk due to its investments in foreign operations whose functional currency is the Euro. As of December 31, 2021, if the US dollar had increased or decreased by 10% against the Euro
Foreign exchange risk exposure									$ 300	110		$ 841
Germany [Member]
IfrsStatementLineItems [Line Items]
Proceeds from cash received										6,109	€ 5,000
Germany [Member] | Nonadjusting Event [Member]
IfrsStatementLineItems [Line Items]
Proceeds from cash received			$ 1,209	€ 1,000
Trade and Other Current Receivables [Member] | Credit risk [member]
IfrsStatementLineItems [Line Items]
Trade accounts receivables									932	1,245
Trade and Other Current Receivables [Member] | Credit risk [member] | Financial assets past due but not impaired [member]
IfrsStatementLineItems [Line Items]
Trade accounts receivables									$ 55	$ 55

Summary of Revenues by Geograph

Summary of Revenues by Geographical Area (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Revenue	$ 5,260	$ 3,652	$ 532
Switzerland [Member]
IfrsStatementLineItems [Line Items]
Revenue	5,075	905
Ireland [Member]
IfrsStatementLineItems [Line Items]
Revenue		73	74
Denmark [Member]
IfrsStatementLineItems [Line Items]
Revenue	185	2,655	413
Other [Member]
IfrsStatementLineItems [Line Items]
Revenue		$ 19	$ 45

Summary of Non-current Assets b

Summary of Non-current Assets by Geographical Area (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
IfrsStatementLineItems [Line Items]
Non-current assets	$ 9,282	$ 9,391
Germany [Member]
IfrsStatementLineItems [Line Items]
Non-current assets	9,212	9,341
United State [Member]
IfrsStatementLineItems [Line Items]
Non-current assets	$ 70	$ 50

Summary of Major Customers (Det

Summary of Major Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Information
Company 1	$ 5,260	$ 3,634	$ 532

Segment information (Details Na

Segment information (Details Narrative)	12 Months Ended
	Dec. 31, 2021Integer
Segment Information
Number of operating segments	1

Summary of Pertinent Data Relat

Summary of Pertinent Data Relating to Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
IfrsStatementLineItems [Line Items]
Net loss	$ (8,368)	$ (5,118)	$ (6,042)
Basic weighted average number of shares outstanding	114,924,497	41,083,163	17,494,472
Diluted weighted average number of shares outstanding	114,924,497	41,083,163	17,494,472
Stock Options and DSUs [Member]
IfrsStatementLineItems [Line Items]
Anti-dilutive shares	1,509,368	679,400	953,557
Warrants [Member]
IfrsStatementLineItems [Line Items]
Anti-dilutive shares	11,441,213	44,901,366	6,629,144

Schedule of Expected Future Min

Schedule of Expected Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2021USD ($)
IfrsStatementLineItems [Line Items]
Total	$ 4,392
Less Than 1 Year [Member]
IfrsStatementLineItems [Line Items]
Total	3,337
1 - 3 Years [Member]
IfrsStatementLineItems [Line Items]
Total	1,055
4 - 5 Years [Member]
IfrsStatementLineItems [Line Items]
Total
More than 5 Years [Member]
IfrsStatementLineItems [Line Items]
Total
Services and Manufacturing [Member]
IfrsStatementLineItems [Line Items]
Total	1,091
Services and Manufacturing [Member] | Less Than 1 Year [Member]
IfrsStatementLineItems [Line Items]
Total	1,085
Services and Manufacturing [Member] | 1 - 3 Years [Member]
IfrsStatementLineItems [Line Items]
Total	6
Services and Manufacturing [Member] | 4 - 5 Years [Member]
IfrsStatementLineItems [Line Items]
Total
Services and Manufacturing [Member] | More than 5 Years [Member]
IfrsStatementLineItems [Line Items]
Total
R&D Contract [Member]
IfrsStatementLineItems [Line Items]
Total	3,301
R&D Contract [Member] | Less Than 1 Year [Member]
IfrsStatementLineItems [Line Items]
Total	2,252
R&D Contract [Member] | 1 - 3 Years [Member]
IfrsStatementLineItems [Line Items]
Total	1,049
R&D Contract [Member] | 4 - 5 Years [Member]
IfrsStatementLineItems [Line Items]
Total
R&D Contract [Member] | More than 5 Years [Member]
IfrsStatementLineItems [Line Items]
Total

Schedule of R&D and Revenue Rel

Schedule of R&D and Revenue Related Milestone Payments (Details) $ in Thousands	Dec. 31, 2021USD ($)
IfrsStatementLineItems [Line Items]
Total	$ 41,879
Less Than 1 Year [Member]
IfrsStatementLineItems [Line Items]
Total	28
1 - 3 Years [Member]
IfrsStatementLineItems [Line Items]
Total	113
4 - 5 Years [Member]
IfrsStatementLineItems [Line Items]
Total	927
More than 5 Years [Member]
IfrsStatementLineItems [Line Items]
Total	40,811
R&D Milestone Payments [Member]
IfrsStatementLineItems [Line Items]
Total	8,937
R&D Milestone Payments [Member] | Less Than 1 Year [Member]
IfrsStatementLineItems [Line Items]
Total	28
R&D Milestone Payments [Member] | 1 - 3 Years [Member]
IfrsStatementLineItems [Line Items]
Total	113
R&D Milestone Payments [Member] | 4 - 5 Years [Member]
IfrsStatementLineItems [Line Items]
Total	927
R&D Milestone Payments [Member] | More than 5 Years [Member]
IfrsStatementLineItems [Line Items]
Total	7,869
Revenue Related Mile Stone Payments [Member]
IfrsStatementLineItems [Line Items]
Total	32,942
Revenue Related Mile Stone Payments [Member] | Less Than 1 Year [Member]
IfrsStatementLineItems [Line Items]
Total
Revenue Related Mile Stone Payments [Member] | 1 - 3 Years [Member]
IfrsStatementLineItems [Line Items]
Total
Revenue Related Mile Stone Payments [Member] | 4 - 5 Years [Member]
IfrsStatementLineItems [Line Items]
Total
Revenue Related Mile Stone Payments [Member] | More than 5 Years [Member]
IfrsStatementLineItems [Line Items]
Total	$ 32,942

Commitments and contingencies_2

Commitments and contingencies (Details Narrative) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
IfrsStatementLineItems [Line Items]
Potential milestone payments description	the Company expects to pay $3,301, including $3,124 (€2.8 million), and $177 (£0.1 million), in R&D contracts and up to $8,937, including $7,386 (€6.5 million) and $1,551 (£1.2 million), in R&D milestone payments and up to $32,942, including $31,255 (€27.6 million) and $1,687 (£1.3 million), in revenue related milestone payments.
Research and Development [Member]
IfrsStatementLineItems [Line Items]
Potential milestone payments	$ 3,301
R&D Contracts [Member]
IfrsStatementLineItems [Line Items]
Potential milestone payments	8,937
R&D Milestone Payments [Member]
IfrsStatementLineItems [Line Items]
Potential milestone payments	$ 32,942